Starpharma - Der Faktenthread - 500 Beiträge pro Seite
eröffnet am 12.05.05 16:14:03 von
neuester Beitrag 12.01.06 16:23:30 von
neuester Beitrag 12.01.06 16:23:30 von
Beiträge: 80
ID: 980.887
ID: 980.887
Aufrufe heute: 0
Gesamt: 9.658
Gesamt: 9.658
Aktive User: 0
ISIN: AU000000SPL0 · WKN: 796461 · Symbol: PQ6
0,0810
EUR
+0,62 %
+0,0005 EUR
Letzter Kurs 26.04.24 Tradegate
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,9000 | +59,66 | |
| 0,5922 | +44,44 | |
| 7,3500 | +43,84 | |
| 11,690 | +40,84 | |
| 0,7000 | +36,69 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 10,110 | -13,44 | |
| 8,2200 | -13,47 | |
| 7,6100 | -17,20 | |
| 1,6100 | -18,27 | |
| 2,1200 | -21,77 |
Feedback
Herzlich Willkommen.
Bitte hierhin nur Fakten bezüglich Starpharma, DNT und anderer Töchter
Bitte hierhin nur Fakten bezüglich Starpharma, DNT und anderer Töchter
mein Vorschlag: wenigstens aus Fakten/Terminen EINEN Sräd machen, das reicht doch wirklich, oder?
Gruß, h.
Gruß, h.
Starpharma hat gute Chancen auf den ersten Nanowirkstoff
Starpharma Pooled Development Ltd., nennt sich ein 1996 in Melbourne, Australien, gegründetes Unternehmen, dessen Spezialgebiet eine am Biomolecular Research Institute in Melbourne erforschte Technologie ist und für die das Unternehmen die weltweiten Exklusivrechte erworben hat.
Die Technologie, die durch eine Anzahl wichtiger Patente geschützt ist, umfasst eine Klasse hochmolekularer stark verzweigter chemischer Verbindungen, sogenannte Dendrimere, die aktiv gegenüber einer großen Anzahl von Viren sein sollen. Der Name Starpharma leitet sich übrigens von den sternförmigen Strukturen der Dendrimer-Moleküle ab, die die Basis für die in der Entwicklung befindlichen Wirkstoffe des Unternehmens sind.
Im Juli 2002 gründete Starpharma speziell zur Entwicklung von nanotechnologischen Anwendungen in den USA ein neues Tochterunternehmen. Dendritic Nanotechnologies wird von Donald Tomalia, einem Spezialisten auf dem Gebiet der Nanotechnologie geleitet und hat zur Entwicklung von VivaGel beigetragen. Das neuartige Vaginalgel auf Wasserbasis, das als aktive Komponente das Polylysin Dendrimer SPL7013 enthält, soll nun auf seine Wirksamkeit gegen HIV getestet werden.
Ebenfalls im Juli erst erhielt Starpharma für sein auf Nanopartikeln basierendes Gel zur HIV-Prävention die FDA-Genehmigung zur Durchführung eines Phase I Versuches. Damit ist das von Starpharma entwickelte VivaGel das erste!!! auf Nanopartikeln basierende Gel, das demnächst am Menschen getestet werden soll.
Die Wirkung von SPL7013 soll darauf beruhen, dass die Dendrimere die Bindung von HIV an Körperzellen blockieren und dadurch eine Infektion verhindern. Das Gel hat aber laut Starpharma gegenüber den üblichen physikalischen Barrieren den Vorteil, dass die Nanopartikel die Viren nicht nur am Eindringen in die Körperzellen hindern, sondern sie gleichzeitig auch zerstören.
Dendrimere sind synthetische Nanostrukturen, die so maßgeschneidert werden können, dass sie sich für pharmazeutische Anwendungen eignen. Mit speziellen chemischen Prozessen wird eine präzise Kontrolle der physikalischen und chemischen Eigenschaften der Dendrimere möglich. Die Dendrimere werden in einer Serie von kontrollierten Reaktionsschritten konstruiert, dabei ordnen sich viele kleine Moleküle um ein Zentralmolekül an. Vorstellen muss man sich so ein Dendrimer wie einen sehr stark verästelten Zweig. Im letzten Reaktionsschritt werden dann die verschiedenen aktiven Gruppen an das stark verzweigte Molekül angelagert. Das so entstehende Dendrimer verfügt dann auf seiner Oberfläche über eine Vielzahl möglicher Reaktionsstellen, die mit verschiedenen Rezeptoren auf der Oberfläche von Viren oder Bakterien in Wechselwirkung treten können.
In der Präklinik war die SPL7013 Nanostruktur nicht nur aktiv gegen HIV, sondern auch gegenüber Genitalherpes, Chlamydien, Hepatitis B, und Genitalwarzen, ausgelöst durch Papillomviren. In Primaten, die dem Affen-AIDS-Virus ausgesetzt wurden, konnte VivaGel die Infektion zu 100 Prozent verhindern. Eine HIV-Infektion erfolgt durch die Bindung des Proteins gp120 auf der Oberfläche des Virus an den CD4-Rezeptor auf der Zielzelle.
Die aktiven Gruppen im Dendrimer SPL7013 binden ihrerseits an gp120 und verhindern dadurch eine Interaktion des Virus mit gesunden Körperzellen, die den CD4-Rezeptor tragen. Umfassende toxikologische Studien in verschiedenen Versuchstieren sprachen zudem für die Sicherheit des neuartigen Gels. Gegenwärtig untersucht Starpharma das Sicherheitsprofil bei wiederholter Verabreichung in der dem Menschen ähnlichsten Affenart, dem Makaken.
Sollten die Phase I Versuche die präklinischen Daten bestätigen, wäre das von Starpharma entwickelte Produkt, auf Basis von Nanostrukturen, eine echte Sensation. Denn mit VivaGel ließe sich die Ausbreitung von Geschlechtskrankheiten, die bereits wieder auf dem Vormarsch sind, effektiv und viel unkomplizierter als mit mechanischen Barrieren eindämmen.
Vor allem die sich rasend verbreitende HPV-Infektion, die durch das humane Papillomvirus ausgelöst wird und sich durch Genitalwarzen bemerkbar macht, wird immer mehr zu einem Problem. Besonders problematisch ist die Tatsache, dass einige Typen von HPV das Risiko für Gebärmutterhalskrebs dramatisch ansteigen lassen. VivaGel wäre also die perfekte Prävention gegen Geschlechtskrankheiten aller Art. Sollte das Produkt bis zur Zulassung gelangen, würde es ein wohl bisher kaum abschätzbares Marktvolumen erwarten.
Eine Studien zum Thema BioNanotechnologie, einschließlich der Vorstellung von interessanten Unternehmen, finden Sie auch auf unserer Webseite unter www.Biotech-Experte.de.
Als Abonnent unseres Service erhalten sie alle einmal monatlich erscheinenden Studien sogar ohne zusätzliche Kosten.
Das Team von Biotech-Experte.de besitzt die erforderliche wissenschaftliche Expertise, die für ein erfolgreiches Investment im LifeScience Sektor unabdingbar ist. Wenn auch Sie von unserem Wissen profitieren wollen, zögern Sie nicht länger, sondern kontaktieren Sie uns noch heute. Unter www.Biotech-Experte.de erfahren Sie näheres zu unserem Service sowie zu unseren Expertisen.
Simone A. Hörrlein
Staatl. gepr. LebChem (Univ.)
(Life Scientist)
Starpharma Pooled Development Ltd., nennt sich ein 1996 in Melbourne, Australien, gegründetes Unternehmen, dessen Spezialgebiet eine am Biomolecular Research Institute in Melbourne erforschte Technologie ist und für die das Unternehmen die weltweiten Exklusivrechte erworben hat.
Die Technologie, die durch eine Anzahl wichtiger Patente geschützt ist, umfasst eine Klasse hochmolekularer stark verzweigter chemischer Verbindungen, sogenannte Dendrimere, die aktiv gegenüber einer großen Anzahl von Viren sein sollen. Der Name Starpharma leitet sich übrigens von den sternförmigen Strukturen der Dendrimer-Moleküle ab, die die Basis für die in der Entwicklung befindlichen Wirkstoffe des Unternehmens sind.
Im Juli 2002 gründete Starpharma speziell zur Entwicklung von nanotechnologischen Anwendungen in den USA ein neues Tochterunternehmen. Dendritic Nanotechnologies wird von Donald Tomalia, einem Spezialisten auf dem Gebiet der Nanotechnologie geleitet und hat zur Entwicklung von VivaGel beigetragen. Das neuartige Vaginalgel auf Wasserbasis, das als aktive Komponente das Polylysin Dendrimer SPL7013 enthält, soll nun auf seine Wirksamkeit gegen HIV getestet werden.
Ebenfalls im Juli erst erhielt Starpharma für sein auf Nanopartikeln basierendes Gel zur HIV-Prävention die FDA-Genehmigung zur Durchführung eines Phase I Versuches. Damit ist das von Starpharma entwickelte VivaGel das erste!!! auf Nanopartikeln basierende Gel, das demnächst am Menschen getestet werden soll.
Die Wirkung von SPL7013 soll darauf beruhen, dass die Dendrimere die Bindung von HIV an Körperzellen blockieren und dadurch eine Infektion verhindern. Das Gel hat aber laut Starpharma gegenüber den üblichen physikalischen Barrieren den Vorteil, dass die Nanopartikel die Viren nicht nur am Eindringen in die Körperzellen hindern, sondern sie gleichzeitig auch zerstören.
Dendrimere sind synthetische Nanostrukturen, die so maßgeschneidert werden können, dass sie sich für pharmazeutische Anwendungen eignen. Mit speziellen chemischen Prozessen wird eine präzise Kontrolle der physikalischen und chemischen Eigenschaften der Dendrimere möglich. Die Dendrimere werden in einer Serie von kontrollierten Reaktionsschritten konstruiert, dabei ordnen sich viele kleine Moleküle um ein Zentralmolekül an. Vorstellen muss man sich so ein Dendrimer wie einen sehr stark verästelten Zweig. Im letzten Reaktionsschritt werden dann die verschiedenen aktiven Gruppen an das stark verzweigte Molekül angelagert. Das so entstehende Dendrimer verfügt dann auf seiner Oberfläche über eine Vielzahl möglicher Reaktionsstellen, die mit verschiedenen Rezeptoren auf der Oberfläche von Viren oder Bakterien in Wechselwirkung treten können.
In der Präklinik war die SPL7013 Nanostruktur nicht nur aktiv gegen HIV, sondern auch gegenüber Genitalherpes, Chlamydien, Hepatitis B, und Genitalwarzen, ausgelöst durch Papillomviren. In Primaten, die dem Affen-AIDS-Virus ausgesetzt wurden, konnte VivaGel die Infektion zu 100 Prozent verhindern. Eine HIV-Infektion erfolgt durch die Bindung des Proteins gp120 auf der Oberfläche des Virus an den CD4-Rezeptor auf der Zielzelle.
Die aktiven Gruppen im Dendrimer SPL7013 binden ihrerseits an gp120 und verhindern dadurch eine Interaktion des Virus mit gesunden Körperzellen, die den CD4-Rezeptor tragen. Umfassende toxikologische Studien in verschiedenen Versuchstieren sprachen zudem für die Sicherheit des neuartigen Gels. Gegenwärtig untersucht Starpharma das Sicherheitsprofil bei wiederholter Verabreichung in der dem Menschen ähnlichsten Affenart, dem Makaken.
Sollten die Phase I Versuche die präklinischen Daten bestätigen, wäre das von Starpharma entwickelte Produkt, auf Basis von Nanostrukturen, eine echte Sensation. Denn mit VivaGel ließe sich die Ausbreitung von Geschlechtskrankheiten, die bereits wieder auf dem Vormarsch sind, effektiv und viel unkomplizierter als mit mechanischen Barrieren eindämmen.
Vor allem die sich rasend verbreitende HPV-Infektion, die durch das humane Papillomvirus ausgelöst wird und sich durch Genitalwarzen bemerkbar macht, wird immer mehr zu einem Problem. Besonders problematisch ist die Tatsache, dass einige Typen von HPV das Risiko für Gebärmutterhalskrebs dramatisch ansteigen lassen. VivaGel wäre also die perfekte Prävention gegen Geschlechtskrankheiten aller Art. Sollte das Produkt bis zur Zulassung gelangen, würde es ein wohl bisher kaum abschätzbares Marktvolumen erwarten.
Eine Studien zum Thema BioNanotechnologie, einschließlich der Vorstellung von interessanten Unternehmen, finden Sie auch auf unserer Webseite unter www.Biotech-Experte.de.
Als Abonnent unseres Service erhalten sie alle einmal monatlich erscheinenden Studien sogar ohne zusätzliche Kosten.
Das Team von Biotech-Experte.de besitzt die erforderliche wissenschaftliche Expertise, die für ein erfolgreiches Investment im LifeScience Sektor unabdingbar ist. Wenn auch Sie von unserem Wissen profitieren wollen, zögern Sie nicht länger, sondern kontaktieren Sie uns noch heute. Unter www.Biotech-Experte.de erfahren Sie näheres zu unserem Service sowie zu unseren Expertisen.
Simone A. Hörrlein
Staatl. gepr. LebChem (Univ.)
(Life Scientist)
aus maydorn report v. 06.02.04:
100-prozentiger AIDS-Schutz: Potenzial zur Verzehnfachung
Hat dieses Unternehmen es geschafft, ein Gel zu entwickeln, das 100-prozentigen Schutz vor AIDS-Infektionen bei ungeschütztem Geschlechtsverkehr bietet? Bei infizierten Menschenaffen zeigte das auf Nanotechnologie basierende Medikament uneingeschränkte Wirkung. Für den „Maydornreport“ hat der Kurs der Aktie des Unternehmens Potenzial auf Kursverzehnfachung.
Starpharma Pooled Development (WKN 796461, PQ6) sitzt im australischen Melbourne und entwickelt auf dem Gebiet der so genannten Dendrimere: synthetische Nanostrukturen, deren Verästelungen so maßgeschneidert werden können, dass sie sich für unterschiedliche pharmazeutische Anwendungen eignen. Eine der interessantesten Dendrimer-Entwicklungen von Starpharma ist ein Gel, mit dem sich die Übertragung von HIV-Viren verhindern lässt. In ersten Versuchen mit infizierten Menschen-Affen zeigte das Gel einen 100-prozentigen Schutz vor einer Aids-Infektion. Sollte sich die Wirksamkeit beim auch für Menschen nachweisen lassen, hätte Starpharma ein Milliardenprodukt in den Händen. Die Marktkapitalisierung von Starpharma beläuft sich derzeit noch auf bescheidene 82 Millionen Australische Dollar, das entspricht 50 Millionen Euro. Der Kurs notiert bei 0,80 Australischen Dollar und damit recht knapp unter dem im Jahr 2002 erreichten All-Time-High von exakt 1,00 Australischen Dollar. Seit einigen Tagen wird Starpharma unter der WKN 796 461 auch in Deutschland an den Börsen Frankfurt und Berlin gehandelt. Der Kurs notierte zum Zeitpunkt der Empfehlung bei 0,52 Euro du hat damit gegenüber dem letzten Kurs in Australien ein Aufgeld von etwa 0,03 Euro. Für das Musterdepot soll der Titel am Freitag, 6. Februar, zur Eröffnung in Australien mit Limit 0,88 Australischen Dollar gekauft werden (ungefähr 0,54 Euro). Gelingt der Ausbruch über die Marke von einem Australischen Dollar, ist laut Maydorn der Weg für Starpharma nach oben frei. Noch ist die Aktie relativ unbekannt, was sich aber schnell ändern könnte.
100-prozentiger AIDS-Schutz: Potenzial zur Verzehnfachung
Hat dieses Unternehmen es geschafft, ein Gel zu entwickeln, das 100-prozentigen Schutz vor AIDS-Infektionen bei ungeschütztem Geschlechtsverkehr bietet? Bei infizierten Menschenaffen zeigte das auf Nanotechnologie basierende Medikament uneingeschränkte Wirkung. Für den „Maydornreport“ hat der Kurs der Aktie des Unternehmens Potenzial auf Kursverzehnfachung.
Starpharma Pooled Development (WKN 796461, PQ6) sitzt im australischen Melbourne und entwickelt auf dem Gebiet der so genannten Dendrimere: synthetische Nanostrukturen, deren Verästelungen so maßgeschneidert werden können, dass sie sich für unterschiedliche pharmazeutische Anwendungen eignen. Eine der interessantesten Dendrimer-Entwicklungen von Starpharma ist ein Gel, mit dem sich die Übertragung von HIV-Viren verhindern lässt. In ersten Versuchen mit infizierten Menschen-Affen zeigte das Gel einen 100-prozentigen Schutz vor einer Aids-Infektion. Sollte sich die Wirksamkeit beim auch für Menschen nachweisen lassen, hätte Starpharma ein Milliardenprodukt in den Händen. Die Marktkapitalisierung von Starpharma beläuft sich derzeit noch auf bescheidene 82 Millionen Australische Dollar, das entspricht 50 Millionen Euro. Der Kurs notiert bei 0,80 Australischen Dollar und damit recht knapp unter dem im Jahr 2002 erreichten All-Time-High von exakt 1,00 Australischen Dollar. Seit einigen Tagen wird Starpharma unter der WKN 796 461 auch in Deutschland an den Börsen Frankfurt und Berlin gehandelt. Der Kurs notierte zum Zeitpunkt der Empfehlung bei 0,52 Euro du hat damit gegenüber dem letzten Kurs in Australien ein Aufgeld von etwa 0,03 Euro. Für das Musterdepot soll der Titel am Freitag, 6. Februar, zur Eröffnung in Australien mit Limit 0,88 Australischen Dollar gekauft werden (ungefähr 0,54 Euro). Gelingt der Ausbruch über die Marke von einem Australischen Dollar, ist laut Maydorn der Weg für Starpharma nach oben frei. Noch ist die Aktie relativ unbekannt, was sich aber schnell ändern könnte.
– STARPHARMA (SPHRF.BB)
SPL. ASX AND DENDRITIC NANOTECHNOLOGIES, INC. (DNI)
I would like to share with the forum my due diligence regarding Starpharma (SPHRF.BB or SPLASP) and DNI. (Private but Starpharma owns 49.9%) First, my impressions from what I will describe later is very positive. These two companies are really at the cutting edge of dendriners technology (nanotechnology) revolution that is going to truly change the means and methods of doing things from the treatment of illnesses to the wires that will deliver electricity in the not to far future. To clarify, the first nanostructures were the large, man-made molecules, such as those in garbage bags and plastic foam cups that were long, spaghetti-like strands that grow only in two directions. The dendriner molecules have a hollow “core” with “sticky” points on the outside to which various chemical units can be attached. These properties can allow them to carry genetic material into human cells to repair birth defects. The hollow core could be filled with a cluster of metal atoms that could store data in binary form, allowing a single molecule to act as a computer. The international excitement over many applicants of dendriners continue to expand as witnessed by new patents, products and dendriner sales. There are few industries that have not been impacted by dendriners such as pharmaceuticals, cosmetics, energy generation and storage display technology and gene transformation that DNT products and Starpharma will be influencing.
First, (SPHRF) is an Australian Company that has about 103 million shares outstanding. It trades on the Australian exchange under the symbol SPL. SPHRF has about Thirteen Million Dollars ($13,000,000.00) in the bank with no debt. SPHRF is traded over the counter in the U.S. They recently completed a new issue of Thirteen Million (13,000,000.00) shares to seven institutions in Australia. These were not obtained Venture Capital funds, but other financial institutions in Australia such as banks that do business with Starpharma and believe in the future of SPHRF. SPHRF has approximately thirty (30) employees and are very active in nanotechnology from drug delivery systems to HIV gels that are being tested by the F.D.A, at this time. In fact, the first phase testing has shown so much promise in monkey tests (100% protection from the HIV virus) that the National Science Institute is footing some of the costs of the phase one tests to expedite the possible future use of the promising gel. SPHRF is, also, working with scientist in New Zealand for drug delivery using dendritic nanotechnologies. SPHRF owns 49.9% of DNI which is a private company that is located in Michigan. SPHRF contributed about $2.5 million for the interest in DNT. DNT recently was named one of the companies to be a part of the Institute For Soldier Technology (“INS”). INS is Ninety Million Dollar ($90,000,000.00) constituim managed by the Massachusetts Institute of Technology to develop nanotechnology for the Army of the future. DNT is one of the seven industrial charter members including Dupont, Raytheon, Dow Corning, Nomadics, Carbon Nanotechnologies and Trinton Systems. In addition to validating DNT’s Science, this program will provide the company with access to leading scientists in Synergestic technologies enhancing the ability to address diverse technical opportunities. Participation in the ISN has significantly increased DNT’s and Starpharma’s profile as key players in nanotechnology. DNT is a leading patent holder in pharmaceutical products for dendriners. There are synthetic polymers with branching parts designed as nanoscale vehicles for delivery of drugs. Starpharma has exclusive commercialized rights to DNT’s technology.
Dr. Donald Tomalin is the founder of DNT. He was formerly with Dow Chemical and was the leading researcher on dendriners. He heads up DNT which has been awarded a number of scientific awards in the area of dendriners. Dr. Tomalin recently received the award for outstanding achievement in polymer science and technology from The Society of Polymer Science in Japan. DNT continues to add very qualified scientist to their staff and are partnering with Central Michigan to be one of the nanotechnology research centers via the recent 3.5 billion nanotechnology bill signed by President Bush.
Dr. John Raff, the Chief Executive officer of Starpharma recently said that “DNT is now successfully established as a significant participant in the U. S. Nanothechology industry and has achieved this with minimum equity funding.”
It should be pointed out that SPHRF and DNT have avoided venture capital funds to keep their independence. However, DNT has received, in the last few years, funding from the federal government in the amount of Thirteen Million Dollars ($13,000,000.00) because of their promising nanotechnology. This commitment by the federal government can only increase because of the advanced technology that Starpharma and DNT have developed. The passage of the Nanotechnology federal law further identifies the strategic importance of nanotechnology to the U. S. Economy, DNT and SPHRF. The Federal Government will surely provide more grants to DNT because of their interest in dendriners technology for protection against chemicals and biological weapons.
The passage of the federal legislation will no doubt lead to further appropriations for SPHRF and DNT. Both companies have strategic intellectual property positions and are pioneers in the areas of nanotechnology. Importantly, dendriners represent a key enabling technology to the building of previously designed minor scale structures for many applicatios. SPHRF has already taken the first drug based on a dendriner (defined nano-structure) through the U.S. F.D.A. regulating system into human trials. See Nature Biotechnology, Vol. 21, No. 10.
Both SPHRF and DNT have numerous products in their pipeline. It should be noted that SPHRF will announce in the not to distant future, a major alliance with a major pharmaceutical companies from the U. S. or Great Britain. Genetech in the U. S. focuses on drug deliveries in the same area as Starpharma: Amgrogenisis. Also, through Starpharma’s 49.9% stake in U. S. based DNT, Starpharma has started selling dendritic research products through chemical giant, Sigma Aldrick. It should be noted that Starpharma has been showing marked R & D in cancer treatments and with the F.D.A.’s showing interest in dendriner technology, it only seems natural that a major pharmaceutical firm will tie in with Starpharma and DNT. Of importance, SPHRA is run by business men and not “professor” types. This means their attention will remain on the bottom line. Further, without interference from venture capitalist restrictions, the products in the pipeline will hopefully make SPHRF profitable in the not to distant future.
Where do these companies compare to the competition? Simply there is not much at the present. However, that will change as time goes by. However, both companies have numerous patents protecting their technology. This should continue for the foreseeable future.
The Viragel being tested by the F.D.A., is a vaginal gel designed to provide women with means to protect themselves from sexual transmission of HIV. This is important to Starpharma because the initial tests with monkeys found Viragel to be 100% effective. The start of these trials have been recognized internationally in several leading journals. The U. S. nanotechnology journal Smalltime has a full page feature titled “Clinical Trials” puts dendriners on course for treating HIV (September/October edition, p. 62). There is also a series of articles highlighting nonobiology in the current edition of Nature Biotechnology (Vol. 21, No. 10, October 2003). In the article “little science, big bucks”, the huge international investment in nanotechnology is outlined with over six billion by government organizations in 2003, in addition to large scale investment by multi-national companies. The article “Commercializing Nanotechnology” cites Starpharma Viragel product as advanced significant application of dendriner nanotechnology in the area of human health. Dr. Raff, CEO of Starpharma said, “Dendriners are a major building block of nanotechnology and we are excited to be at the forefront of practical human health application for this new field of opportunity.”
SPL. ASX AND DENDRITIC NANOTECHNOLOGIES, INC. (DNI)
I would like to share with the forum my due diligence regarding Starpharma (SPHRF.BB or SPLASP) and DNI. (Private but Starpharma owns 49.9%) First, my impressions from what I will describe later is very positive. These two companies are really at the cutting edge of dendriners technology (nanotechnology) revolution that is going to truly change the means and methods of doing things from the treatment of illnesses to the wires that will deliver electricity in the not to far future. To clarify, the first nanostructures were the large, man-made molecules, such as those in garbage bags and plastic foam cups that were long, spaghetti-like strands that grow only in two directions. The dendriner molecules have a hollow “core” with “sticky” points on the outside to which various chemical units can be attached. These properties can allow them to carry genetic material into human cells to repair birth defects. The hollow core could be filled with a cluster of metal atoms that could store data in binary form, allowing a single molecule to act as a computer. The international excitement over many applicants of dendriners continue to expand as witnessed by new patents, products and dendriner sales. There are few industries that have not been impacted by dendriners such as pharmaceuticals, cosmetics, energy generation and storage display technology and gene transformation that DNT products and Starpharma will be influencing.
First, (SPHRF) is an Australian Company that has about 103 million shares outstanding. It trades on the Australian exchange under the symbol SPL. SPHRF has about Thirteen Million Dollars ($13,000,000.00) in the bank with no debt. SPHRF is traded over the counter in the U.S. They recently completed a new issue of Thirteen Million (13,000,000.00) shares to seven institutions in Australia. These were not obtained Venture Capital funds, but other financial institutions in Australia such as banks that do business with Starpharma and believe in the future of SPHRF. SPHRF has approximately thirty (30) employees and are very active in nanotechnology from drug delivery systems to HIV gels that are being tested by the F.D.A, at this time. In fact, the first phase testing has shown so much promise in monkey tests (100% protection from the HIV virus) that the National Science Institute is footing some of the costs of the phase one tests to expedite the possible future use of the promising gel. SPHRF is, also, working with scientist in New Zealand for drug delivery using dendritic nanotechnologies. SPHRF owns 49.9% of DNI which is a private company that is located in Michigan. SPHRF contributed about $2.5 million for the interest in DNT. DNT recently was named one of the companies to be a part of the Institute For Soldier Technology (“INS”). INS is Ninety Million Dollar ($90,000,000.00) constituim managed by the Massachusetts Institute of Technology to develop nanotechnology for the Army of the future. DNT is one of the seven industrial charter members including Dupont, Raytheon, Dow Corning, Nomadics, Carbon Nanotechnologies and Trinton Systems. In addition to validating DNT’s Science, this program will provide the company with access to leading scientists in Synergestic technologies enhancing the ability to address diverse technical opportunities. Participation in the ISN has significantly increased DNT’s and Starpharma’s profile as key players in nanotechnology. DNT is a leading patent holder in pharmaceutical products for dendriners. There are synthetic polymers with branching parts designed as nanoscale vehicles for delivery of drugs. Starpharma has exclusive commercialized rights to DNT’s technology.
Dr. Donald Tomalin is the founder of DNT. He was formerly with Dow Chemical and was the leading researcher on dendriners. He heads up DNT which has been awarded a number of scientific awards in the area of dendriners. Dr. Tomalin recently received the award for outstanding achievement in polymer science and technology from The Society of Polymer Science in Japan. DNT continues to add very qualified scientist to their staff and are partnering with Central Michigan to be one of the nanotechnology research centers via the recent 3.5 billion nanotechnology bill signed by President Bush.
Dr. John Raff, the Chief Executive officer of Starpharma recently said that “DNT is now successfully established as a significant participant in the U. S. Nanothechology industry and has achieved this with minimum equity funding.”
It should be pointed out that SPHRF and DNT have avoided venture capital funds to keep their independence. However, DNT has received, in the last few years, funding from the federal government in the amount of Thirteen Million Dollars ($13,000,000.00) because of their promising nanotechnology. This commitment by the federal government can only increase because of the advanced technology that Starpharma and DNT have developed. The passage of the Nanotechnology federal law further identifies the strategic importance of nanotechnology to the U. S. Economy, DNT and SPHRF. The Federal Government will surely provide more grants to DNT because of their interest in dendriners technology for protection against chemicals and biological weapons.
The passage of the federal legislation will no doubt lead to further appropriations for SPHRF and DNT. Both companies have strategic intellectual property positions and are pioneers in the areas of nanotechnology. Importantly, dendriners represent a key enabling technology to the building of previously designed minor scale structures for many applicatios. SPHRF has already taken the first drug based on a dendriner (defined nano-structure) through the U.S. F.D.A. regulating system into human trials. See Nature Biotechnology, Vol. 21, No. 10.
Both SPHRF and DNT have numerous products in their pipeline. It should be noted that SPHRF will announce in the not to distant future, a major alliance with a major pharmaceutical companies from the U. S. or Great Britain. Genetech in the U. S. focuses on drug deliveries in the same area as Starpharma: Amgrogenisis. Also, through Starpharma’s 49.9% stake in U. S. based DNT, Starpharma has started selling dendritic research products through chemical giant, Sigma Aldrick. It should be noted that Starpharma has been showing marked R & D in cancer treatments and with the F.D.A.’s showing interest in dendriner technology, it only seems natural that a major pharmaceutical firm will tie in with Starpharma and DNT. Of importance, SPHRA is run by business men and not “professor” types. This means their attention will remain on the bottom line. Further, without interference from venture capitalist restrictions, the products in the pipeline will hopefully make SPHRF profitable in the not to distant future.
Where do these companies compare to the competition? Simply there is not much at the present. However, that will change as time goes by. However, both companies have numerous patents protecting their technology. This should continue for the foreseeable future.
The Viragel being tested by the F.D.A., is a vaginal gel designed to provide women with means to protect themselves from sexual transmission of HIV. This is important to Starpharma because the initial tests with monkeys found Viragel to be 100% effective. The start of these trials have been recognized internationally in several leading journals. The U. S. nanotechnology journal Smalltime has a full page feature titled “Clinical Trials” puts dendriners on course for treating HIV (September/October edition, p. 62). There is also a series of articles highlighting nonobiology in the current edition of Nature Biotechnology (Vol. 21, No. 10, October 2003). In the article “little science, big bucks”, the huge international investment in nanotechnology is outlined with over six billion by government organizations in 2003, in addition to large scale investment by multi-national companies. The article “Commercializing Nanotechnology” cites Starpharma Viragel product as advanced significant application of dendriner nanotechnology in the area of human health. Dr. Raff, CEO of Starpharma said, “Dendriners are a major building block of nanotechnology and we are excited to be at the forefront of practical human health application for this new field of opportunity.”
Trading Spotlight
Hier ein Ausschnitt von www.starpharma.com
Sexually Transmitted Diseases
A global epidemic...
In the US, sexually transmitted diseases (STDs) affect more than 13 million people annually. It is estimated that more than 4 million Americans are infected by Chlamydia each year and that chlamydial infections and the other problems they cause cost Americans more than US$2 billion a year. It is estimated that genital herpes affects about 60 million Americans. In 1999, it was estimated that the annual cost of all STDs was more than US$10 billion annually. Research has also shown that having an STD makes infection with HIV more likely. Throughout the world, more than 42 million people are living with HIV, and approximately 50 percent of the adults living with HIV are women. 8000 children and young people aged 24 years and under were infected with HIV every day in 2002. An additional 45 million people are estimated to be infected with HIV between 2003 and 2010.
In March 1999, after consultation with world experts in the field of STDs, Starpharma initiated a research program to develop a dendrimer-based topical microbicide. This research has resulted in the development of VivaGel™, which is a topical microbicide that can potentially prevent or reduce the transmission of HIV and other STDs when applied to the vagina or rectum prior to sexual intercourse. Other products being investigated for development in this area include a topical treatment for recurrent genital herpes infection.
Starpharma’s contribution to a global effort...
VivaGel™ is a water-based gel that contains the polyvalent, polylysine dendrimer, SPL7013, as the active ingredient. SPL7013 has shown activity against multiple viral STDs:
* Human immunodeficiency virus (HIV)
* Chlamydia
* Herpes simplex virus
* Hepatitis B virus
* Human papilloma virus (genital warts)
A safe and effective microbicide will offer women, who are generally more vulnerable to HIV infection than men due to biological, sociological and cultural factors, an alternative to dependence on male condoms for STD prevention. Initiatives to encourage the development of microbicides and to ensure that a safe and effective microbicide is accessible to all women include government funded R&D support and pricing subsidies.
In July 2003, Starpharma gained clearance to proceed with a Phase I clinical trial under US Food & Drug Administration (FDA) regulations to test the safety of VivaGel™ in humans. These clinical trials commenced in Adelaide, Australia, in January 2004.
For a summary of the licensing opportunities arising out of this project visit LICENSING OPPORTUNITIES.
For more information, see flyer Product Focus: VivaGel™.
Respiratory Viruses
Starpharma’s dendrimers have shown exciting activity individually against several respiratory diseases including respiratory syncitial virus (RSV), influenza and adenovirus. Starpharma has an active dendrimer-based drug discovery program aimed at developing inhalational, respiratory pharmaceuticals. Dendrimers are currently being assessed against a range of respiratory viruses and emerging pathogens (e.g. SARS).
For a summary of the licensing opportunities arising out of this project visit LICENSING OPPORTUNITIES.
Systemic Viral Diseases
Systemic viral diseases include hepatitis B virus (HBV). Chronic HBV infection is a global health problem with approximately 350 million carriers worldwide. Many of these carriers develop severe liver disease, such as cirrhosis and cancer. While there is a vaccine for HBV available, it is not widely distributed. There are also few therapeutic options available. Starpharma is developing dendrimers as novel HBV therapeutic agents. Some dendrimers have demonstrated broad-spectrum antiviral activity and early studies suggest a novel mechanism of action compared with existing HBV therapeutics.
Oncology
Starpharma oncology projects focus on:
* small molecules to inhibit angiogenesis;
* the development of a dendrimer-cisplatin complex for drug delivery.
Angiogenesis...
Angiogenesis is the process of small blood vessel formation and growth. Angiogenesis has been associated with the growth and spread of cancer. Starpharma has a range of small molecules in development that have been shown to reduce angiogenesis in in vitro assays.
For a summary of the licensing opportunities arising out of this project visit LICENSING OPPORTUNITIES.
Dendrimer-cisplatin complex...
Cisplatin is a drug commonly used for the treatment of cancer. However, treatment with cisplatin is associated with significant side effects that limit the success achievable with the drug. Starpharma, in collaboration with Dendritic Nanotechnologies, Inc., is examining the potential of a dendrimer-cisplatin complex to act as a delivery agent. Cisplatin can be complexed with the dendrimer, protecting the cisplatin.
For more information, see flyer Novel Chemotherapeutic Agents.
Biodefense and Tropical Diseases
The US government is providing significant funding to research programs aimed at improving detection and countering of bioterrorist attacks. Starpharma’s development programs in this area focus on dendrimer-based products with activity against:
* exotic viral diseases (e.g. Ebola virus);
* toxins (e.g. Cholera toxin).
Dendrimers possess several advantages as drugs or surface decontamination agents:
* polyvalent (multiple surface groups results in efficient attachment to biological target sites);
* do not induce antigenic activity (no immune response);
* stable (use in a wide variety of environments and formulations);
* low toxicity (safe to use);
* predictable properties (easily tailored to give desired effects).
Sexually Transmitted Diseases
A global epidemic...
In the US, sexually transmitted diseases (STDs) affect more than 13 million people annually. It is estimated that more than 4 million Americans are infected by Chlamydia each year and that chlamydial infections and the other problems they cause cost Americans more than US$2 billion a year. It is estimated that genital herpes affects about 60 million Americans. In 1999, it was estimated that the annual cost of all STDs was more than US$10 billion annually. Research has also shown that having an STD makes infection with HIV more likely. Throughout the world, more than 42 million people are living with HIV, and approximately 50 percent of the adults living with HIV are women. 8000 children and young people aged 24 years and under were infected with HIV every day in 2002. An additional 45 million people are estimated to be infected with HIV between 2003 and 2010.
In March 1999, after consultation with world experts in the field of STDs, Starpharma initiated a research program to develop a dendrimer-based topical microbicide. This research has resulted in the development of VivaGel™, which is a topical microbicide that can potentially prevent or reduce the transmission of HIV and other STDs when applied to the vagina or rectum prior to sexual intercourse. Other products being investigated for development in this area include a topical treatment for recurrent genital herpes infection.
Starpharma’s contribution to a global effort...
VivaGel™ is a water-based gel that contains the polyvalent, polylysine dendrimer, SPL7013, as the active ingredient. SPL7013 has shown activity against multiple viral STDs:
* Human immunodeficiency virus (HIV)
* Chlamydia
* Herpes simplex virus
* Hepatitis B virus
* Human papilloma virus (genital warts)
A safe and effective microbicide will offer women, who are generally more vulnerable to HIV infection than men due to biological, sociological and cultural factors, an alternative to dependence on male condoms for STD prevention. Initiatives to encourage the development of microbicides and to ensure that a safe and effective microbicide is accessible to all women include government funded R&D support and pricing subsidies.
In July 2003, Starpharma gained clearance to proceed with a Phase I clinical trial under US Food & Drug Administration (FDA) regulations to test the safety of VivaGel™ in humans. These clinical trials commenced in Adelaide, Australia, in January 2004.
For a summary of the licensing opportunities arising out of this project visit LICENSING OPPORTUNITIES.
For more information, see flyer Product Focus: VivaGel™.
Respiratory Viruses
Starpharma’s dendrimers have shown exciting activity individually against several respiratory diseases including respiratory syncitial virus (RSV), influenza and adenovirus. Starpharma has an active dendrimer-based drug discovery program aimed at developing inhalational, respiratory pharmaceuticals. Dendrimers are currently being assessed against a range of respiratory viruses and emerging pathogens (e.g. SARS).
For a summary of the licensing opportunities arising out of this project visit LICENSING OPPORTUNITIES.
Systemic Viral Diseases
Systemic viral diseases include hepatitis B virus (HBV). Chronic HBV infection is a global health problem with approximately 350 million carriers worldwide. Many of these carriers develop severe liver disease, such as cirrhosis and cancer. While there is a vaccine for HBV available, it is not widely distributed. There are also few therapeutic options available. Starpharma is developing dendrimers as novel HBV therapeutic agents. Some dendrimers have demonstrated broad-spectrum antiviral activity and early studies suggest a novel mechanism of action compared with existing HBV therapeutics.
Oncology
Starpharma oncology projects focus on:
* small molecules to inhibit angiogenesis;
* the development of a dendrimer-cisplatin complex for drug delivery.
Angiogenesis...
Angiogenesis is the process of small blood vessel formation and growth. Angiogenesis has been associated with the growth and spread of cancer. Starpharma has a range of small molecules in development that have been shown to reduce angiogenesis in in vitro assays.
For a summary of the licensing opportunities arising out of this project visit LICENSING OPPORTUNITIES.
Dendrimer-cisplatin complex...
Cisplatin is a drug commonly used for the treatment of cancer. However, treatment with cisplatin is associated with significant side effects that limit the success achievable with the drug. Starpharma, in collaboration with Dendritic Nanotechnologies, Inc., is examining the potential of a dendrimer-cisplatin complex to act as a delivery agent. Cisplatin can be complexed with the dendrimer, protecting the cisplatin.
For more information, see flyer Novel Chemotherapeutic Agents.
Biodefense and Tropical Diseases
The US government is providing significant funding to research programs aimed at improving detection and countering of bioterrorist attacks. Starpharma’s development programs in this area focus on dendrimer-based products with activity against:
* exotic viral diseases (e.g. Ebola virus);
* toxins (e.g. Cholera toxin).
Dendrimers possess several advantages as drugs or surface decontamination agents:
* polyvalent (multiple surface groups results in efficient attachment to biological target sites);
* do not induce antigenic activity (no immune response);
* stable (use in a wide variety of environments and formulations);
* low toxicity (safe to use);
* predictable properties (easily tailored to give desired effects).
SPHRF owns 49.9% of DNI which is a private company that is located in Michigan. SPHRF contributed about $2.5 million for the interest in DNT. DNT recently was named one of the companies to be a part of the Institute For Soldier Technology (“INS”). INS is Ninety Million Dollar ($90,000,000.00) constituim managed by the Massachusetts Institute of Technology to develop nanotechnology for the Army of the future. DNT is one of the seven industrial charter members including Dupont, Raytheon, Dow Corning, Nomadics, Carbon Nanotechnologies and Trinton Systems. In addition to validating DNT’s Science, this program will provide the company with access to leading scientists in Synergestic technologies enhancing the ability to address diverse technical opportunities. Participation in the ISN has significantly increased DNT’s and Starpharma’s profile as key players in nanotechnology. DNT is a leading patent holder in pharmaceutical products for dendriners. There are synthetic polymers with branching parts designed as nanoscale vehicles for delivery of drugs. Starpharma has exclusive commercialized rights to DNT’s technology.
Nur für den Fall, dass jemand noch ein Schmankerl braucht:
http://web.mit.edu/isn/aboutisn/
Sind ein paar nette Videos dabei und zeigt euch mal, woran ich bei Militär denke.
Wenn ich MIT höre, gibts nur noch einen Button und der heisst : Strong buy!!!!
http://web.mit.edu/isn/aboutisn/
Sind ein paar nette Videos dabei und zeigt euch mal, woran ich bei Militär denke.
Wenn ich MIT höre, gibts nur noch einen Button und der heisst : Strong buy!!!!
Das Nanogel von Starpharma hat in den Tierversuchen einen 100%igen Schutz vor Aids erbracht.
Damit hat Starpharma weltweit eine Alleinstellung im Kampf gegen Aids.
Schaue dir dringend die Starpharma Seiten nochmal an, insbesondere die Reports zurück bis November 2003.
Wir reden über die einzige Firma weltweit, die ein Produkt in der Entwicklung hat und jetzt an Patienten ausprobiert, das 100%igen Schutz vor Ansteckung vor
Aids
Ebola
Influenza
und einer Menge anderen Erreger bietet.
Die wesentliche Forschung spielt sich in den Staaten unter Leitung des MIT ab.
Glaubst du, Firmen wie Raytheon oder Unis wie das MIT z.Bsp. hätten gerne zugestimmt, das alle Entwicklungen aus dem Programm Armee der Zukunft, das mit 90 Mio US $ von der Regierung gefördert wird zu 100% für Starpharma patentiert werden und Starpharma das alleinige weltweite Vermarktungsrecht hat??????
Das wurde doch nur gemacht, weil man es bei Starpharma verstanden hat, die führenden Experten weltweit auf dem Gebiet der Dendrimerforschung als Direktoren zu verpflichten.
Schau dir mal die amerikanische Tochter an, respektive das Board of Direktors von DNT. Da ist alles vertreten, was in der amerikanischen Top-Industrie zur ersten Sahne gehört undzwar mit Recht, denn die Forschungen von Starpharma und DNT sind eine Frage der nationalen Sicherheit und dermaßen zukunftsweisend, das namhafte Universitäten sich um eine Zusammenarbeit reissen.
Hier mal ein kleiner Auszug Wissenswertes:
Chairman’s Address
Annual General Meeting
of
Starpharma Pooled Development Limited
Wednesday 19 November 2003
I joined the Board of Starpharma in August of this year to replace retiring
Chairman Richard Oliver, who was the inaugural Chairman of this Company.
Richard Oliver joined Starpharma at its inception seven years ago, when it was
created as a spin-off company with a vision of commercialising pharmaceutical
applications for a new class of compounds called dendrimers. Starpharma has
achieved a great deal over the last seven years, and on behalf of the Board
and Management I would like to thank Richard for his substantial contribution
to these achievements, and for his leadership, guidance and judgement
throughout this period.
The past year has seen a number of exciting developments for the Starpharma
group, and I will briefly mention some of these.
VivaGel™
We recently announced a further stage in the development path for the
company’s VivaGel™ product, with volunteer enrolments now underway for
Phase I human safety trials, to be conduced at Royal Adelaide Hospital.
VivaGel™ is a vaginal gel designed to provide women with a means of
protecting themselves from the sexual transmission of the HIV virus. The US
Federal Drug Administration’s clearance to commence the VivaGel™ trials is
being recognised internationally as a significant milestone in the application of
nanotechnology to human health. It is exciting to be involved in an emerging
area of science with the potential to have such a significant positive impact on
the lives of many people around the world.
Other projects/collaboration
In addition to the VivaGel™ project Starpharma has a number of other projects
in various stages of development, and a broad range of opportunities in the
applications of dendrimer nanotechnology to human health. Starpharma is
well placed within the biotech industry, having a sound scientific base, a strong
management team and a range of opportunities with the potential to greatly
increase shareholder value.
Our corporate strategy includes collaborating and working with other biotech
groups, and we have established a number of alliances with Australian and
overseas companies. For example we recently announced a collaboration
with local biotech company AGT Biosciences Limited in the field of Type 2
Diabetes, and in June this year we announced a major nanotechnology
alliance with New Zealand’s Industrial Research Limited.
1
DNT
A little over two years ago Starpharma made the strategic decision to join with
the US pioneer of dendrimers, Dr Donald Tomalia, in establishing a new
company to develop complementary applications of dendrimer
nanotechnology. The company, Dendritic Nanotechnologies Inc, or ‘DNT’, was
established with a total Starpharma equity investment of only 2.18 million US
dollars, and Starpharma currently owns 49.9% of DNT.
DNT is based at Mt Pleasant in the state of Michigan, and has already been
recognised at both state and federal levels in the US for its achievements.
DNT has received significant funding support from the US Army and other
sources, and is also generating income from the sale of dendrimer research
products. In October this year DNT received an award from the Michigan
Economic Development Corporation recognising the company’s innovation,
marketplace success and contribution to the State’s economy.
In addition to the equity investment the arrangement with DNT has other
benefits for Starpharma, as it has fortified and extended the group’s intellectual
property position in the field of dendrimer nanotechnology.
Share Placement
On 10th September 2003 the Company announced a share placement of
13.335 million new shares, raising 6.9 million dollars before issue expenses.
This placement has substantially strengthened our share register, and we now
have strong support from institutional investors complementing the long term
support Starpharma has enjoyed from its early stage investors.
The evaluation of opportunities for growth through mergers & acquisitions is an
integral part of the company’s corporate strategy. The Board continues to
consider all possibilities for maximising returns to shareholders.
Starpharma was initially structured as a Pooled Development Fund and since
its establishment we have worked closely with the PDF board to ensure that
our various corporate activities have met both the broad objectives and the
legal requirements of the PDF Act. In fact Starpharma has been used and
publicised by AusIndustry as an example of a highly successful PDF. Our
conversion of DNT to a US entity posed particular challenges for our continued
compliance with the PDF Act and although we received PDF Board approval
for the restructure, we were not permitted to hold more than 49.9% of this
strategically important US business.
Starpharma, like most other Australian biotechs, recognises that a level of
industry consolidation is inevitable. However this Board will be careful to
ensure that involvement in any corporate reorganisation would be
overwhelmingly in the interests of all shareholders. Industry mergers pose
particular difficulties for a company registered as a PDF. We have considered
the possibility that at some time in the future it may be appropriate to ask
shareholders to give the Board authority to relinquish the PDF licence in a
2
situation where this was a necessary part of a corporate restructure in the best
interests of Starpharma shareholders. This item is not on the agenda today,
and would require approval at a future general meeting of shareholders.
Board Remuneration/cash burn
Starpharma is not a high cost company - it has a history of achieving its
milestones with a relatively low cash burn. Levels of Board remuneration are
modest, and employee share options currently amount to less than 1% of total
issued shares. This year we have asked shareholders to approve an increase
in the total Board remuneration available for disbursement to Directors. The
Board does not intend to fully utilise these available funds under the current
board structure, but we need the flexibility to be able to do what is necessary
to take advantage of opportunities as they arise, and to attract and retain high
calibre Directors.
Corporate Governance
The Board has reviewed its procedures and practices in light of the ASX
Corporate Governance guidelines released earlier this year. Our current
practices substantially accord with the ASX principles and recommendations,
and we have committed to achieving conformity with the guidelines wherever
possible and practicable. For example we have recently added a third
member to the Board’s Audit Committee - Dr Peter Jenkins, who is an
independent director as defined in the ASX guidelines. We will be reporting
fully on our compliance with the ASX best practice recommendations in our
2004 Annual Report.
I will now hand over to our Chief Executive Officer Dr John Raff to address the
meeting, after which we will proceed to the formal business on the agenda.
3
Und zu Patenten (einige von sehr vielen!!!!)
DNT INC. – NEW PATENTS GRANTED AND RECEIVES
SUBSTANTIAL ADDITIONAL GRANT FUNDING
MELBOURNE, 18 NOVEMBER 2003: Starpharma Pooled Development Limited
(ASX: SPL) today made the following announcements regarding its 49.9%
owned associate Dendritic Nanotechnologies, Inc. (“DNT”):
US Patents Granted 1.
The US Patent Office has issued a new patent relating to convergent
self-branching polymerization (US Pat 6632889 B1). DNT has an
exclusive worldwide royalty-free license to this technology, which
relates to novel techniques for production of low cost large dendritic
structures. The technology has applications for a wide range of
industrial products where cost of production has been a critical
development hurdle.
DNT also has royalty-free license rights to another patent recently
granted by the US Patent Office relating to core shell tecto dendrimers
(US Pat 6635720 B1). This patent covers the building of larger
nanotech structures using multiple dendrimer arrays. The intellectual
property covered by the patent allows the creation of large precisely
manufactured nanostructures with new properties. Applications are
very broad across medical, electronic, and chemical industries and
DNT is exploring opportunities to exploit the technology in each of
these fields.
DNT President and Chief Scientific Officer Dr Donald A. Tomalia is an
inventor on all of the above patents.
Additional US Army Grant Funding 2.
DNT continues to be very successful in attracting significant grant
funding. In 2002 DNT and Central Michigan University together
received a grant from the US Army for US$3.5 million to establish “The
Center for Dendrimer Based Nanotechnology”. These funds are being
applied to purchase state-of-the-art nanoscience equipment, attract key
nanoscience experts, and support several subcontracts. The original
grant has now been extended with an additional US$3.0 million, and
further to this continuing grants and contracts of at least this level are
anticipated until 2008.
DNT was also a successful applicant amongst strong competition to be a part
of the Institute for Soldier Nanotechnology (“ISN”). The ISN is a US$90
million consortium managed by Massachusetts Institute of Technology to
develop nanotechnology for the army of the future. DNT is one of seven
industrial charter members including DuPont, Raytheon, Dow Corning,
Nomadics, Carbon Nanotechnologies and Triton Systems. In addition to
validating DNT’s science, this program provides the company with access to
many leading scientists in synergistic technologies enhancing the ability to
address diverse technical opportunities. Participation in the ISN has also
significantly increased DNT’s profile as a key player in nanotechnology in the
US.
The level of US government and other international support for
nanotechnology, and DNT’s position in the nanotechnology industry, are
referred to in a series of articles highlighting nanobiotechnology in the October
2003 edition of Nature Biotechnology (Volume 21 Number 10).
Starpharma established DNT with the pioneer of dendrimer nanotechnology
Dr Donald Tomalia and now has a 49.9% equity interest in DNT together with
commercialization rights to pharmaceutical applications relating to DNT
dendrimer intellectual property.
Dr John Raff, the Chief Executive Officer of Starpharma, said “DNT is now
successfully established as a significant participant in the US nanotechnology
industry and has achieved this with minimal equity funding. DNT continues to
be a very important strategic partner and investment for Starpharma and we
are excited about its future prospects in both the short and medium term”.
Starpharma Pooled Development Limited (ASX:SPL) is a registered pooled development
fund with investments in wholly owned subsidiary biopharmaceutical companies focused on
the development and application of dendrimer nanotechnologies as drugs against major
diseases. Starpharma lead dendrimer product, VivaGel™ recently received clearance from
the US FDA for human clinical trials. VivaGel™ is a topical microbicide gel product that has
been developed for women as a preventative against the sexual transmission of HIV. It is
also active in animal studies for the prevention of other sexually transmitted diseases
including Genital Herpes and Chlamydia.
CONTACTS:
Company Secretary
+61 3 8532 2702
+61 3 8532 2701
Dr John Raff Mr Ben Rogers
Chief Executive Officer
www.starpharma.com
Damit hat Starpharma weltweit eine Alleinstellung im Kampf gegen Aids.
Schaue dir dringend die Starpharma Seiten nochmal an, insbesondere die Reports zurück bis November 2003.
Wir reden über die einzige Firma weltweit, die ein Produkt in der Entwicklung hat und jetzt an Patienten ausprobiert, das 100%igen Schutz vor Ansteckung vor
Aids
Ebola
Influenza
und einer Menge anderen Erreger bietet.
Die wesentliche Forschung spielt sich in den Staaten unter Leitung des MIT ab.
Glaubst du, Firmen wie Raytheon oder Unis wie das MIT z.Bsp. hätten gerne zugestimmt, das alle Entwicklungen aus dem Programm Armee der Zukunft, das mit 90 Mio US $ von der Regierung gefördert wird zu 100% für Starpharma patentiert werden und Starpharma das alleinige weltweite Vermarktungsrecht hat??????
Das wurde doch nur gemacht, weil man es bei Starpharma verstanden hat, die führenden Experten weltweit auf dem Gebiet der Dendrimerforschung als Direktoren zu verpflichten.
Schau dir mal die amerikanische Tochter an, respektive das Board of Direktors von DNT. Da ist alles vertreten, was in der amerikanischen Top-Industrie zur ersten Sahne gehört undzwar mit Recht, denn die Forschungen von Starpharma und DNT sind eine Frage der nationalen Sicherheit und dermaßen zukunftsweisend, das namhafte Universitäten sich um eine Zusammenarbeit reissen.
Hier mal ein kleiner Auszug Wissenswertes:
Chairman’s Address
Annual General Meeting
of
Starpharma Pooled Development Limited
Wednesday 19 November 2003
I joined the Board of Starpharma in August of this year to replace retiring
Chairman Richard Oliver, who was the inaugural Chairman of this Company.
Richard Oliver joined Starpharma at its inception seven years ago, when it was
created as a spin-off company with a vision of commercialising pharmaceutical
applications for a new class of compounds called dendrimers. Starpharma has
achieved a great deal over the last seven years, and on behalf of the Board
and Management I would like to thank Richard for his substantial contribution
to these achievements, and for his leadership, guidance and judgement
throughout this period.
The past year has seen a number of exciting developments for the Starpharma
group, and I will briefly mention some of these.
VivaGel™
We recently announced a further stage in the development path for the
company’s VivaGel™ product, with volunteer enrolments now underway for
Phase I human safety trials, to be conduced at Royal Adelaide Hospital.
VivaGel™ is a vaginal gel designed to provide women with a means of
protecting themselves from the sexual transmission of the HIV virus. The US
Federal Drug Administration’s clearance to commence the VivaGel™ trials is
being recognised internationally as a significant milestone in the application of
nanotechnology to human health. It is exciting to be involved in an emerging
area of science with the potential to have such a significant positive impact on
the lives of many people around the world.
Other projects/collaboration
In addition to the VivaGel™ project Starpharma has a number of other projects
in various stages of development, and a broad range of opportunities in the
applications of dendrimer nanotechnology to human health. Starpharma is
well placed within the biotech industry, having a sound scientific base, a strong
management team and a range of opportunities with the potential to greatly
increase shareholder value.
Our corporate strategy includes collaborating and working with other biotech
groups, and we have established a number of alliances with Australian and
overseas companies. For example we recently announced a collaboration
with local biotech company AGT Biosciences Limited in the field of Type 2
Diabetes, and in June this year we announced a major nanotechnology
alliance with New Zealand’s Industrial Research Limited.
1
DNT
A little over two years ago Starpharma made the strategic decision to join with
the US pioneer of dendrimers, Dr Donald Tomalia, in establishing a new
company to develop complementary applications of dendrimer
nanotechnology. The company, Dendritic Nanotechnologies Inc, or ‘DNT’, was
established with a total Starpharma equity investment of only 2.18 million US
dollars, and Starpharma currently owns 49.9% of DNT.
DNT is based at Mt Pleasant in the state of Michigan, and has already been
recognised at both state and federal levels in the US for its achievements.
DNT has received significant funding support from the US Army and other
sources, and is also generating income from the sale of dendrimer research
products. In October this year DNT received an award from the Michigan
Economic Development Corporation recognising the company’s innovation,
marketplace success and contribution to the State’s economy.
In addition to the equity investment the arrangement with DNT has other
benefits for Starpharma, as it has fortified and extended the group’s intellectual
property position in the field of dendrimer nanotechnology.
Share Placement
On 10th September 2003 the Company announced a share placement of
13.335 million new shares, raising 6.9 million dollars before issue expenses.
This placement has substantially strengthened our share register, and we now
have strong support from institutional investors complementing the long term
support Starpharma has enjoyed from its early stage investors.
The evaluation of opportunities for growth through mergers & acquisitions is an
integral part of the company’s corporate strategy. The Board continues to
consider all possibilities for maximising returns to shareholders.
Starpharma was initially structured as a Pooled Development Fund and since
its establishment we have worked closely with the PDF board to ensure that
our various corporate activities have met both the broad objectives and the
legal requirements of the PDF Act. In fact Starpharma has been used and
publicised by AusIndustry as an example of a highly successful PDF. Our
conversion of DNT to a US entity posed particular challenges for our continued
compliance with the PDF Act and although we received PDF Board approval
for the restructure, we were not permitted to hold more than 49.9% of this
strategically important US business.
Starpharma, like most other Australian biotechs, recognises that a level of
industry consolidation is inevitable. However this Board will be careful to
ensure that involvement in any corporate reorganisation would be
overwhelmingly in the interests of all shareholders. Industry mergers pose
particular difficulties for a company registered as a PDF. We have considered
the possibility that at some time in the future it may be appropriate to ask
shareholders to give the Board authority to relinquish the PDF licence in a
2
situation where this was a necessary part of a corporate restructure in the best
interests of Starpharma shareholders. This item is not on the agenda today,
and would require approval at a future general meeting of shareholders.
Board Remuneration/cash burn
Starpharma is not a high cost company - it has a history of achieving its
milestones with a relatively low cash burn. Levels of Board remuneration are
modest, and employee share options currently amount to less than 1% of total
issued shares. This year we have asked shareholders to approve an increase
in the total Board remuneration available for disbursement to Directors. The
Board does not intend to fully utilise these available funds under the current
board structure, but we need the flexibility to be able to do what is necessary
to take advantage of opportunities as they arise, and to attract and retain high
calibre Directors.
Corporate Governance
The Board has reviewed its procedures and practices in light of the ASX
Corporate Governance guidelines released earlier this year. Our current
practices substantially accord with the ASX principles and recommendations,
and we have committed to achieving conformity with the guidelines wherever
possible and practicable. For example we have recently added a third
member to the Board’s Audit Committee - Dr Peter Jenkins, who is an
independent director as defined in the ASX guidelines. We will be reporting
fully on our compliance with the ASX best practice recommendations in our
2004 Annual Report.
I will now hand over to our Chief Executive Officer Dr John Raff to address the
meeting, after which we will proceed to the formal business on the agenda.
3
Und zu Patenten (einige von sehr vielen!!!!)
DNT INC. – NEW PATENTS GRANTED AND RECEIVES
SUBSTANTIAL ADDITIONAL GRANT FUNDING
MELBOURNE, 18 NOVEMBER 2003: Starpharma Pooled Development Limited
(ASX: SPL) today made the following announcements regarding its 49.9%
owned associate Dendritic Nanotechnologies, Inc. (“DNT”):
US Patents Granted 1.
The US Patent Office has issued a new patent relating to convergent
self-branching polymerization (US Pat 6632889 B1). DNT has an
exclusive worldwide royalty-free license to this technology, which
relates to novel techniques for production of low cost large dendritic
structures. The technology has applications for a wide range of
industrial products where cost of production has been a critical
development hurdle.
DNT also has royalty-free license rights to another patent recently
granted by the US Patent Office relating to core shell tecto dendrimers
(US Pat 6635720 B1). This patent covers the building of larger
nanotech structures using multiple dendrimer arrays. The intellectual
property covered by the patent allows the creation of large precisely
manufactured nanostructures with new properties. Applications are
very broad across medical, electronic, and chemical industries and
DNT is exploring opportunities to exploit the technology in each of
these fields.
DNT President and Chief Scientific Officer Dr Donald A. Tomalia is an
inventor on all of the above patents.
Additional US Army Grant Funding 2.
DNT continues to be very successful in attracting significant grant
funding. In 2002 DNT and Central Michigan University together
received a grant from the US Army for US$3.5 million to establish “The
Center for Dendrimer Based Nanotechnology”. These funds are being
applied to purchase state-of-the-art nanoscience equipment, attract key
nanoscience experts, and support several subcontracts. The original
grant has now been extended with an additional US$3.0 million, and
further to this continuing grants and contracts of at least this level are
anticipated until 2008.
DNT was also a successful applicant amongst strong competition to be a part
of the Institute for Soldier Nanotechnology (“ISN”). The ISN is a US$90
million consortium managed by Massachusetts Institute of Technology to
develop nanotechnology for the army of the future. DNT is one of seven
industrial charter members including DuPont, Raytheon, Dow Corning,
Nomadics, Carbon Nanotechnologies and Triton Systems. In addition to
validating DNT’s science, this program provides the company with access to
many leading scientists in synergistic technologies enhancing the ability to
address diverse technical opportunities. Participation in the ISN has also
significantly increased DNT’s profile as a key player in nanotechnology in the
US.
The level of US government and other international support for
nanotechnology, and DNT’s position in the nanotechnology industry, are
referred to in a series of articles highlighting nanobiotechnology in the October
2003 edition of Nature Biotechnology (Volume 21 Number 10).
Starpharma established DNT with the pioneer of dendrimer nanotechnology
Dr Donald Tomalia and now has a 49.9% equity interest in DNT together with
commercialization rights to pharmaceutical applications relating to DNT
dendrimer intellectual property.
Dr John Raff, the Chief Executive Officer of Starpharma, said “DNT is now
successfully established as a significant participant in the US nanotechnology
industry and has achieved this with minimal equity funding. DNT continues to
be a very important strategic partner and investment for Starpharma and we
are excited about its future prospects in both the short and medium term”.
Starpharma Pooled Development Limited (ASX:SPL) is a registered pooled development
fund with investments in wholly owned subsidiary biopharmaceutical companies focused on
the development and application of dendrimer nanotechnologies as drugs against major
diseases. Starpharma lead dendrimer product, VivaGel™ recently received clearance from
the US FDA for human clinical trials. VivaGel™ is a topical microbicide gel product that has
been developed for women as a preventative against the sexual transmission of HIV. It is
also active in animal studies for the prevention of other sexually transmitted diseases
including Genital Herpes and Chlamydia.
CONTACTS:
Company Secretary
+61 3 8532 2702
+61 3 8532 2701
Dr John Raff Mr Ben Rogers
Chief Executive Officer
www.starpharma.com
Starpharma hat gute Chancen auf den ersten Nanowirkstoff
Starpharma Pooled Development Ltd., nennt sich ein 1996 in Melbourne, Australien, gegründetes Unternehmen, dessen Spezialgebiet eine am Biomolecular Research Institute in Melbourne erforschte Technologie ist und für die das Unternehmen die weltweiten Exklusivrechte erworben hat.
Die Technologie, die durch eine Anzahl wichtiger Patente geschützt ist, umfasst eine Klasse hochmolekularer stark verzweigter chemischer Verbindungen, sogenannte Dendrimere, die aktiv gegenüber einer großen Anzahl von Viren sein sollen. Der Name Starpharma leitet sich übrigens von den sternförmigen Strukturen der Dendrimer-Moleküle ab, die die Basis für die in der Entwicklung befindlichen Wirkstoffe des Unternehmens sind.
Im Juli 2002 gründete Starpharma speziell zur Entwicklung von nanotechnologischen Anwendungen in den USA ein neues Tochterunternehmen. Dendritic Nanotechnologies wird von Donald Tomalia, einem Spezialisten auf dem Gebiet der Nanotechnologie geleitet und hat zur Entwicklung von VivaGel beigetragen. Das neuartige Vaginalgel auf Wasserbasis, das als aktive Komponente das Polylysin Dendrimer SPL7013 enthält, soll nun auf seine Wirksamkeit gegen HIV getestet werden.
Ebenfalls im Juli erst erhielt Starpharma für sein auf Nanopartikeln basierendes Gel zur HIV-Prävention die FDA-Genehmigung zur Durchführung eines Phase I Versuches. Damit ist das von Starpharma entwickelte VivaGel das erste!!! auf Nanopartikeln basierende Gel, das demnächst am Menschen getestet werden soll.
Die Wirkung von SPL7013 soll darauf beruhen, dass die Dendrimere die Bindung von HIV an Körperzellen blockieren und dadurch eine Infektion verhindern. Das Gel hat aber laut Starpharma gegenüber den üblichen physikalischen Barrieren den Vorteil, dass die Nanopartikel die Viren nicht nur am Eindringen in die Körperzellen hindern, sondern sie gleichzeitig auch zerstören.
Dendrimere sind synthetische Nanostrukturen, die so maßgeschneidert werden können, dass sie sich für pharmazeutische Anwendungen eignen. Mit speziellen chemischen Prozessen wird eine präzise Kontrolle der physikalischen und chemischen Eigenschaften der Dendrimere möglich. Die Dendrimere werden in einer Serie von kontrollierten Reaktionsschritten konstruiert, dabei ordnen sich viele kleine Moleküle um ein Zentralmolekül an. Vorstellen muss man sich so ein Dendrimer wie einen sehr stark verästelten Zweig. Im letzten Reaktionsschritt werden dann die verschiedenen aktiven Gruppen an das stark verzweigte Molekül angelagert. Das so entstehende Dendrimer verfügt dann auf seiner Oberfläche über eine Vielzahl möglicher Reaktionsstellen, die mit verschiedenen Rezeptoren auf der Oberfläche von Viren oder Bakterien in Wechselwirkung treten können.
In der Präklinik war die SPL7013 Nanostruktur nicht nur aktiv gegen HIV, sondern auch gegenüber Genitalherpes, Chlamydien, Hepatitis B, und Genitalwarzen, ausgelöst durch Papillomviren. In Primaten, die dem Affen-AIDS-Virus ausgesetzt wurden, konnte VivaGel die Infektion zu 100 Prozent verhindern. Eine HIV-Infektion erfolgt durch die Bindung des Proteins gp120 auf der Oberfläche des Virus an den CD4-Rezeptor auf der Zielzelle.
Die aktiven Gruppen im Dendrimer SPL7013 binden ihrerseits an gp120 und verhindern dadurch eine Interaktion des Virus mit gesunden Körperzellen, die den CD4-Rezeptor tragen. Umfassende toxikologische Studien in verschiedenen Versuchstieren sprachen zudem für die Sicherheit des neuartigen Gels. Gegenwärtig untersucht Starpharma das Sicherheitsprofil bei wiederholter Verabreichung in der dem Menschen ähnlichsten Affenart, dem Makaken.
Sollten die Phase I Versuche die präklinischen Daten bestätigen, wäre das von Starpharma entwickelte Produkt, auf Basis von Nanostrukturen, eine echte Sensation. Denn mit VivaGel ließe sich die Ausbreitung von Geschlechtskrankheiten, die bereits wieder auf dem Vormarsch sind, effektiv und viel unkomplizierter als mit mechanischen Barrieren eindämmen.
Vor allem die sich rasend verbreitende HPV-Infektion, die durch das humane Papillomvirus ausgelöst wird und sich durch Genitalwarzen bemerkbar macht, wird immer mehr zu einem Problem. Besonders problematisch ist die Tatsache, dass einige Typen von HPV das Risiko für Gebärmutterhalskrebs dramatisch ansteigen lassen. VivaGel wäre also die perfekte Prävention gegen Geschlechtskrankheiten aller Art. Sollte das Produkt bis zur Zulassung gelangen, würde es ein wohl bisher kaum abschätzbares Marktvolumen erwarten.
Eine Studien zum Thema BioNanotechnologie, einschließlich der Vorstellung von interessanten Unternehmen, finden Sie auch auf unserer Webseite unter www.Biotech-Experte.de.
Als Abonnent unseres Service erhalten sie alle einmal monatlich erscheinenden Studien sogar ohne zusätzliche Kosten.
Das Team von Biotech-Experte.de besitzt die erforderliche wissenschaftliche Expertise, die für ein erfolgreiches Investment im LifeScience Sektor unabdingbar ist. Wenn auch Sie von unserem Wissen profitieren wollen, zögern Sie nicht länger, sondern kontaktieren Sie uns noch heute. Unter www.Biotech-Experte.de erfahren Sie näheres zu unserem Service sowie zu unseren Expertisen
Starpharma Pooled Development Ltd., nennt sich ein 1996 in Melbourne, Australien, gegründetes Unternehmen, dessen Spezialgebiet eine am Biomolecular Research Institute in Melbourne erforschte Technologie ist und für die das Unternehmen die weltweiten Exklusivrechte erworben hat.
Die Technologie, die durch eine Anzahl wichtiger Patente geschützt ist, umfasst eine Klasse hochmolekularer stark verzweigter chemischer Verbindungen, sogenannte Dendrimere, die aktiv gegenüber einer großen Anzahl von Viren sein sollen. Der Name Starpharma leitet sich übrigens von den sternförmigen Strukturen der Dendrimer-Moleküle ab, die die Basis für die in der Entwicklung befindlichen Wirkstoffe des Unternehmens sind.
Im Juli 2002 gründete Starpharma speziell zur Entwicklung von nanotechnologischen Anwendungen in den USA ein neues Tochterunternehmen. Dendritic Nanotechnologies wird von Donald Tomalia, einem Spezialisten auf dem Gebiet der Nanotechnologie geleitet und hat zur Entwicklung von VivaGel beigetragen. Das neuartige Vaginalgel auf Wasserbasis, das als aktive Komponente das Polylysin Dendrimer SPL7013 enthält, soll nun auf seine Wirksamkeit gegen HIV getestet werden.
Ebenfalls im Juli erst erhielt Starpharma für sein auf Nanopartikeln basierendes Gel zur HIV-Prävention die FDA-Genehmigung zur Durchführung eines Phase I Versuches. Damit ist das von Starpharma entwickelte VivaGel das erste!!! auf Nanopartikeln basierende Gel, das demnächst am Menschen getestet werden soll.
Die Wirkung von SPL7013 soll darauf beruhen, dass die Dendrimere die Bindung von HIV an Körperzellen blockieren und dadurch eine Infektion verhindern. Das Gel hat aber laut Starpharma gegenüber den üblichen physikalischen Barrieren den Vorteil, dass die Nanopartikel die Viren nicht nur am Eindringen in die Körperzellen hindern, sondern sie gleichzeitig auch zerstören.
Dendrimere sind synthetische Nanostrukturen, die so maßgeschneidert werden können, dass sie sich für pharmazeutische Anwendungen eignen. Mit speziellen chemischen Prozessen wird eine präzise Kontrolle der physikalischen und chemischen Eigenschaften der Dendrimere möglich. Die Dendrimere werden in einer Serie von kontrollierten Reaktionsschritten konstruiert, dabei ordnen sich viele kleine Moleküle um ein Zentralmolekül an. Vorstellen muss man sich so ein Dendrimer wie einen sehr stark verästelten Zweig. Im letzten Reaktionsschritt werden dann die verschiedenen aktiven Gruppen an das stark verzweigte Molekül angelagert. Das so entstehende Dendrimer verfügt dann auf seiner Oberfläche über eine Vielzahl möglicher Reaktionsstellen, die mit verschiedenen Rezeptoren auf der Oberfläche von Viren oder Bakterien in Wechselwirkung treten können.
In der Präklinik war die SPL7013 Nanostruktur nicht nur aktiv gegen HIV, sondern auch gegenüber Genitalherpes, Chlamydien, Hepatitis B, und Genitalwarzen, ausgelöst durch Papillomviren. In Primaten, die dem Affen-AIDS-Virus ausgesetzt wurden, konnte VivaGel die Infektion zu 100 Prozent verhindern. Eine HIV-Infektion erfolgt durch die Bindung des Proteins gp120 auf der Oberfläche des Virus an den CD4-Rezeptor auf der Zielzelle.
Die aktiven Gruppen im Dendrimer SPL7013 binden ihrerseits an gp120 und verhindern dadurch eine Interaktion des Virus mit gesunden Körperzellen, die den CD4-Rezeptor tragen. Umfassende toxikologische Studien in verschiedenen Versuchstieren sprachen zudem für die Sicherheit des neuartigen Gels. Gegenwärtig untersucht Starpharma das Sicherheitsprofil bei wiederholter Verabreichung in der dem Menschen ähnlichsten Affenart, dem Makaken.
Sollten die Phase I Versuche die präklinischen Daten bestätigen, wäre das von Starpharma entwickelte Produkt, auf Basis von Nanostrukturen, eine echte Sensation. Denn mit VivaGel ließe sich die Ausbreitung von Geschlechtskrankheiten, die bereits wieder auf dem Vormarsch sind, effektiv und viel unkomplizierter als mit mechanischen Barrieren eindämmen.
Vor allem die sich rasend verbreitende HPV-Infektion, die durch das humane Papillomvirus ausgelöst wird und sich durch Genitalwarzen bemerkbar macht, wird immer mehr zu einem Problem. Besonders problematisch ist die Tatsache, dass einige Typen von HPV das Risiko für Gebärmutterhalskrebs dramatisch ansteigen lassen. VivaGel wäre also die perfekte Prävention gegen Geschlechtskrankheiten aller Art. Sollte das Produkt bis zur Zulassung gelangen, würde es ein wohl bisher kaum abschätzbares Marktvolumen erwarten.
Eine Studien zum Thema BioNanotechnologie, einschließlich der Vorstellung von interessanten Unternehmen, finden Sie auch auf unserer Webseite unter www.Biotech-Experte.de.
Als Abonnent unseres Service erhalten sie alle einmal monatlich erscheinenden Studien sogar ohne zusätzliche Kosten.
Das Team von Biotech-Experte.de besitzt die erforderliche wissenschaftliche Expertise, die für ein erfolgreiches Investment im LifeScience Sektor unabdingbar ist. Wenn auch Sie von unserem Wissen profitieren wollen, zögern Sie nicht länger, sondern kontaktieren Sie uns noch heute. Unter www.Biotech-Experte.de erfahren Sie näheres zu unserem Service sowie zu unseren Expertisen
Ende März ist die Riesen Nanotec Konferenz, CEO von DNT hält Eröffnungsrede, MIT und Raytheon usw. werden dort auch richtig Dampf machen, dabei ist natürlich auch riesig von der Dendrimer Technologie die Rede und den Leuten wird klar werden, dass Biotech eben nur ein kleiner Anwendungsbereich ist. Wenn die mit den ersten Ergebnissen aus Elektronik, Sicherheitstechnik, Materialtechnik, Lasertechnik rauskommen und dabei den Investoren klarwird, dass alle Patente und Verwertungen exklusive über Starpharma gehen fliegt denen der Deckel weg.
Im Grunde genommen hat sich Starpharma bereits alle führenden Köpfe der Nanotechnologie an Bord genommen (als Direktoren). Schaut euch mal auf Starpharma.com die Reports an, speziell Oktober bis Dezember 2003 und die Besetzung von DNT. Zumindest die Industrie und die entscheidenden Wissenschaftler scheinen der Meinung zu sein, das die Schlüsseltechnologie bei DNT liegt und damit ist klar, wohin der Zug geht. Ich sehe das Kursziel 1,50 bis 2 Euro bis Ende März fest.
Die Technologie, die durch eine Anzahl wichtiger Patente geschützt ist, umfasst eine Klasse hochmolekularer stark verzweigter chemischer Verbindungen, sogenannte Dendrimere, die aktiv gegenüber einer großen Anzahl von Viren sein sollen. Der Name Starpharma leitet sich übrigens von den sternförmigen Strukturen der Dendrimer-Moleküle ab, die die Basis für die in der Entwicklung befindlichen Wirkstoffe des Unternehmens sind.
Im Juli 2002 gründete Starpharma speziell zur Entwicklung von nanotechnologischen Anwendungen in den USA ein neues Tochterunternehmen. Dendritic Nanotechnologies wird von Donald Tomalia, einem Spezialisten auf dem Gebiet der Nanotechnologie geleitet und hat zur Entwicklung von VivaGel beigetragen. Das neuartige Vaginalgel auf Wasserbasis, das als aktive Komponente das Polylysin Dendrimer SPL7013 enthält, soll nun auf seine Wirksamkeit gegen HIV getestet werden.
Ebenfalls im Juli erst erhielt Starpharma für sein auf Nanopartikeln basierendes Gel zur HIV-Prävention die FDA-Genehmigung zur Durchführung eines Phase I Versuches. Damit ist das von Starpharma entwickelte VivaGel das erste!!! auf Nanopartikeln basierende Gel, das demnächst am Menschen getestet werden soll.
Die Wirkung von SPL7013 soll darauf beruhen, dass die Dendrimere die Bindung von HIV an Körperzellen blockieren und dadurch eine Infektion verhindern. Das Gel hat aber laut Starpharma gegenüber den üblichen physikalischen Barrieren den Vorteil, dass die Nanopartikel die Viren nicht nur am Eindringen in die Körperzellen hindern, sondern sie gleichzeitig auch zerstören.
Dendrimere sind synthetische Nanostrukturen, die so maßgeschneidert werden können, dass sie sich für pharmazeutische Anwendungen eignen. Mit speziellen chemischen Prozessen wird eine präzise Kontrolle der physikalischen und chemischen Eigenschaften der Dendrimere möglich. Die Dendrimere werden in einer Serie von kontrollierten Reaktionsschritten konstruiert, dabei ordnen sich viele kleine Moleküle um ein Zentralmolekül an. Vorstellen muss man sich so ein Dendrimer wie einen sehr stark verästelten Zweig. Im letzten Reaktionsschritt werden dann die verschiedenen aktiven Gruppen an das stark verzweigte Molekül angelagert. Das so entstehende Dendrimer verfügt dann auf seiner Oberfläche über eine Vielzahl möglicher Reaktionsstellen, die mit verschiedenen Rezeptoren auf der Oberfläche von Viren oder Bakterien in Wechselwirkung treten können.
In der Präklinik war die SPL7013 Nanostruktur nicht nur aktiv gegen HIV, sondern auch gegenüber Genitalherpes, Chlamydien, Hepatitis B, und Genitalwarzen, ausgelöst durch Papillomviren. In Primaten, die dem Affen-AIDS-Virus ausgesetzt wurden, konnte VivaGel die Infektion zu 100 Prozent verhindern. Eine HIV-Infektion erfolgt durch die Bindung des Proteins gp120 auf der Oberfläche des Virus an den CD4-Rezeptor auf der Zielzelle.
Die aktiven Gruppen im Dendrimer SPL7013 binden ihrerseits an gp120 und verhindern dadurch eine Interaktion des Virus mit gesunden Körperzellen, die den CD4-Rezeptor tragen. Umfassende toxikologische Studien in verschiedenen Versuchstieren sprachen zudem für die Sicherheit des neuartigen Gels. Gegenwärtig untersucht Starpharma das Sicherheitsprofil bei wiederholter Verabreichung in der dem Menschen ähnlichsten Affenart, dem Makaken.
Sollten die Phase I Versuche die präklinischen Daten bestätigen, wäre das von Starpharma entwickelte Produkt, auf Basis von Nanostrukturen, eine echte Sensation. Denn mit VivaGel ließe sich die Ausbreitung von Geschlechtskrankheiten, die bereits wieder auf dem Vormarsch sind, effektiv und viel unkomplizierter als mit mechanischen Barrieren eindämmen.
Vor allem die sich rasend verbreitende HPV-Infektion, die durch das humane Papillomvirus ausgelöst wird und sich durch Genitalwarzen bemerkbar macht, wird immer mehr zu einem Problem. Besonders problematisch ist die Tatsache, dass einige Typen von HPV das Risiko für Gebärmutterhalskrebs dramatisch ansteigen lassen. VivaGel wäre also die perfekte Prävention gegen Geschlechtskrankheiten aller Art. Sollte das Produkt bis zur Zulassung gelangen, würde es ein wohl bisher kaum abschätzbares Marktvolumen erwarten.
Eine Studien zum Thema BioNanotechnologie, einschließlich der Vorstellung von interessanten Unternehmen, finden Sie auch auf unserer Webseite unter www.Biotech-Experte.de.
Als Abonnent unseres Service erhalten sie alle einmal monatlich erscheinenden Studien sogar ohne zusätzliche Kosten.
Das Team von Biotech-Experte.de besitzt die erforderliche wissenschaftliche Expertise, die für ein erfolgreiches Investment im LifeScience Sektor unabdingbar ist. Wenn auch Sie von unserem Wissen profitieren wollen, zögern Sie nicht länger, sondern kontaktieren Sie uns noch heute. Unter www.Biotech-Experte.de erfahren Sie näheres zu unserem Service sowie zu unseren Expertisen
Im Grunde genommen hat sich Starpharma bereits alle führenden Köpfe der Nanotechnologie an Bord genommen (als Direktoren). Schaut euch mal auf Starpharma.com die Reports an, speziell Oktober bis Dezember 2003 und die Besetzung von DNT. Zumindest die Industrie und die entscheidenden Wissenschaftler scheinen der Meinung zu sein, das die Schlüsseltechnologie bei DNT liegt und damit ist klar, wohin der Zug geht. Ich sehe das Kursziel 1,50 bis 2 Euro bis Ende März fest.
Die Technologie, die durch eine Anzahl wichtiger Patente geschützt ist, umfasst eine Klasse hochmolekularer stark verzweigter chemischer Verbindungen, sogenannte Dendrimere, die aktiv gegenüber einer großen Anzahl von Viren sein sollen. Der Name Starpharma leitet sich übrigens von den sternförmigen Strukturen der Dendrimer-Moleküle ab, die die Basis für die in der Entwicklung befindlichen Wirkstoffe des Unternehmens sind.
Im Juli 2002 gründete Starpharma speziell zur Entwicklung von nanotechnologischen Anwendungen in den USA ein neues Tochterunternehmen. Dendritic Nanotechnologies wird von Donald Tomalia, einem Spezialisten auf dem Gebiet der Nanotechnologie geleitet und hat zur Entwicklung von VivaGel beigetragen. Das neuartige Vaginalgel auf Wasserbasis, das als aktive Komponente das Polylysin Dendrimer SPL7013 enthält, soll nun auf seine Wirksamkeit gegen HIV getestet werden.
Ebenfalls im Juli erst erhielt Starpharma für sein auf Nanopartikeln basierendes Gel zur HIV-Prävention die FDA-Genehmigung zur Durchführung eines Phase I Versuches. Damit ist das von Starpharma entwickelte VivaGel das erste!!! auf Nanopartikeln basierende Gel, das demnächst am Menschen getestet werden soll.
Die Wirkung von SPL7013 soll darauf beruhen, dass die Dendrimere die Bindung von HIV an Körperzellen blockieren und dadurch eine Infektion verhindern. Das Gel hat aber laut Starpharma gegenüber den üblichen physikalischen Barrieren den Vorteil, dass die Nanopartikel die Viren nicht nur am Eindringen in die Körperzellen hindern, sondern sie gleichzeitig auch zerstören.
Dendrimere sind synthetische Nanostrukturen, die so maßgeschneidert werden können, dass sie sich für pharmazeutische Anwendungen eignen. Mit speziellen chemischen Prozessen wird eine präzise Kontrolle der physikalischen und chemischen Eigenschaften der Dendrimere möglich. Die Dendrimere werden in einer Serie von kontrollierten Reaktionsschritten konstruiert, dabei ordnen sich viele kleine Moleküle um ein Zentralmolekül an. Vorstellen muss man sich so ein Dendrimer wie einen sehr stark verästelten Zweig. Im letzten Reaktionsschritt werden dann die verschiedenen aktiven Gruppen an das stark verzweigte Molekül angelagert. Das so entstehende Dendrimer verfügt dann auf seiner Oberfläche über eine Vielzahl möglicher Reaktionsstellen, die mit verschiedenen Rezeptoren auf der Oberfläche von Viren oder Bakterien in Wechselwirkung treten können.
In der Präklinik war die SPL7013 Nanostruktur nicht nur aktiv gegen HIV, sondern auch gegenüber Genitalherpes, Chlamydien, Hepatitis B, und Genitalwarzen, ausgelöst durch Papillomviren. In Primaten, die dem Affen-AIDS-Virus ausgesetzt wurden, konnte VivaGel die Infektion zu 100 Prozent verhindern. Eine HIV-Infektion erfolgt durch die Bindung des Proteins gp120 auf der Oberfläche des Virus an den CD4-Rezeptor auf der Zielzelle.
Die aktiven Gruppen im Dendrimer SPL7013 binden ihrerseits an gp120 und verhindern dadurch eine Interaktion des Virus mit gesunden Körperzellen, die den CD4-Rezeptor tragen. Umfassende toxikologische Studien in verschiedenen Versuchstieren sprachen zudem für die Sicherheit des neuartigen Gels. Gegenwärtig untersucht Starpharma das Sicherheitsprofil bei wiederholter Verabreichung in der dem Menschen ähnlichsten Affenart, dem Makaken.
Sollten die Phase I Versuche die präklinischen Daten bestätigen, wäre das von Starpharma entwickelte Produkt, auf Basis von Nanostrukturen, eine echte Sensation. Denn mit VivaGel ließe sich die Ausbreitung von Geschlechtskrankheiten, die bereits wieder auf dem Vormarsch sind, effektiv und viel unkomplizierter als mit mechanischen Barrieren eindämmen.
Vor allem die sich rasend verbreitende HPV-Infektion, die durch das humane Papillomvirus ausgelöst wird und sich durch Genitalwarzen bemerkbar macht, wird immer mehr zu einem Problem. Besonders problematisch ist die Tatsache, dass einige Typen von HPV das Risiko für Gebärmutterhalskrebs dramatisch ansteigen lassen. VivaGel wäre also die perfekte Prävention gegen Geschlechtskrankheiten aller Art. Sollte das Produkt bis zur Zulassung gelangen, würde es ein wohl bisher kaum abschätzbares Marktvolumen erwarten.
Eine Studien zum Thema BioNanotechnologie, einschließlich der Vorstellung von interessanten Unternehmen, finden Sie auch auf unserer Webseite unter www.Biotech-Experte.de.
Als Abonnent unseres Service erhalten sie alle einmal monatlich erscheinenden Studien sogar ohne zusätzliche Kosten.
Das Team von Biotech-Experte.de besitzt die erforderliche wissenschaftliche Expertise, die für ein erfolgreiches Investment im LifeScience Sektor unabdingbar ist. Wenn auch Sie von unserem Wissen profitieren wollen, zögern Sie nicht länger, sondern kontaktieren Sie uns noch heute. Unter www.Biotech-Experte.de erfahren Sie näheres zu unserem Service sowie zu unseren Expertisen
Starpharma Pooled Development Ltd., nennt sich ein 1996 in Melbourne, Australien, gegründetes Unternehmen, dessen Spezialgebiet eine am Biomolecular Research Institute in Melbourne erforschte Technologie ist und für die das Unternehmen die weltweiten Exklusivrechte erworben hat. Die Technologie, die durch eine Anzahl wichtiger Patente geschützt ist, umfasst eine Klasse hochmolekularer stark verzweigter chemischer Verbindungen, sogenannte Dendrimere, die aktiv gegenüber einer großen Anzahl von Viren und anderen bisher nur inadäquat behandelbaren Erkrankungen sein sollen. Der Name Starpharma leitet sich übrigens von den sternförmigen Strukturen der Dendrimer-Moleküle ab, die die Basis für die in der Entwicklung befindlichen Wirkstoffe des Unternehmens sind.
Auf zwei Programme konzentriert sich Starpharma gegenwärtig, diese sollen bis in die Phase II, also bis zur Ermittlung einer Wirksamkeit im Menschen, geführt werden und im Anschluss daran an ein großes Pharmaunternehmen lizenziert werden. Das „Vaginal Microbicide Program“, zur Prävention von Erkrankungen die durch Geschlechtsverkehr übertragen werden, und das “Angiogenesis Inhibitor Program”, zur möglichen Therapie von Krebserkrankungen, befinden sich gegenwärtig noch in der präklinischen Entwicklung. Allerdings hat Starpharma für das zur HIV-Prävention entwickelte Gel, VivaGel, das auf Nanopartikeln basiert, erst im Juli die FDA-Genehmigung zur Durchführung eines Phase I Versuches erhalten. Damit ist VivaGel das erste auf Nanopartikeln basierende Gel, das demnächst am Menschen getestet werden soll.
Im Juli 2002 gründete Starpharma speziell zur Entwicklung von nanotechnologischen Anwendungen in den USA ein neues Tochterunternehmen. Dendritic Nanotechnologies wird von Donald Tomalia, einem Spezialisten auf dem Gebiet der Nanotechnologie geleitet und hat zur Entwicklung von VivaGel beigetragen. Das neuartige Vaginalgel auf Wasserbasis, das als aktive Komponente das Polylysin Dendrimer SPL7013 enthält, soll zuerst auf seine Wirksamkeit gegen HIV getestet werden. Allerdings konnten präklinische Studien auch eine Aktivität des Gels gegenüber Chlamydien und Genital-Herpes zeigen.
Die Wirkung von SPL7013 soll darauf beruhen, dass die Dendrimere die Bindung von HIV an Körperzellen verhindern, wodurch keine Infektion zustande kommen kann. Das Gel hat aber laut Starpharma gegenüber den üblichen physikalischen Barrieren den Vorteil, dass die Nanopartikel die Viren nicht nur am Eindringen in die Körperzellen hindern, sondern sie gleichzeitig auch zerstören.
Dendrimere sind synthetische Nanostrukturen, die so maßgeschneidert werden können, dass sie sich für pharmazeutische Anwendungen eignen. Spezialisierte chemische Prozesse erlauben es, die physikalischen und chemischen Eigenschaften der Dendrimere präzise zu kontrollieren. Die Dendrimere werden in einer Serie von einzelnen kontrollierten Reaktionen konstruiert, dabei ordnet sich eine Vielzahl von kleinen Molekülen um ein Zentralmolekül an. Vorstellen muss man sich so ein Dendrimer wie einen sehr stark verästelten Zweig. Im letzten Reaktionsschritt werden dann die verschiedenen aktiven Gruppen an das stark verzweigte Molekül angelagert. Das so entstehende Dendrimer verfügt dann auf seiner Oberfläche über eine Vielzahl möglicher Reaktionsstellen, die mit verschiedenen Rezeptoren auf der Oberfläche von Viren oder Bakterien in Wechselwirkung treten können.
In der Präklinik war die SPL7013 Nanostruktur nicht nur aktiv gegen HIV, sondern auch gegenüber Genitalherpes, Chlamydien, Hepatitis B, und Genitalwarzen, ausgelöst durch Papillomviren. In Primaten, die dem Affen-AIDS-Virus ausgesetzt wurden, konnte VivaGel die Infektion zu 100 Prozent verhindern. Eine HIV-Infektion erfolgt durch die Bindung des Proteins gp120 auf der Oberfläche des Virus an den CD4-Rezeptor auf der Zielzelle. Die aktiven Gruppen im Dendrimer SPL7013 binden ihrerseits an gp120 und verhindern dadurch eine Interaktion des Virus mit gesunden Körperzellen, die den CD4-Rezeptor tragen. Umfassende toxikologische Studien in verschiedenen Versuchstieren sprechen zudem für die Sicherheit des neuartigen Gels. Gegenwärtig untersucht Starpharma das Sicherheitsprofil bei wiederholter Verabreichung in der dem Menschen ähnlichsten Affenart, dem Makaken.
Auf zwei Programme konzentriert sich Starpharma gegenwärtig, diese sollen bis in die Phase II, also bis zur Ermittlung einer Wirksamkeit im Menschen, geführt werden und im Anschluss daran an ein großes Pharmaunternehmen lizenziert werden. Das „Vaginal Microbicide Program“, zur Prävention von Erkrankungen die durch Geschlechtsverkehr übertragen werden, und das “Angiogenesis Inhibitor Program”, zur möglichen Therapie von Krebserkrankungen, befinden sich gegenwärtig noch in der präklinischen Entwicklung. Allerdings hat Starpharma für das zur HIV-Prävention entwickelte Gel, VivaGel, das auf Nanopartikeln basiert, erst im Juli die FDA-Genehmigung zur Durchführung eines Phase I Versuches erhalten. Damit ist VivaGel das erste auf Nanopartikeln basierende Gel, das demnächst am Menschen getestet werden soll.
Im Juli 2002 gründete Starpharma speziell zur Entwicklung von nanotechnologischen Anwendungen in den USA ein neues Tochterunternehmen. Dendritic Nanotechnologies wird von Donald Tomalia, einem Spezialisten auf dem Gebiet der Nanotechnologie geleitet und hat zur Entwicklung von VivaGel beigetragen. Das neuartige Vaginalgel auf Wasserbasis, das als aktive Komponente das Polylysin Dendrimer SPL7013 enthält, soll zuerst auf seine Wirksamkeit gegen HIV getestet werden. Allerdings konnten präklinische Studien auch eine Aktivität des Gels gegenüber Chlamydien und Genital-Herpes zeigen.
Die Wirkung von SPL7013 soll darauf beruhen, dass die Dendrimere die Bindung von HIV an Körperzellen verhindern, wodurch keine Infektion zustande kommen kann. Das Gel hat aber laut Starpharma gegenüber den üblichen physikalischen Barrieren den Vorteil, dass die Nanopartikel die Viren nicht nur am Eindringen in die Körperzellen hindern, sondern sie gleichzeitig auch zerstören.
Dendrimere sind synthetische Nanostrukturen, die so maßgeschneidert werden können, dass sie sich für pharmazeutische Anwendungen eignen. Spezialisierte chemische Prozesse erlauben es, die physikalischen und chemischen Eigenschaften der Dendrimere präzise zu kontrollieren. Die Dendrimere werden in einer Serie von einzelnen kontrollierten Reaktionen konstruiert, dabei ordnet sich eine Vielzahl von kleinen Molekülen um ein Zentralmolekül an. Vorstellen muss man sich so ein Dendrimer wie einen sehr stark verästelten Zweig. Im letzten Reaktionsschritt werden dann die verschiedenen aktiven Gruppen an das stark verzweigte Molekül angelagert. Das so entstehende Dendrimer verfügt dann auf seiner Oberfläche über eine Vielzahl möglicher Reaktionsstellen, die mit verschiedenen Rezeptoren auf der Oberfläche von Viren oder Bakterien in Wechselwirkung treten können.
In der Präklinik war die SPL7013 Nanostruktur nicht nur aktiv gegen HIV, sondern auch gegenüber Genitalherpes, Chlamydien, Hepatitis B, und Genitalwarzen, ausgelöst durch Papillomviren. In Primaten, die dem Affen-AIDS-Virus ausgesetzt wurden, konnte VivaGel die Infektion zu 100 Prozent verhindern. Eine HIV-Infektion erfolgt durch die Bindung des Proteins gp120 auf der Oberfläche des Virus an den CD4-Rezeptor auf der Zielzelle. Die aktiven Gruppen im Dendrimer SPL7013 binden ihrerseits an gp120 und verhindern dadurch eine Interaktion des Virus mit gesunden Körperzellen, die den CD4-Rezeptor tragen. Umfassende toxikologische Studien in verschiedenen Versuchstieren sprechen zudem für die Sicherheit des neuartigen Gels. Gegenwärtig untersucht Starpharma das Sicherheitsprofil bei wiederholter Verabreichung in der dem Menschen ähnlichsten Affenart, dem Makaken.
Hier Kurzinfo zu Dr. Tomalia, President of DNT
Dr. Tomalia, known as the " Father of Dendrimers," launched his academic / entrepreneurial ventures after a 25 year management and senior scientist career with The Dow Chemical Company. During that time, he was credited with numerous commercial developments which included Citrucel (now marketed by GlaxoSmithKline), cationic polymerization of 2-oxazolines and discovery of the fourth major class of macromolecular architecture; namely, " dendritic polymers." He is the inventor and originator of the term " dendrimers," and is listed on over 100 U.S. patents and more than 180 peer reviewed publications. Over 150 of these publications are focused on the dendrimer and dendritic polymer field, including a monograph entitled " Dendrimers and Other Dendritic Polymers" . Dr. Tomalia serves as the President and Chief Technology Officer of Dendritic Nanotechnologies, Inc. while he remains active in the academic community as Distinguished Visiting Professor (Columbia University), Distinguished Research Scientist/Professor (Central Michigan University), Co-Director of the National Center for Dendrimer Based Nanotechnology (Central Michigan University) and serves on the editorial advisory boards of Bioconjugate Chemistry and NanoLetters.
Dr. Tomalia, known as the " Father of Dendrimers," launched his academic / entrepreneurial ventures after a 25 year management and senior scientist career with The Dow Chemical Company. During that time, he was credited with numerous commercial developments which included Citrucel (now marketed by GlaxoSmithKline), cationic polymerization of 2-oxazolines and discovery of the fourth major class of macromolecular architecture; namely, " dendritic polymers." He is the inventor and originator of the term " dendrimers," and is listed on over 100 U.S. patents and more than 180 peer reviewed publications. Over 150 of these publications are focused on the dendrimer and dendritic polymer field, including a monograph entitled " Dendrimers and Other Dendritic Polymers" . Dr. Tomalia serves as the President and Chief Technology Officer of Dendritic Nanotechnologies, Inc. while he remains active in the academic community as Distinguished Visiting Professor (Columbia University), Distinguished Research Scientist/Professor (Central Michigan University), Co-Director of the National Center for Dendrimer Based Nanotechnology (Central Michigan University) and serves on the editorial advisory boards of Bioconjugate Chemistry and NanoLetters.
147
Wow, Cyber, da hast du dir ja echt ne Menge Arbeit gemacht und haufenweise facts zusammengetragen; 
Mal sehen, ob der SPL-Freundeskreis hier in Deutschland noch etwas größer wird..
An alle Interessierten hier noch der link zum Haupthread Thread: Starpharma: "Parkettgeflüster".. Sammelthread - wann kommen die 1. Kaufempfehlungen?, wo es auch immer einen aktuellen "Kurs- und Umrechnungservice" von der Heimatbörse Australien gibt.
Über asx.com.au oder stocknessmonster.com lassen sich im übrigen unter dem Kürzel SPL für jeden nachvollziehbar Kurse und News von Starpharma abfragen.
Interessant zum Beispiel auch, daß Starpharma als eines von 7 Nanotech-Unternehmen vom australischen Staat für die Weiterentwicklung seiner Präparate für die nächsten 4 Jahre mehrere Millionen Dollar zur Verfügung gestellt bekommen hat, an einem weiteren aussichtsreichen Start-Up-Unternehmen (Dimerix) zu 30% beteiligt ist, mit Dow Chemical Anfang des Jahres eine strategische Partnerschaft eingegangen ist, und und und...
Es lohnt sich, sich da an einem regnerischen Tag einfach mal durch die news der letzten Monate zu klicken...
Happy trading,
h.
Mal sehen, ob der SPL-Freundeskreis hier in Deutschland noch etwas größer wird..
An alle Interessierten hier noch der link zum Haupthread Thread: Starpharma: "Parkettgeflüster".. Sammelthread - wann kommen die 1. Kaufempfehlungen?, wo es auch immer einen aktuellen "Kurs- und Umrechnungservice" von der Heimatbörse Australien gibt.
Über asx.com.au oder stocknessmonster.com lassen sich im übrigen unter dem Kürzel SPL für jeden nachvollziehbar Kurse und News von Starpharma abfragen.
Interessant zum Beispiel auch, daß Starpharma als eines von 7 Nanotech-Unternehmen vom australischen Staat für die Weiterentwicklung seiner Präparate für die nächsten 4 Jahre mehrere Millionen Dollar zur Verfügung gestellt bekommen hat, an einem weiteren aussichtsreichen Start-Up-Unternehmen (Dimerix) zu 30% beteiligt ist, mit Dow Chemical Anfang des Jahres eine strategische Partnerschaft eingegangen ist, und und und...
Es lohnt sich, sich da an einem regnerischen Tag einfach mal durch die news der letzten Monate zu klicken...
Happy trading,
h.
Es wird wohl noch eine Weile dauern, alle News und Fakten zu Starpharma zusammenzutragen, deswegen hier gleich mal die neueste:
Friday, May 20, 2005
CMU SMARTZONE COMPANY’S BREAKTHROUGH PROCESS MAKES PRECISE DENDRIMERS AVAILABLE AT LOW COST
MEDIA CONTACT: Pat Lichtman, (989) 774-3197
CMU CONTACT: Nathan Long, (989) 774-1574
DNT CONTACT: Robert Berry, (989) 774-1799
Precise dendrimer nanostructures are available at low cost for commercial applications because of a breakthrough by a company at Central Michigan University.
Priostar™ dendrimers, created by Dendritic NanoTechnologies Inc. at CMU’s Center for Applied Research and Technology, may be used as nanoscale building blocks in the medical, food and agriculture, energy, electronics, environmental and industrial safety, personal, household, chemical, and manufacturing markets.
Dendrimers are sphere-shaped nanostructures that can be precisely engineered to carry molecules — either encapsulated in the interior or attached to the surface. The size and shape of a dendrimer is determined by shells, called generations, which are grown around the core structure. The reactivity of the dendrimer is determined by its surface chemical functionality together with size and shape. Until dendrimers reach a certain generation, other functions cannot be added to them.
Priostar™ dendrimers radically change the economics of nanotechnology and have broad commercial applications. They share and improve the physical properties of the original PAMAM dendrimers that were invented about 25 years ago by DNT president and chief technology officer Donald Tomalia while he was at The Dow Chemical Co.
To create a PAMAM Generation 3 dendrimer, it took eight steps and one month of processing time. Priostar™ Generation 3 dendrimers can be created in three steps and a few days.
“Our new dendrimer process vastly reduces the amount of labor and reagents normally required by our PAMAM process,” said Tomalia. “An exciting new feature of the Priostar™ family of dendrimers is the ability to add extenders or functionality to the interior of the dendrimer to customize interior spaces and reactivity.”
The Priostar™ dendrimers may be engineered in more than 50,000 variations of size, composition, surface function and interior nanocontainer space, said DNT CEO Robert Berry.
“Our new Priostar™ dendrimers place DNT in the enviable position of controlling a dominant nanoscale platform with many applications in multiple billion-dollar markets,” said Berry. “This new technology will establish a price point for an essential technology.”
DNT is located in one of Michigan’s premier SmartZones for technology development at CMU.
On May 17, CMU broke ground for a new wet lab facility to house the research activities of companies such as DNT, with laboratory facilities currently in CMU’s Dow Science Complex, and MultiGEN Diagnostic Inc., which specializes in developing new DNA-based technologies used for detection and diagnosis of microbes and biological threats. MultiGEN is currently housed in CMU’s Health Professions Building.
Research that can change the world is just what a university needs, said CMU President Michael Rao.
“We’re all amazed at the great opportunities to advance life through dendrimers,” said Rao. “The laboratory that will be built on this site has the power to change CMU, Mount Pleasant, mid-Michigan and even the state. It will provide research opportunities for faculty and students, be a critical faculty recruitment tool, and make a significant impact on economic development.”
Nanotechnology growth is expected to increase exponentially across manufactured goods in the next 10 years. In 2005 $13 billion worth of products will incorporate emerging nanotechnology, less than 1 percent of the global manufacturing output. That figure is expected to reach $2.6 trillion and 15 percent of manufacturing output in 2014.
Nature magazine recently named Mount Pleasant one of the country’s major “biotech hotspots.”
Friday, May 20, 2005
CMU SMARTZONE COMPANY’S BREAKTHROUGH PROCESS MAKES PRECISE DENDRIMERS AVAILABLE AT LOW COST
MEDIA CONTACT: Pat Lichtman, (989) 774-3197
CMU CONTACT: Nathan Long, (989) 774-1574
DNT CONTACT: Robert Berry, (989) 774-1799
Precise dendrimer nanostructures are available at low cost for commercial applications because of a breakthrough by a company at Central Michigan University.
Priostar™ dendrimers, created by Dendritic NanoTechnologies Inc. at CMU’s Center for Applied Research and Technology, may be used as nanoscale building blocks in the medical, food and agriculture, energy, electronics, environmental and industrial safety, personal, household, chemical, and manufacturing markets.
Dendrimers are sphere-shaped nanostructures that can be precisely engineered to carry molecules — either encapsulated in the interior or attached to the surface. The size and shape of a dendrimer is determined by shells, called generations, which are grown around the core structure. The reactivity of the dendrimer is determined by its surface chemical functionality together with size and shape. Until dendrimers reach a certain generation, other functions cannot be added to them.
Priostar™ dendrimers radically change the economics of nanotechnology and have broad commercial applications. They share and improve the physical properties of the original PAMAM dendrimers that were invented about 25 years ago by DNT president and chief technology officer Donald Tomalia while he was at The Dow Chemical Co.
To create a PAMAM Generation 3 dendrimer, it took eight steps and one month of processing time. Priostar™ Generation 3 dendrimers can be created in three steps and a few days.
“Our new dendrimer process vastly reduces the amount of labor and reagents normally required by our PAMAM process,” said Tomalia. “An exciting new feature of the Priostar™ family of dendrimers is the ability to add extenders or functionality to the interior of the dendrimer to customize interior spaces and reactivity.”
The Priostar™ dendrimers may be engineered in more than 50,000 variations of size, composition, surface function and interior nanocontainer space, said DNT CEO Robert Berry.
“Our new Priostar™ dendrimers place DNT in the enviable position of controlling a dominant nanoscale platform with many applications in multiple billion-dollar markets,” said Berry. “This new technology will establish a price point for an essential technology.”
DNT is located in one of Michigan’s premier SmartZones for technology development at CMU.
On May 17, CMU broke ground for a new wet lab facility to house the research activities of companies such as DNT, with laboratory facilities currently in CMU’s Dow Science Complex, and MultiGEN Diagnostic Inc., which specializes in developing new DNA-based technologies used for detection and diagnosis of microbes and biological threats. MultiGEN is currently housed in CMU’s Health Professions Building.
Research that can change the world is just what a university needs, said CMU President Michael Rao.
“We’re all amazed at the great opportunities to advance life through dendrimers,” said Rao. “The laboratory that will be built on this site has the power to change CMU, Mount Pleasant, mid-Michigan and even the state. It will provide research opportunities for faculty and students, be a critical faculty recruitment tool, and make a significant impact on economic development.”
Nanotechnology growth is expected to increase exponentially across manufactured goods in the next 10 years. In 2005 $13 billion worth of products will incorporate emerging nanotechnology, less than 1 percent of the global manufacturing output. That figure is expected to reach $2.6 trillion and 15 percent of manufacturing output in 2014.
Nature magazine recently named Mount Pleasant one of the country’s major “biotech hotspots.”
Dendritic NanoTechnologies Announces New Low-Cost Family of Precision Nanostructures
Wednesday May 18, 7:00 am ET
DNT`s Priostar Dendrimer Family Broadens Potential Applications of DNT`s Dendritic Nanotechnology to a Wide Range of Industries
MOUNT PLEASANT, Mich., May 18 /PRNewswire/ -- Dendritic NanoTechnologies Inc. (DNT), a technology company that develops advanced dendritic polymers used to produce commercial products, today announced a patent-pending development: a new family of scalable, precision dendrimer nanostructures. The new technology, developed by DNT, is called Priostar(TM) and offers a significant advantage over other precision nanostructures by reducing the complexity and duration of the synthesis process. The new Priostar family of scalable, precision dendrimers breaks through previous cost barriers and addresses industry needs for nanostructures that can be manufactured in high volumes at costs attractive for a wide variety of uses.
ADVERTISEMENT
" Our new Priostar dendrimers, as nanoscale building blocks, radically change the current economics of nanotechnology. They place DNT in the enviable position of controlling a dominant nanoscale platform with many applications in multiple billion-dollar markets," said Robert Berry, DNT`s chief executive officer. " This new technology is a potentially disruptive technology since it will establish a new price point for an essential technology. Furthermore, Priostar extends DNT`s patent estate while accelerating commercialization of our dendrimer technology."
Priostar dendrimers (" Prio" comes from the Greek for fast, while " star" represents the shape of the dendrimer) are unique in that they can be produced in large quantities to precise tolerances. For example, they can be engineered to meet the FDA`s rigid requirements for precision, scalability, and reproducibility needed for biomedical products, and yet can be produced in the larger quantities required for use in advanced materials, coatings, personal and household applications, and other commercial markets. The Priostar family of dendrimers promises to offer unique competitive advantages to DNT`s commercial business partners.
In a recent research report, " Sizing Nanotechnology`s Value Chain," leading nano-research firm Lux Research noted that: " Nanotechnology is approaching a phase change that will see it spread exponentially across manufactured goods in the next 10 years. In 2004, $13 billion worth of products will incorporate emerging nanotechnology, less than one-tenth of 1% of global manufacturing output. In 2014, we project that this figure will rise to $2.6 trillion -- 15% of manufacturing output in that year." (1)
Priostar Dendrimers Break New Ground in Time, Cost to Produce
The Priostar family of dendrimers share and improve upon the physical properties of the widely researched PAMAM dendrimers, which were invented by Dr. Donald Tomalia, DNT`s president and chief technology officer. Dendrimers are sphere-shaped nanostructures that can be precisely engineered to carry molecules -- either encapsulated in the interior or attached to the surface. The size and shape of a dendrimer are determined by shells (known as generations) grown around a core structure, while the reactivity of the dendrimer is determined by its surface chemical functionality together with size and shape. The ability to attach many different biological and chemical compounds to the surface or to encapsulate them within the interior of the dendrimer have made PAMAM dendrimers attractive to pharmaceutical, biotechnology and materials companies.
The traditional process for creating PAMAM dendrimers includes an amidation step that involves thermodynamically driven, lower reaction rate, chemistry, accompanied by long reaction times involving non-differentiated, difunctional intermediates (i.e. ethylene diamine and methyl acrylate). These process features require high excesses of reagents and high dilutions resulting in low production capacities per reactor volume and thus high costs, particularly at higher generations.
The Priostar family of dendrimers involves the use of faster, kinetically driven chemistry (e.g. " click type" or other fast reactions), combined with the use of polyfunctional branch cell reagents to rapidly and precisely build dendrimer structures in a controlled way, generation by generation. This present process yields precise structures with cleaner chemistry, requires lower excesses of reagents, and lower levels of dilution, thus offering a higher capacity method that is more easily scaled to commercial dimensions, and providing new ranges of materials at lower costs. Preliminary studies show a cost reduction of between two to three orders of magnitude.
The Priostar family of dendrimers is based on a proprietary production process that is both rapid and selective. This new process allows the introduction and control of six critical nanostructure design parameters that may be used to engineer over 50,000 different major variations of sizes, compositions, surface functionalities and interior nanocontainer spaces that are expected to offer new properties for use in a wide variety of commercial applications.
" Industry researchers are always looking for innovations and new technology to enhance their businesses," said Ryan Hayes, DNT`s director of development. " Such new technologies must be easy to manufacture, scale to large volumes, have unique properties that clearly establish a sustainable competitive advantage for them, and be inexpensive. The new DNT Priostar family of dendrimers meets these criteria. Many of our industry contacts have always been enthusiastic about the versatility of the dendrimer platform but, in the past, cost and manufacturing complexity were concerns."
New Process Takes Less Time and Adds Functionality
" It takes approximately eight steps and one month of processing time to create Generation 3 of a PAMAM generation. In contrast, Generation 3 of a Priostar dendrimer can be created in three steps and just a few days. Our new dendrimer process also vastly reduces the amount of labor and reagents normally required by the PAMAM process," said Dr. Donald Tomalia, DNT`s president and chief technology officer. " An exciting and new feature of the Priostar family of dendrimers is the ability to add extenders or functionality to the interior of the dendrimer to customize interior spaces and reactivity. These features give the Priostar dendrimers customizable encapsulation properties that allow for greater flexibility to tailor a solution for our customers."
According to Tomalia, the Priostar family of dendrimers captures all of the important PAMAM dendrimer properties and exhibits encapsulation properties in earlier generations, thus making it less expensive and easier to produce this highly desired feature. A new unique feature is the amplification process. Priostar dendrimers surface groups increase by a factor of three (3) for each succeeding generation (G1=12 surface groups, G2=36 surface groups, G3=108 surface groups). The PAMAM surface groups only increase by a factor of 2 for each succeeding generation (G1=8 surface groups, G2=16 surface groups, G3=32 surface groups). This unique amplification process allows rapid building of surface functionality and molecular weight, therefore obtaining container properties in fewer generations than for PAMAM. Since each generational addition adds significant costs due to increases in unit operations, the attainment of high molecular weights and surface functionality in fewer steps indicates significant cost reduction potential. In addition, Priostar dendrimers are more thermally stable (approximately 350 degrees C for Priostar versus 130 degrees C for PAMAM).
Target Markets and Availability
The Priostar family of dendrimers serves as a major nanostructure platform that will have broad commercial application. The Priostar family of dendrimers could have a significant impact on many markets including medical and health, food and agriculture, energy and electronics, environmental and industrial safety, personal and household, and chemicals and manufacturing. These dendrimers will find value in all these industries as they are used to develop new products and improve existing technologies for diagnostic imaging, drug delivery, gene therapy, surface coatings, sensors, catalysts, nanofabrication, solid state lighting, surfactants, binders, antimicrobials, lotions, cosmetics, pigments, dyes, ion exchange media, and ultrafiltration.
Initially, Priostar dendrimers will not be made available to the research community. However, DNT plans to establish a limited number of business partnerships for commercial research which could lead to direct commercialization.
About DNT
DENDRITIC NANOTECHNOLOGIES INC. (DNT) develops dendrimer structures that assist business partners in producing commercial products -- where dendrimers are the added value differentiator. DNT was incorporated in 2003, is a U.S. company with 19 employees, and is located in Mount Pleasant, Michigan. DNT`s technology development is directed by Donald A. Tomalia, Ph.D., President and Chief Technical Officer. Dr. Tomalia is the inventor of dendrimers and has led numerous commercial developments during a 25-year management and senior scientist career with The Dow Chemical Company.
Dendrimers are nanostructures with specific, precise and predictable physical properties that make them especially useful for pharmaceuticals, medical imaging, electronics, materials, and the mass commercial markets. DNT has a broad and comprehensive IP portfolio that comprises over 200 patents in 41 patent families-a unique level of IP concentration among nanotechnology companies-and has existing licensing agreements with established revenue streams for dendrimer technology. See http://www.dnanotech.com .
Starpharma (ASX: SPL - News) is an equity holder in DNT is focused on the development and application of dendrimer nanotechnologies as drugs against major diseases. Starpharma`s lead dendrimer product, VivaGel(TM) is currently in U.S. FDA Phase II human clinical trials. VivaGel is a topical microbicide gel product that has been developed for women as a preventative against the sexual transmission of HIV.
NOTE: Priostar is a trademark of Dendritic Nanotechnologies Inc. All other trademarks mentioned herein are held by their respective owners.
(1)" Sizing Nanotechnology`s Value Chain," October 2004, Lux Research Inc www.luxresearchinc.com
Wednesday May 18, 7:00 am ET
DNT`s Priostar Dendrimer Family Broadens Potential Applications of DNT`s Dendritic Nanotechnology to a Wide Range of Industries
MOUNT PLEASANT, Mich., May 18 /PRNewswire/ -- Dendritic NanoTechnologies Inc. (DNT), a technology company that develops advanced dendritic polymers used to produce commercial products, today announced a patent-pending development: a new family of scalable, precision dendrimer nanostructures. The new technology, developed by DNT, is called Priostar(TM) and offers a significant advantage over other precision nanostructures by reducing the complexity and duration of the synthesis process. The new Priostar family of scalable, precision dendrimers breaks through previous cost barriers and addresses industry needs for nanostructures that can be manufactured in high volumes at costs attractive for a wide variety of uses.
ADVERTISEMENT
" Our new Priostar dendrimers, as nanoscale building blocks, radically change the current economics of nanotechnology. They place DNT in the enviable position of controlling a dominant nanoscale platform with many applications in multiple billion-dollar markets," said Robert Berry, DNT`s chief executive officer. " This new technology is a potentially disruptive technology since it will establish a new price point for an essential technology. Furthermore, Priostar extends DNT`s patent estate while accelerating commercialization of our dendrimer technology."
Priostar dendrimers (" Prio" comes from the Greek for fast, while " star" represents the shape of the dendrimer) are unique in that they can be produced in large quantities to precise tolerances. For example, they can be engineered to meet the FDA`s rigid requirements for precision, scalability, and reproducibility needed for biomedical products, and yet can be produced in the larger quantities required for use in advanced materials, coatings, personal and household applications, and other commercial markets. The Priostar family of dendrimers promises to offer unique competitive advantages to DNT`s commercial business partners.
In a recent research report, " Sizing Nanotechnology`s Value Chain," leading nano-research firm Lux Research noted that: " Nanotechnology is approaching a phase change that will see it spread exponentially across manufactured goods in the next 10 years. In 2004, $13 billion worth of products will incorporate emerging nanotechnology, less than one-tenth of 1% of global manufacturing output. In 2014, we project that this figure will rise to $2.6 trillion -- 15% of manufacturing output in that year." (1)
Priostar Dendrimers Break New Ground in Time, Cost to Produce
The Priostar family of dendrimers share and improve upon the physical properties of the widely researched PAMAM dendrimers, which were invented by Dr. Donald Tomalia, DNT`s president and chief technology officer. Dendrimers are sphere-shaped nanostructures that can be precisely engineered to carry molecules -- either encapsulated in the interior or attached to the surface. The size and shape of a dendrimer are determined by shells (known as generations) grown around a core structure, while the reactivity of the dendrimer is determined by its surface chemical functionality together with size and shape. The ability to attach many different biological and chemical compounds to the surface or to encapsulate them within the interior of the dendrimer have made PAMAM dendrimers attractive to pharmaceutical, biotechnology and materials companies.
The traditional process for creating PAMAM dendrimers includes an amidation step that involves thermodynamically driven, lower reaction rate, chemistry, accompanied by long reaction times involving non-differentiated, difunctional intermediates (i.e. ethylene diamine and methyl acrylate). These process features require high excesses of reagents and high dilutions resulting in low production capacities per reactor volume and thus high costs, particularly at higher generations.
The Priostar family of dendrimers involves the use of faster, kinetically driven chemistry (e.g. " click type" or other fast reactions), combined with the use of polyfunctional branch cell reagents to rapidly and precisely build dendrimer structures in a controlled way, generation by generation. This present process yields precise structures with cleaner chemistry, requires lower excesses of reagents, and lower levels of dilution, thus offering a higher capacity method that is more easily scaled to commercial dimensions, and providing new ranges of materials at lower costs. Preliminary studies show a cost reduction of between two to three orders of magnitude.
The Priostar family of dendrimers is based on a proprietary production process that is both rapid and selective. This new process allows the introduction and control of six critical nanostructure design parameters that may be used to engineer over 50,000 different major variations of sizes, compositions, surface functionalities and interior nanocontainer spaces that are expected to offer new properties for use in a wide variety of commercial applications.
" Industry researchers are always looking for innovations and new technology to enhance their businesses," said Ryan Hayes, DNT`s director of development. " Such new technologies must be easy to manufacture, scale to large volumes, have unique properties that clearly establish a sustainable competitive advantage for them, and be inexpensive. The new DNT Priostar family of dendrimers meets these criteria. Many of our industry contacts have always been enthusiastic about the versatility of the dendrimer platform but, in the past, cost and manufacturing complexity were concerns."
New Process Takes Less Time and Adds Functionality
" It takes approximately eight steps and one month of processing time to create Generation 3 of a PAMAM generation. In contrast, Generation 3 of a Priostar dendrimer can be created in three steps and just a few days. Our new dendrimer process also vastly reduces the amount of labor and reagents normally required by the PAMAM process," said Dr. Donald Tomalia, DNT`s president and chief technology officer. " An exciting and new feature of the Priostar family of dendrimers is the ability to add extenders or functionality to the interior of the dendrimer to customize interior spaces and reactivity. These features give the Priostar dendrimers customizable encapsulation properties that allow for greater flexibility to tailor a solution for our customers."
According to Tomalia, the Priostar family of dendrimers captures all of the important PAMAM dendrimer properties and exhibits encapsulation properties in earlier generations, thus making it less expensive and easier to produce this highly desired feature. A new unique feature is the amplification process. Priostar dendrimers surface groups increase by a factor of three (3) for each succeeding generation (G1=12 surface groups, G2=36 surface groups, G3=108 surface groups). The PAMAM surface groups only increase by a factor of 2 for each succeeding generation (G1=8 surface groups, G2=16 surface groups, G3=32 surface groups). This unique amplification process allows rapid building of surface functionality and molecular weight, therefore obtaining container properties in fewer generations than for PAMAM. Since each generational addition adds significant costs due to increases in unit operations, the attainment of high molecular weights and surface functionality in fewer steps indicates significant cost reduction potential. In addition, Priostar dendrimers are more thermally stable (approximately 350 degrees C for Priostar versus 130 degrees C for PAMAM).
Target Markets and Availability
The Priostar family of dendrimers serves as a major nanostructure platform that will have broad commercial application. The Priostar family of dendrimers could have a significant impact on many markets including medical and health, food and agriculture, energy and electronics, environmental and industrial safety, personal and household, and chemicals and manufacturing. These dendrimers will find value in all these industries as they are used to develop new products and improve existing technologies for diagnostic imaging, drug delivery, gene therapy, surface coatings, sensors, catalysts, nanofabrication, solid state lighting, surfactants, binders, antimicrobials, lotions, cosmetics, pigments, dyes, ion exchange media, and ultrafiltration.
Initially, Priostar dendrimers will not be made available to the research community. However, DNT plans to establish a limited number of business partnerships for commercial research which could lead to direct commercialization.
About DNT
DENDRITIC NANOTECHNOLOGIES INC. (DNT) develops dendrimer structures that assist business partners in producing commercial products -- where dendrimers are the added value differentiator. DNT was incorporated in 2003, is a U.S. company with 19 employees, and is located in Mount Pleasant, Michigan. DNT`s technology development is directed by Donald A. Tomalia, Ph.D., President and Chief Technical Officer. Dr. Tomalia is the inventor of dendrimers and has led numerous commercial developments during a 25-year management and senior scientist career with The Dow Chemical Company.
Dendrimers are nanostructures with specific, precise and predictable physical properties that make them especially useful for pharmaceuticals, medical imaging, electronics, materials, and the mass commercial markets. DNT has a broad and comprehensive IP portfolio that comprises over 200 patents in 41 patent families-a unique level of IP concentration among nanotechnology companies-and has existing licensing agreements with established revenue streams for dendrimer technology. See http://www.dnanotech.com .
Starpharma (ASX: SPL - News) is an equity holder in DNT is focused on the development and application of dendrimer nanotechnologies as drugs against major diseases. Starpharma`s lead dendrimer product, VivaGel(TM) is currently in U.S. FDA Phase II human clinical trials. VivaGel is a topical microbicide gel product that has been developed for women as a preventative against the sexual transmission of HIV.
NOTE: Priostar is a trademark of Dendritic Nanotechnologies Inc. All other trademarks mentioned herein are held by their respective owners.
(1)" Sizing Nanotechnology`s Value Chain," October 2004, Lux Research Inc www.luxresearchinc.com
@cyberCoach
hab jetzt verstanden bezüglich "Gas geben". Schöner Thread.
Habe hier auch noch was von:Jack Uldrich
Tuesday, May 24, 2005
Dendritic NanoTechnologies: A Nanotech Rule Breaker
Last week, privately-held Dendritic NanoTechnologies Inc. (DNT) announced that it had developed a new family of scalable, precision dendrimer nanostructures. The technology is called Priostar ™ and it could radically change the economics of nanotechnology.
The news is not only important for the emerging nanotech industry, it is especially good news for Dow Chemical (NYSE: DOW) and Starpharma (Nasdaq: SPHRY) -- both of whom own 30% of DNT apiece. (Starpharma is now traded as an American Depository Receipt on the Nasdaq.)
Dendrimers are nanostructures that can be synthetically made with specific, precise and predictable properties. This “tailorability” implies a variety of commercial applications.
Over the past few years, 6000 research papers have written about dendrimers and there has been no shortage of ideas of how they might be employed. To date, however, applications have been limited to a handful of biotech and pharma uses. The limiting factor has been price. The previous top-of-the-line dendrimer took over 30 days to manufacture and cost about $2000 a gram.
Priostar dendrimers are so potentially disruptive because they can be made 2 or 3 days for about $10 a gram. As an added benefit, the new dendrimers are more thermally stable up to 350 Celsius. (The old ones were stable only to 130 Celsius).
The price reduction radically alters the economics of dendrimers and warrants DNT consideration as a possible rule breaker. This is because at $10 a gram, the list of uses for dendrimers suddenly mushrooms well beyond niche applications in the pharmaceutical arena to everything from water filtration to nutraceuticals.
To understand why these new applications become feasible, readers must understand that the branches of tiny devices can now be quickly and inexpensively tailored in such a way as to either hold or capture individual molecules. For instance, pharmaceutical firms could use the new dendrimers to deliver drug molecules to their exact intended destination or, alternatively, a new Priostar dendrimer could be produced to store a vast amount of hydrogen atoms -- thereby making fuel cell technology more economical.
Because the process is repeatable, scalable and precise, not only is FDA is likely to look favorably upon these new dendrimers so are a host of commercial users who can now expect to receive quality dendrimers in amounts suitable for industrial applications. Be it pharmaceuticals, coatings, batteries, catalysts or advanced materials, these new dendrimers have the prospect of adding a significant amount of value to a host of existing products as well as create a variety of new ones.
Lux Research, one of nanotech’s top research firms, recently predicted that nanotechnology will account for 15% of manufacturing output -- or $2.6. trillion -- by 2014. If this aggressive figure is achieved, these new dendrimers could be responsible for a large portion of that output.
Moving forward, investors are encouraged to put DNT on their radar screens. If the company’s technology is as good and as economical as it claims, there should be no shortage of companies knocking at its doors.
In the meantime, investors looking to make a play on this advance might consider an investment in either of the two publicly-traded stakeholders of DNT. Dow Chemical is definitely the more conservative approach as its 30% stake represents but a small fraction of its overall value. The more aggressive strategy is Starpharma. Its 30% stake in DNT represents a significantly greater portion of its overall value. Investors, however, must remember Starpharma is a tiny stock with a market cap of only $50 million and is subject to great volatility. Great caution is advised and limit orders are advisable. (Full Disclosure: I own stock in Starpharma).
posted by Jack Uldrich
hier der link:http://www.nanoveritas.com/nanonovus/index.html
P.S.: hoffe der Kurs bewegt sich nun wieder ein bischen mehr nach Norden. Ich stocke nochmals auf bei den Kursen.
Schönes sonniges WE
tomhead
hab jetzt verstanden bezüglich "Gas geben". Schöner Thread.
Habe hier auch noch was von:Jack Uldrich
Tuesday, May 24, 2005
Dendritic NanoTechnologies: A Nanotech Rule Breaker
Last week, privately-held Dendritic NanoTechnologies Inc. (DNT) announced that it had developed a new family of scalable, precision dendrimer nanostructures. The technology is called Priostar ™ and it could radically change the economics of nanotechnology.
The news is not only important for the emerging nanotech industry, it is especially good news for Dow Chemical (NYSE: DOW) and Starpharma (Nasdaq: SPHRY) -- both of whom own 30% of DNT apiece. (Starpharma is now traded as an American Depository Receipt on the Nasdaq.)
Dendrimers are nanostructures that can be synthetically made with specific, precise and predictable properties. This “tailorability” implies a variety of commercial applications.
Over the past few years, 6000 research papers have written about dendrimers and there has been no shortage of ideas of how they might be employed. To date, however, applications have been limited to a handful of biotech and pharma uses. The limiting factor has been price. The previous top-of-the-line dendrimer took over 30 days to manufacture and cost about $2000 a gram.
Priostar dendrimers are so potentially disruptive because they can be made 2 or 3 days for about $10 a gram. As an added benefit, the new dendrimers are more thermally stable up to 350 Celsius. (The old ones were stable only to 130 Celsius).
The price reduction radically alters the economics of dendrimers and warrants DNT consideration as a possible rule breaker. This is because at $10 a gram, the list of uses for dendrimers suddenly mushrooms well beyond niche applications in the pharmaceutical arena to everything from water filtration to nutraceuticals.
To understand why these new applications become feasible, readers must understand that the branches of tiny devices can now be quickly and inexpensively tailored in such a way as to either hold or capture individual molecules. For instance, pharmaceutical firms could use the new dendrimers to deliver drug molecules to their exact intended destination or, alternatively, a new Priostar dendrimer could be produced to store a vast amount of hydrogen atoms -- thereby making fuel cell technology more economical.
Because the process is repeatable, scalable and precise, not only is FDA is likely to look favorably upon these new dendrimers so are a host of commercial users who can now expect to receive quality dendrimers in amounts suitable for industrial applications. Be it pharmaceuticals, coatings, batteries, catalysts or advanced materials, these new dendrimers have the prospect of adding a significant amount of value to a host of existing products as well as create a variety of new ones.
Lux Research, one of nanotech’s top research firms, recently predicted that nanotechnology will account for 15% of manufacturing output -- or $2.6. trillion -- by 2014. If this aggressive figure is achieved, these new dendrimers could be responsible for a large portion of that output.
Moving forward, investors are encouraged to put DNT on their radar screens. If the company’s technology is as good and as economical as it claims, there should be no shortage of companies knocking at its doors.
In the meantime, investors looking to make a play on this advance might consider an investment in either of the two publicly-traded stakeholders of DNT. Dow Chemical is definitely the more conservative approach as its 30% stake represents but a small fraction of its overall value. The more aggressive strategy is Starpharma. Its 30% stake in DNT represents a significantly greater portion of its overall value. Investors, however, must remember Starpharma is a tiny stock with a market cap of only $50 million and is subject to great volatility. Great caution is advised and limit orders are advisable. (Full Disclosure: I own stock in Starpharma).
posted by Jack Uldrich
hier der link:http://www.nanoveritas.com/nanonovus/index.html
P.S.: hoffe der Kurs bewegt sich nun wieder ein bischen mehr nach Norden. Ich stocke nochmals auf bei den Kursen.
Schönes sonniges WE
tomhead
Source: Central Michigan University Released: Fri 03-Jun-2005, 10:20 ET
Printer-friendly Version
Low-Cost Dendrimers Revolutionize Industry
Libraries
Science News Keywords
DENDRIMER, NANOTECHNOLOGY, NANOSTRUCTURES, PAMAM, PRIOSTAR,
Contact Information
Available for logged-in reporters only
Description
Dendritic NanoTechnologies Inc. at Central Michigan University makes precise denrimers that can be engineered for function and interior nanocontainer space available at low cost.
Newswise — Precise dendrimer nanostructures are available at low cost for commercial applications because of a breakthrough by a company at Central Michigan University.
Priostar™ dendrimers, created by Dendritic NanoTechnologies Inc. at CMU’s Center for Applied Research and Technology, may be used as nanoscale building blocks in the medical, food and agriculture, energy, electronics, environmental and industrial safety, personal, household, chemical, and manufacturing markets.
Dendrimers are sphere-shaped nanostructures that can be precisely engineered to carry molecules — either encapsulated in the interior or attached to the surface. The size and shape of a dendrimer is determined by shells, called generations, which are grown around the core structure. The reactivity of the dendrimer is determined by its surface chemical functionality together with size and shape. Until dendrimers reach a certain generation, other functions cannot be added to them.
Priostar™ dendrimers radically change the economics of nanotechnology and have broad commercial applications. They share and improve the physical properties of the original PAMAM dendrimers that were invented about 25 years ago by DNT president and chief technology officer Donald Tomalia while he was at The Dow Chemical Co.
To create a PAMAM Generation 3 dendrimer, it took eight steps and one month of processing time. Priostar™ Generation 3 dendrimers can be created in three steps and a few days.
“Our new dendrimer process vastly reduces the amount of labor and reagents normally required by our PAMAM process,” said Tomalia. “An exciting new feature of the Priostar™ family of dendrimers is the ability to add extenders or functionality to the interior of the dendrimer to customize interior spaces and reactivity.”
The Priostar™ dendrimers may be engineered in more than 50,000 variations of size, composition, surface function and interior nanocontainer space, said DNT CEO Robert Berry.
“Our new Priostar™ dendrimers place DNT in the enviable position of controlling a dominant nanoscale platform with many applications in multiple billion-dollar markets,” said Berry. “This new technology will establish a price point for an essential technology.”
DNT is located in one of Michigan’s premier SmartZones for technology development at CMU.
On May 17, CMU broke ground for a new wet lab facility to house the research activities of companies such as DNT, with laboratory facilities currently in CMU’s Dow Science Complex, and MultiGEN Diagnostic Inc., which specializes in developing new DNA-based technologies used for detection and diagnosis of microbes and biological threats. MultiGEN is currently housed in CMU’s Health Professions Building.
Research that can change the world is just what a university needs, said CMU President Michael Rao.
“We’re all amazed at the great opportunities to advance life through dendrimers,” said Rao. “The laboratory that will be built on this site has the power to change CMU, Mount Pleasant, mid-Michigan and even the state. It will provide research opportunities for faculty and students, be a critical faculty recruitment tool, and make a significant impact on economic development.”
Nanotechnology growth is expected to increase exponentially across manufactured goods in the next 10 years. In 2005 $13 billion worth of products will incorporate emerging nanotechnology, less than 1 percent of the global manufacturing output. That figure is expected to reach $2.6 trillion and 15 percent of manufacturing output in 2014.
Nature magazine recently named Mount Pleasant one of the country’s major “biotech hotspots.”
© 2005 Newswise. All Rights Reserved.
Printer-friendly Version
Low-Cost Dendrimers Revolutionize Industry
Libraries
Science News Keywords
DENDRIMER, NANOTECHNOLOGY, NANOSTRUCTURES, PAMAM, PRIOSTAR,
Contact Information
Available for logged-in reporters only
Description
Dendritic NanoTechnologies Inc. at Central Michigan University makes precise denrimers that can be engineered for function and interior nanocontainer space available at low cost.
Newswise — Precise dendrimer nanostructures are available at low cost for commercial applications because of a breakthrough by a company at Central Michigan University.
Priostar™ dendrimers, created by Dendritic NanoTechnologies Inc. at CMU’s Center for Applied Research and Technology, may be used as nanoscale building blocks in the medical, food and agriculture, energy, electronics, environmental and industrial safety, personal, household, chemical, and manufacturing markets.
Dendrimers are sphere-shaped nanostructures that can be precisely engineered to carry molecules — either encapsulated in the interior or attached to the surface. The size and shape of a dendrimer is determined by shells, called generations, which are grown around the core structure. The reactivity of the dendrimer is determined by its surface chemical functionality together with size and shape. Until dendrimers reach a certain generation, other functions cannot be added to them.
Priostar™ dendrimers radically change the economics of nanotechnology and have broad commercial applications. They share and improve the physical properties of the original PAMAM dendrimers that were invented about 25 years ago by DNT president and chief technology officer Donald Tomalia while he was at The Dow Chemical Co.
To create a PAMAM Generation 3 dendrimer, it took eight steps and one month of processing time. Priostar™ Generation 3 dendrimers can be created in three steps and a few days.
“Our new dendrimer process vastly reduces the amount of labor and reagents normally required by our PAMAM process,” said Tomalia. “An exciting new feature of the Priostar™ family of dendrimers is the ability to add extenders or functionality to the interior of the dendrimer to customize interior spaces and reactivity.”
The Priostar™ dendrimers may be engineered in more than 50,000 variations of size, composition, surface function and interior nanocontainer space, said DNT CEO Robert Berry.
“Our new Priostar™ dendrimers place DNT in the enviable position of controlling a dominant nanoscale platform with many applications in multiple billion-dollar markets,” said Berry. “This new technology will establish a price point for an essential technology.”
DNT is located in one of Michigan’s premier SmartZones for technology development at CMU.
On May 17, CMU broke ground for a new wet lab facility to house the research activities of companies such as DNT, with laboratory facilities currently in CMU’s Dow Science Complex, and MultiGEN Diagnostic Inc., which specializes in developing new DNA-based technologies used for detection and diagnosis of microbes and biological threats. MultiGEN is currently housed in CMU’s Health Professions Building.
Research that can change the world is just what a university needs, said CMU President Michael Rao.
“We’re all amazed at the great opportunities to advance life through dendrimers,” said Rao. “The laboratory that will be built on this site has the power to change CMU, Mount Pleasant, mid-Michigan and even the state. It will provide research opportunities for faculty and students, be a critical faculty recruitment tool, and make a significant impact on economic development.”
Nanotechnology growth is expected to increase exponentially across manufactured goods in the next 10 years. In 2005 $13 billion worth of products will incorporate emerging nanotechnology, less than 1 percent of the global manufacturing output. That figure is expected to reach $2.6 trillion and 15 percent of manufacturing output in 2014.
Nature magazine recently named Mount Pleasant one of the country’s major “biotech hotspots.”
© 2005 Newswise. All Rights Reserved.
Hi,
hier wurde ja jede Menge Interessantes über DNT hereingestellt, (zu recht - die sind sehr!! interessant)
Starpharma ist doch aber, wie ich es verstehe, dort Kunde
und lässt forschen. Was ja nicht heißt, dass Starpharma
die "besitzen" würde. Insofern müßte man etwas auseinander-
halten, was man hier als Erfolgsmeldung für Starpharma einordnet - und was für DNT, (von denen es leider!! keine Aktien gibt).
Überlege jedenfalls, auch hier einzusteigen.
De Fakto steht doch wohl aber nur das Gel ins Haus (Phase 1) ??
oder wie isses?
Ferner habe ich die MK nicht mehr im Kopf, wer´s weiß...
......d7
hier wurde ja jede Menge Interessantes über DNT hereingestellt, (zu recht - die sind sehr!! interessant)
Starpharma ist doch aber, wie ich es verstehe, dort Kunde
und lässt forschen. Was ja nicht heißt, dass Starpharma
die "besitzen" würde. Insofern müßte man etwas auseinander-
halten, was man hier als Erfolgsmeldung für Starpharma einordnet - und was für DNT, (von denen es leider!! keine Aktien gibt).
Überlege jedenfalls, auch hier einzusteigen.
De Fakto steht doch wohl aber nur das Gel ins Haus (Phase 1) ??
oder wie isses?
Ferner habe ich die MK nicht mehr im Kopf, wer´s weiß...
......d7
....oder sind sie Lizenznehmer?
Hallo Doktor, DNT ist ein Spin-Off von Starpharma und Dr. Thomalla. Heute ist Starpharma neben Dow Chemical Mehrheitseigner. Starpharma besitzt immer noch 30% der Aktien .
Danke
@cyber
fließen die Einnahmen von DNT ggf. dann auch zu 30% Starpharma zu ?
Außerdem hatte ich von denen keine Aktien
gefunden, als ich mal vor einiger Zeit suchte - egal....
Ich bin übrigens über DNT zu Starpharma gestoßen, da bei denen das Geld, welches
von Starpharma gezahlt wird, als Erfolgsmeldung verbucht wurde.
Wie sieht der Geldfluss in dieser "Beziehung" genau aus?
hab noch dies hier gefunden:
aus der Nano-World:
--Dendritic Nanotechnologies in Mount Pleasant, Mich., holds Dow Corning`s foundational patents for dendrimers -- tree-like branching molecules that scientists can customize precisely at the tips. This ability gives dendrimers extraordinary diversity of applications. Starpharma in Melbourne, Australia, is developing dendrimers as pharmaceuticals that can be readily tailored to treat specific diseases, tissues or organs.
Despite its partnership with Dow Corning, Dendritic remains small at 10 to 15 employees. It is funded by government and university grants, with no significant venture capital, Serrato said. "This company has chosen a path of slow, organic growth," he noted.
gruß..............d7
fließen die Einnahmen von DNT ggf. dann auch zu 30% Starpharma zu ?
Außerdem hatte ich von denen keine Aktien
gefunden, als ich mal vor einiger Zeit suchte - egal....
Ich bin übrigens über DNT zu Starpharma gestoßen, da bei denen das Geld, welches
von Starpharma gezahlt wird, als Erfolgsmeldung verbucht wurde.
Wie sieht der Geldfluss in dieser "Beziehung" genau aus?
hab noch dies hier gefunden:
aus der Nano-World:
--Dendritic Nanotechnologies in Mount Pleasant, Mich., holds Dow Corning`s foundational patents for dendrimers -- tree-like branching molecules that scientists can customize precisely at the tips. This ability gives dendrimers extraordinary diversity of applications. Starpharma in Melbourne, Australia, is developing dendrimers as pharmaceuticals that can be readily tailored to treat specific diseases, tissues or organs.
Despite its partnership with Dow Corning, Dendritic remains small at 10 to 15 employees. It is funded by government and university grants, with no significant venture capital, Serrato said. "This company has chosen a path of slow, organic growth," he noted.
gruß..............d7
dann noch dies:
"Melbourne, Australien (ots/PRNewswire) -
- Dow-Beteiligung katapultiert DNT und Starpharma an die Spitze
der Nanotechnologie-Entwicklung für die Pharma- und
Biotechnologie-Branche
Dendritic NanoTechnologies Inc. (DNT), The Dow Chemical Company
(NYSE: DOW) und Starpharma Holdings Limited (ASX: SPL, OTC: SPHRY)
aus Melbourne, Australien, haben ein Abkommen unterzeichnet,
demzufolge DNT und Starpharma Eigentümer des weltweit grössten
Patent-Portfolio im Bereich der Dendrimere werden, bzw. Zugang dazu
erhalten. Dadurch werden die Unternehmen zu den führenden Anbietern
marktorientierter Nanotechnologie mit kurzfristig zu erwartenden,
konkreten kommerziellen Anwendungen"
........d7
"Melbourne, Australien (ots/PRNewswire) -
- Dow-Beteiligung katapultiert DNT und Starpharma an die Spitze
der Nanotechnologie-Entwicklung für die Pharma- und
Biotechnologie-Branche
Dendritic NanoTechnologies Inc. (DNT), The Dow Chemical Company
(NYSE: DOW) und Starpharma Holdings Limited (ASX: SPL, OTC: SPHRY)
aus Melbourne, Australien, haben ein Abkommen unterzeichnet,
demzufolge DNT und Starpharma Eigentümer des weltweit grössten
Patent-Portfolio im Bereich der Dendrimere werden, bzw. Zugang dazu
erhalten. Dadurch werden die Unternehmen zu den führenden Anbietern
marktorientierter Nanotechnologie mit kurzfristig zu erwartenden,
konkreten kommerziellen Anwendungen"
........d7
Source: Central Michigan University Released: Fri 03-Jun-2005, 10:20 ET
Printer-friendly Version
Low-Cost Dendrimers Revolutionize Industry
Libraries
Science News Keywords
DENDRIMER, NANOTECHNOLOGY, NANOSTRUCTURES, PAMAM, PRIOSTAR,
Contact Information
Available for logged-in reporters only
Description
Dendritic NanoTechnologies Inc. at Central Michigan University makes precise denrimers that can be engineered for function and interior nanocontainer space available at low cost.
Newswise — Precise dendrimer nanostructures are available at low cost for commercial applications because of a breakthrough by a company at Central Michigan University.
Priostar™ dendrimers, created by Dendritic NanoTechnologies Inc. at CMU’s Center for Applied Research and Technology, may be used as nanoscale building blocks in the medical, food and agriculture, energy, electronics, environmental and industrial safety, personal, household, chemical, and manufacturing markets.
Dendrimers are sphere-shaped nanostructures that can be precisely engineered to carry molecules — either encapsulated in the interior or attached to the surface. The size and shape of a dendrimer is determined by shells, called generations, which are grown around the core structure. The reactivity of the dendrimer is determined by its surface chemical functionality together with size and shape. Until dendrimers reach a certain generation, other functions cannot be added to them.
Priostar™ dendrimers radically change the economics of nanotechnology and have broad commercial applications. They share and improve the physical properties of the original PAMAM dendrimers that were invented about 25 years ago by DNT president and chief technology officer Donald Tomalia while he was at The Dow Chemical Co.
To create a PAMAM Generation 3 dendrimer, it took eight steps and one month of processing time. Priostar™ Generation 3 dendrimers can be created in three steps and a few days.
“Our new dendrimer process vastly reduces the amount of labor and reagents normally required by our PAMAM process,” said Tomalia. “An exciting new feature of the Priostar™ family of dendrimers is the ability to add extenders or functionality to the interior of the dendrimer to customize interior spaces and reactivity.”
The Priostar™ dendrimers may be engineered in more than 50,000 variations of size, composition, surface function and interior nanocontainer space, said DNT CEO Robert Berry.
“Our new Priostar™ dendrimers place DNT in the enviable position of controlling a dominant nanoscale platform with many applications in multiple billion-dollar markets,” said Berry. “This new technology will establish a price point for an essential technology.”
DNT is located in one of Michigan’s premier SmartZones for technology development at CMU.
On May 17, CMU broke ground for a new wet lab facility to house the research activities of companies such as DNT, with laboratory facilities currently in CMU’s Dow Science Complex, and MultiGEN Diagnostic Inc., which specializes in developing new DNA-based technologies used for detection and diagnosis of microbes and biological threats. MultiGEN is currently housed in CMU’s Health Professions Building.
Research that can change the world is just what a university needs, said CMU President Michael Rao.
“We’re all amazed at the great opportunities to advance life through dendrimers,” said Rao. “The laboratory that will be built on this site has the power to change CMU, Mount Pleasant, mid-Michigan and even the state. It will provide research opportunities for faculty and students, be a critical faculty recruitment tool, and make a significant impact on economic development.”
Nanotechnology growth is expected to increase exponentially across manufactured goods in the next 10 years. In 2005 $13 billion worth of products will incorporate emerging nanotechnology, less than 1 percent of the global manufacturing output. That figure is expected to reach $2.6 trillion and 15 percent of manufacturing output in 2014.
Nature magazine recently named Mount Pleasant one of the country’s major “biotech hotspots.”
© 2005 Newswise. All Rights Reserved.
Printer-friendly Version
Low-Cost Dendrimers Revolutionize Industry
Libraries
Science News Keywords
DENDRIMER, NANOTECHNOLOGY, NANOSTRUCTURES, PAMAM, PRIOSTAR,
Contact Information
Available for logged-in reporters only
Description
Dendritic NanoTechnologies Inc. at Central Michigan University makes precise denrimers that can be engineered for function and interior nanocontainer space available at low cost.
Newswise — Precise dendrimer nanostructures are available at low cost for commercial applications because of a breakthrough by a company at Central Michigan University.
Priostar™ dendrimers, created by Dendritic NanoTechnologies Inc. at CMU’s Center for Applied Research and Technology, may be used as nanoscale building blocks in the medical, food and agriculture, energy, electronics, environmental and industrial safety, personal, household, chemical, and manufacturing markets.
Dendrimers are sphere-shaped nanostructures that can be precisely engineered to carry molecules — either encapsulated in the interior or attached to the surface. The size and shape of a dendrimer is determined by shells, called generations, which are grown around the core structure. The reactivity of the dendrimer is determined by its surface chemical functionality together with size and shape. Until dendrimers reach a certain generation, other functions cannot be added to them.
Priostar™ dendrimers radically change the economics of nanotechnology and have broad commercial applications. They share and improve the physical properties of the original PAMAM dendrimers that were invented about 25 years ago by DNT president and chief technology officer Donald Tomalia while he was at The Dow Chemical Co.
To create a PAMAM Generation 3 dendrimer, it took eight steps and one month of processing time. Priostar™ Generation 3 dendrimers can be created in three steps and a few days.
“Our new dendrimer process vastly reduces the amount of labor and reagents normally required by our PAMAM process,” said Tomalia. “An exciting new feature of the Priostar™ family of dendrimers is the ability to add extenders or functionality to the interior of the dendrimer to customize interior spaces and reactivity.”
The Priostar™ dendrimers may be engineered in more than 50,000 variations of size, composition, surface function and interior nanocontainer space, said DNT CEO Robert Berry.
“Our new Priostar™ dendrimers place DNT in the enviable position of controlling a dominant nanoscale platform with many applications in multiple billion-dollar markets,” said Berry. “This new technology will establish a price point for an essential technology.”
DNT is located in one of Michigan’s premier SmartZones for technology development at CMU.
On May 17, CMU broke ground for a new wet lab facility to house the research activities of companies such as DNT, with laboratory facilities currently in CMU’s Dow Science Complex, and MultiGEN Diagnostic Inc., which specializes in developing new DNA-based technologies used for detection and diagnosis of microbes and biological threats. MultiGEN is currently housed in CMU’s Health Professions Building.
Research that can change the world is just what a university needs, said CMU President Michael Rao.
“We’re all amazed at the great opportunities to advance life through dendrimers,” said Rao. “The laboratory that will be built on this site has the power to change CMU, Mount Pleasant, mid-Michigan and even the state. It will provide research opportunities for faculty and students, be a critical faculty recruitment tool, and make a significant impact on economic development.”
Nanotechnology growth is expected to increase exponentially across manufactured goods in the next 10 years. In 2005 $13 billion worth of products will incorporate emerging nanotechnology, less than 1 percent of the global manufacturing output. That figure is expected to reach $2.6 trillion and 15 percent of manufacturing output in 2014.
Nature magazine recently named Mount Pleasant one of the country’s major “biotech hotspots.”
© 2005 Newswise. All Rights Reserved.
ups......kein Datum, ------war vom Jan.
wie sieht also die finanzielle Aufteilung aus?
.........d7
wie sieht also die finanzielle Aufteilung aus?
.........d7
was hier im Fakt-Thread auch noch mal
schön wär, als Zusammenstellung:
1. aktuelle Aktienanzahl, incl. OS etc.
2. Cash-Burne-Rate
3. aktueller Cash-Bestand
gruß......d7
schön wär, als Zusammenstellung:
1. aktuelle Aktienanzahl, incl. OS etc.
2. Cash-Burne-Rate
3. aktueller Cash-Bestand
gruß......d7
von der DNT-HP:
"Under terms of the deal, Dow will assign its entire intellectual property portfolio and associated royalties in the field of dendrimers (196 patents comprising 41 patent families) to DNT in exchange for a significant equity stake in DNT. Starpharma, which already held a 42% interest in DNT, will make an additional cash equity investment in DNT in exchange for exclusive rights to DNT and former Dow intellectual property for polyvalent, dendrimer-based pharmaceutical applications.."
......also ein 42% Interest.
Mein Interesse steigt langsam!
der Chart schreit allerdings nicht unbedingt nach einem Einstieg.
Abwärtstrend bisher ungebrochen. Umsätze in D leider auch recht bescheiden.
Hatte Starpharma vor gut einem Jahr schon einmal auf der Watchlist.
Der jetzige Zeitpunkt scheint mir eigentlich aussichtsreicher.
Die Zahlen würde ich vorher aber schon gern noch abchecken (siehe #29)
wer hat sie parat?
gruß......d7
"Under terms of the deal, Dow will assign its entire intellectual property portfolio and associated royalties in the field of dendrimers (196 patents comprising 41 patent families) to DNT in exchange for a significant equity stake in DNT. Starpharma, which already held a 42% interest in DNT, will make an additional cash equity investment in DNT in exchange for exclusive rights to DNT and former Dow intellectual property for polyvalent, dendrimer-based pharmaceutical applications.."
......also ein 42% Interest.
Mein Interesse steigt langsam!
der Chart schreit allerdings nicht unbedingt nach einem Einstieg.
Abwärtstrend bisher ungebrochen. Umsätze in D leider auch recht bescheiden.
Hatte Starpharma vor gut einem Jahr schon einmal auf der Watchlist.
Der jetzige Zeitpunkt scheint mir eigentlich aussichtsreicher.
Die Zahlen würde ich vorher aber schon gern noch abchecken (siehe #29)
wer hat sie parat?
gruß......d7
Hallo doc,
hier die letzten Zahlen aus dem Quartalsbericht:
April 2005 15
Cash Resources & Capital StructureCash:•$10m in the bank•
Sufficient cash in the bank for more than two years operation, at current burn rate•Expenditure is on budgetCapital Structure:•
111,235,000 ordinary stock on issue (no listed options)•
ADR-I Program: 334,779 on issue (ratio 10:1)•
2,189 shareholders•
20% issued stock held by directors•
30-35% of issued stock held by Institutional Investors
Gruß, hooray
hier die letzten Zahlen aus dem Quartalsbericht:
April 2005 15
Cash Resources & Capital StructureCash:•$10m in the bank•
Sufficient cash in the bank for more than two years operation, at current burn rate•Expenditure is on budgetCapital Structure:•
111,235,000 ordinary stock on issue (no listed options)•
ADR-I Program: 334,779 on issue (ratio 10:1)•
2,189 shareholders•
20% issued stock held by directors•
30-35% of issued stock held by Institutional Investors
Gruß, hooray
Bei den Beteiligungen von SPL sind im letzten Quartalsbericht übrigens folgende Zahlen angegeben:
- Beteiligung an DNT 33%
- Beteiligung an Dimerix 30%
Gruß, h.
- Beteiligung an DNT 33%
- Beteiligung an Dimerix 30%
Gruß, h.
Die Rechnung sieht also folgendermaßen aus:
Shares gesamt (incl. ADRs, mit Faktor 10 multipliziert): 114.582.790
Bei einem derzeitigen Kurs von AUD 0,50 ergibt das eine Börsenkapitalisierung von von etwas mehr als 57 Mio AUD, entsprechend 36 Mio Euro.
Der Cashbestand von 10 Mio AUD ergibt bei 114.582.790 outstanding shares einen Wert von circa 0,087 AUD/share, umgerechnet etwa 0,055 Euro pro Aktie!
Schaut doch gar nicht so furchtbar übel aus, oder?
Gruß, h.
Shares gesamt (incl. ADRs, mit Faktor 10 multipliziert): 114.582.790
Bei einem derzeitigen Kurs von AUD 0,50 ergibt das eine Börsenkapitalisierung von von etwas mehr als 57 Mio AUD, entsprechend 36 Mio Euro.
Der Cashbestand von 10 Mio AUD ergibt bei 114.582.790 outstanding shares einen Wert von circa 0,087 AUD/share, umgerechnet etwa 0,055 Euro pro Aktie!
Schaut doch gar nicht so furchtbar übel aus, oder?
Gruß, h.
Danke Hooray.
Nein, so "furchtbar übel" sieht es nicht aus.
Trotzdem sehe ich die ersten Umsätze eigentlich
in weiterer Ferne (frühestens Ende 2006) und die
wirklich teuren Testphasen für das Gel kommen ja
auch erst noch.
oder sehe ich das falsch?
Langfristig aber bestimmt sehr interessant!
gruß........d7
Nein, so "furchtbar übel" sieht es nicht aus.
Trotzdem sehe ich die ersten Umsätze eigentlich
in weiterer Ferne (frühestens Ende 2006) und die
wirklich teuren Testphasen für das Gel kommen ja
auch erst noch.
oder sehe ich das falsch?
Langfristig aber bestimmt sehr interessant!
gruß........d7
zum 30.6.04 wurden ja, wenn ich es richtig sehe,
ca. 5,5Mio operativer Verlust bei 1,5 Revenues
eingefahren. Ist ganz schön happig, wenn auch nicht
ungewöhnlich für eine Firma in diesem Stadium der
Entwicklung. Das Fiskal-Jahr endet ja zum 30.6.
Weiß jemand, wann dann die Zahlen veröffentlicht werden?
...........d7
ca. 5,5Mio operativer Verlust bei 1,5 Revenues
eingefahren. Ist ganz schön happig, wenn auch nicht
ungewöhnlich für eine Firma in diesem Stadium der
Entwicklung. Das Fiskal-Jahr endet ja zum 30.6.
Weiß jemand, wann dann die Zahlen veröffentlicht werden?
...........d7
Hallo doc,
der letzte Quartalsbericht wurde am 4. April veröffentlicht, also schon kurz nach Ende des Quartals..
Natürlich ist das Ganze im Moment recht teuer, man sollte aber nicht übersehen, daß
- die Geschichte so erfolgversprechend ist, daß der australische Staat für weitere Forschungsvorhaben erst kürzlich eine Geldspritze von über 5 Millionen AUD beigesteuert hat
- Gewinne auch kurzfristig durch das anlaufende Patentgeschäft generiert werden können (ein Lizenzfachmann von Dow Chemical wurde erst kürzlich deswegen zu Starpharma abgestellt)
- die Technologie auch dadurch interessanter geworden ist, daß sie sich anscheinend jetzt um einiges kostengünstiger herstellen läßt (was wiederum auch für potenzielle Lizenznehmer interessant sein dürfte).
Daß man eine Aktie immer gerade am Tiefstpunkt erwischt, dürfte ohnehin eher die Ausnahme sein, oder?
Und da SPL für mich auch eher langfristig interessant ist, spielen ein paar Cent mehr oder weniger eigentlich kaum eine Rolle; deswegen hab ICH mich lieber jetzt schon entsprechend positioniert - der Aktie nachlaufen dürfen dann meinetwegen später andere..
Gruß, h.
der letzte Quartalsbericht wurde am 4. April veröffentlicht, also schon kurz nach Ende des Quartals..
Natürlich ist das Ganze im Moment recht teuer, man sollte aber nicht übersehen, daß
- die Geschichte so erfolgversprechend ist, daß der australische Staat für weitere Forschungsvorhaben erst kürzlich eine Geldspritze von über 5 Millionen AUD beigesteuert hat
- Gewinne auch kurzfristig durch das anlaufende Patentgeschäft generiert werden können (ein Lizenzfachmann von Dow Chemical wurde erst kürzlich deswegen zu Starpharma abgestellt)
- die Technologie auch dadurch interessanter geworden ist, daß sie sich anscheinend jetzt um einiges kostengünstiger herstellen läßt (was wiederum auch für potenzielle Lizenznehmer interessant sein dürfte).
Daß man eine Aktie immer gerade am Tiefstpunkt erwischt, dürfte ohnehin eher die Ausnahme sein, oder?
Und da SPL für mich auch eher langfristig interessant ist, spielen ein paar Cent mehr oder weniger eigentlich kaum eine Rolle; deswegen hab ICH mich lieber jetzt schon entsprechend positioniert - der Aktie nachlaufen dürfen dann meinetwegen später andere..
Gruß, h.
@hooray
wobei man bedenken muß, daß Starpharma trotzdem in den
letzten Monaten soweit runter gingen, daß annähernd 100%
Gewinn nötig wären, um einen entsprechenden Kurs,
(bei gleicher Nachrichtenlage zum Frühjahr), zu erreichen.
Von "ein paar Cent", mehr oder weniger zu sprechen, trifft
das Problem, hier den richtigen Einstieg zu wählen, also
nur unzureichend.
Gebe Dir aber andererseits auch recht, weil der Absturz
vieler AUS-Biotechs durch den Rückzug diverser Fonds
aus dem BIO-Tech-Sektor, zu (übertrieben) dramatisch
gefallenen Kursen geführt hat.
Der "Absturz" des Kurses in letzter Zeit, ist aber für mich
noch nicht wirklich aufgeklärt. Somit warte ich wohl eher
auf eine Bodenbildung.
Oder die "Riecher-Gier" siegt - mal sehen.
Ich liebäugele aber mit einer größeren Position und bin daher "positiv-skeptisch" gestimmt.
.................d7
wobei man bedenken muß, daß Starpharma trotzdem in den
letzten Monaten soweit runter gingen, daß annähernd 100%
Gewinn nötig wären, um einen entsprechenden Kurs,
(bei gleicher Nachrichtenlage zum Frühjahr), zu erreichen.
Von "ein paar Cent", mehr oder weniger zu sprechen, trifft
das Problem, hier den richtigen Einstieg zu wählen, also
nur unzureichend.
Gebe Dir aber andererseits auch recht, weil der Absturz
vieler AUS-Biotechs durch den Rückzug diverser Fonds
aus dem BIO-Tech-Sektor, zu (übertrieben) dramatisch
gefallenen Kursen geführt hat.
Der "Absturz" des Kurses in letzter Zeit, ist aber für mich
noch nicht wirklich aufgeklärt. Somit warte ich wohl eher
auf eine Bodenbildung.
Oder die "Riecher-Gier" siegt - mal sehen
. Ich liebäugele aber mit einer größeren Position und bin daher "positiv-skeptisch" gestimmt.
.................d7
Hallo zusammen, hallo doktor, willkommen an Bord!
Wenn ich das überhaupt so sagen darf, habe mich ja schon länger nicht mehr gemeldet. Ich denke Starpharma hat nach wie vor - trotz der auch für mich enttäuschenden Kursentwicklung (und ich bin Dank Neoes frühem Hinweis noch immer im plus) - als sehr aussichtsreiches Investment zu gelten. Vielleicht sogar gerade jetzt, da sich fundamental nichts zum Schlechteren gewand hat (zumindest wissen wir davon noch nichts), im Gegenteil, die wenigen News waren durchaus verheißungsvoll. Aber wer langfristig investiert ist, der schert sich sowieso nicht um den heutigen Kurs.
Gruß, greenhorn (der mal wieder Hallo sagen wollte)
Wenn ich das überhaupt so sagen darf, habe mich ja schon länger nicht mehr gemeldet. Ich denke Starpharma hat nach wie vor - trotz der auch für mich enttäuschenden Kursentwicklung (und ich bin Dank Neoes frühem Hinweis noch immer im plus) - als sehr aussichtsreiches Investment zu gelten. Vielleicht sogar gerade jetzt, da sich fundamental nichts zum Schlechteren gewand hat (zumindest wissen wir davon noch nichts), im Gegenteil, die wenigen News waren durchaus verheißungsvoll. Aber wer langfristig investiert ist, der schert sich sowieso nicht um den heutigen Kurs.
Gruß, greenhorn (der mal wieder Hallo sagen wollte)
Moin Leutz,
also, ich kann mir nicht vorstellen, daß wir fundamental noch sehr viel Luft nach unten haben - unter 0,50 AUD wird sie jedenfalls beobachtungsgemäß immer gleich wieder weggekauft..
Natürlich hätte ich mir auch einen anderen Kursverlauf in den letzten Monaten gewünscht, allerdings habe ich die Kursschwächen immer wieder zu Nachkäufen genutzt - so lange sich fundamental nichts zum negativen verändert hat, sehe ich keinen Grund für eine 50%-ige Abwertung zu den Januarkursen, als wir die Meldung von der strategischen Partnerschaft mit Dow bekommen haben..
Wie auch immer, schau`n mer mal...
Gruß, h.
also, ich kann mir nicht vorstellen, daß wir fundamental noch sehr viel Luft nach unten haben - unter 0,50 AUD wird sie jedenfalls beobachtungsgemäß immer gleich wieder weggekauft..
Natürlich hätte ich mir auch einen anderen Kursverlauf in den letzten Monaten gewünscht, allerdings habe ich die Kursschwächen immer wieder zu Nachkäufen genutzt - so lange sich fundamental nichts zum negativen verändert hat, sehe ich keinen Grund für eine 50%-ige Abwertung zu den Januarkursen, als wir die Meldung von der strategischen Partnerschaft mit Dow bekommen haben..
Wie auch immer, schau`n mer mal...
Gruß, h.
Kleiner Auszug aus der neuen DNT Seite:
Partnerships
Innovate - Collaborate - Succeed
At DNT, we strongly believe that our technology can serve as an enabler of innovations across a wide range of fields. Therefore, we encourage other companies to collaborate with us for innovative product development. Combining DNT’s technologies with other technologies can and has lead to innovative commercial breakthroughs. Our engagement methodologies are business friendly and we have a powerful intellectual portfolio from which to work. A few of the companies that have business and /or research agreements with DNT are:
* Dharmacon
* The Dow Chemical Company
* Precision Detectors
* The Army Research Laboratory
* MIT’s Institute for Soldier Nanotechnologies
* Central Michigan University
* Sigma-Aldrich
* Starpharma
* Pfizer
Partnerships
Innovate - Collaborate - Succeed
At DNT, we strongly believe that our technology can serve as an enabler of innovations across a wide range of fields. Therefore, we encourage other companies to collaborate with us for innovative product development. Combining DNT’s technologies with other technologies can and has lead to innovative commercial breakthroughs. Our engagement methodologies are business friendly and we have a powerful intellectual portfolio from which to work. A few of the companies that have business and /or research agreements with DNT are:
* Dharmacon
* The Dow Chemical Company
* Precision Detectors
* The Army Research Laboratory
* MIT’s Institute for Soldier Nanotechnologies
* Central Michigan University
* Sigma-Aldrich
* Starpharma
* Pfizer
Farewell and hail
When Amrad Corporation staff hit the turps in honour of departing chief Peter Smith, it was a case of "see you Monday" rather than "nice knowing you".
Smith, who quit in May after a boardroom upheaval, has finally served out his notice with the floundering drug developer.
But leaving the building is a different matter. He`s taken a job as CEO at Cerylid Biosciences - a non-listed entity that is part-owned by Amrad and shares its digs by the Yarra in Richmond.
Smith apparently joined the company in a temporary and part-time capacity to replace Jackie Fairley, who joined Starpharma this month as its chief operating officer.
Amrad directors have yet to announce Smith`s replacement.
When Amrad Corporation staff hit the turps in honour of departing chief Peter Smith, it was a case of "see you Monday" rather than "nice knowing you".
Smith, who quit in May after a boardroom upheaval, has finally served out his notice with the floundering drug developer.
But leaving the building is a different matter. He`s taken a job as CEO at Cerylid Biosciences - a non-listed entity that is part-owned by Amrad and shares its digs by the Yarra in Richmond.
Smith apparently joined the company in a temporary and part-time capacity to replace Jackie Fairley, who joined Starpharma this month as its chief operating officer.
Amrad directors have yet to announce Smith`s replacement.
Dendrimere im Einsatz gegen Tumore:
http://www.med.umich.edu/opm/newspage/2005/nanoparticles.htm
http://www.med.umich.edu/opm/newspage/2005/nanoparticles.htm
June 15, 2005
Nanoparticles transport cancer-killing drug into tumor cells to increase efficacy, lower drug toxicity in mice
U-M scientists use folic acid as bait to get methotrexate inside tumor cells
Contact information for:
JOURNALISTS & MEDIA
Information for:
PATIENTS, FAMILIES & HEALTH PROFESSIONALS
Radio news
Current UMHS Releases
Recent UMHS Releases
UMHS in the media
UM main campus news
Subscribe to online UMHS newsletter
ANN ARBOR, MI - University of Michigan scientists have created the nanotechnology equivalent of a Trojan horse to smuggle a powerful chemotherapeutic drug inside tumor cells – increasing the drug`s cancer-killing activity and reducing its toxic side effects.
nanoparticle
This simplified computer model of the U-M nanoparticle shows the dendrimer`s branching structure and how molecules and drugs are attached. Photo credit: Jolanta Kukowska-Latello, Michigan Nanotechnology Institute for Medicine and the Biological Sciences. (click on image for larger view)
Previous studies in cell cultures have suggested that attaching anticancer drugs to nanoparticles for targeted delivery to tumor cells could increase the therapeutic response. Now, U-M scientists have shown that this nanotechnology-based treatment is effective in living animals.
“This is the first study to demonstrate a nanoparticle-targeted drug actually leaving the bloodstream, being concentrated in cancer cells, and having a biological effect on the animal`s tumor,” says James R. Baker Jr., M.D., the Ruth Dow Doan Professor of Biologic Nanotechnology at the University of Michigan, who directed the study.
“We`re very optimistic that nanotechnology can markedly improve cancer therapy,” says Baker, who directs the Michigan Nanotechnology Institute for Medicine and the Biological Sciences. “Targeting drugs directly to cancer cells reduces the amount that gets to normal cells, increases the drug`s anti-cancer effect and reduces its toxicity. By improving the therapeutic index of cancer drugs, we hope to turn cancer into a chronic, manageable disease.”
Results of the study will be published in the June 15, 2005, issue of Cancer Research.
The drug delivery vehicle used by U-M scientists is a manmade polymer molecule called a dendrimer. Less than five nanometers in diameter, these dendrimers are small enough to slip through tiny openings in cell membranes. One nanometer equals one-billionth of a meter, which means it would take 100,000 nanometers lined up side-by-side to equal the diameter of a human hair.
Dendrimers have a tree-like structure with many branches where scientists can attach a variety of molecules, including drugs. In experiments reported in Cancer Research, U-M scientists attached methotrexate, a powerful anticancer drug, to branches of the dendrimer. On other branches, they attached fluorescent imaging agents and their secret ingredient – a vitamin called folic acid.
Folic acid, or folate, is an important vitamin required for the healthy functioning of all cells. But cancer cells, in particular, seem to need more than average amounts. To soak up as much folate as possible, some cancer cells display more docking sites called folate receptors on their cell membranes. By taking advantage of a cancer cell`s appetite for folate, U-M scientists are able to prevent the cells from developing resistance to chemotherapeutic drugs.
James Baker
James R. Baker Jr., M.D.
“It`s like a Trojan horse,” Baker explains. “Folate molecules on the nanoparticle bind to receptors on tumor cell membranes and the cell immediately internalizes it, because it thinks it`s getting the vitamin it needs. But while it`s bringing folate across the cell membrane, the cell also draws in the methotrexate that will poison it.”
In conventional chemotherapy, drugs like methotrexate must diffuse across a cell membrane to get inside cancer cells, according to Baker. It`s a slow process and requires a high concentration of drug in the extra-cellular fluid, which can damage normal cells and tissues.
When tested in laboratory mice that had received injections of human epithelial cancer cells, the nanoparticle-based therapy using folic acid and methotrexate was 10 times more effective at delaying tumor growth than the drug given alone. Nanoparticle treatment also proved to be far less toxic to mice in the study than the anticancer drug alone.
“In our longest trial, which lasted 99 days, 30 percent to 40 percent of the mice given the nanoparticle with methotrexate survived,” says Jolanta Kukowska-Latallo, Ph.D., a U-M research investigator and first author of the study. “All the mice receiving free methotrexate died – either from overgrowth of the tumor or from toxic effects of the drug.
“We saw statistically significant tumor growth reduction in all the mice given targeted nanoparticle therapy, as opposed to mice receiving either free methotrexate or the dendrimer alone,” adds Kukowska-Latallo. “Effectively, we achieved a 30-day tumor growth delay. Taking into account the length of a mouse`s life, that is significant. One month for a mouse is about three years for a person.”
Before they began to study the effects of targeted nanoparticle therapy on cancer, U-M scientists injected dendrimers with fluorescent tags into the bloodstream of laboratory mice to determine where they would be retained in the body. The results showed that the kidneys quickly filtered free nanoparticles from blood and eliminated them in urine. The researchers found no evidence that nanoparticles were able to leave the bloodstream and enter the brain. The nanoparticles did not appear to generate an immune response in mice in the study.
In future research, scientists at the Michigan Nanotechnology Institute will determine the maximum therapeutic dose, in research animals, of targeted nanotherapy with methotrexate, and complete other preliminary studies in preparation for the first human clinical trial, which Baker says is scheduled to begin within two years.
Researchers at the Michigan Nanotechnology Institute also are planning to explore the use of nanotechnology-based therapies using other chemotherapeutic drugs. “There are many cancer drugs that are very effective, but they can`t be used now, because they are too toxic,” Baker says. “If these drugs can be delivered with a targeted nanoparticle system, we may be able to overcome the toxicity problem and provide a broader range of therapeutic agents for people with cancer.”
By attaching different targeting molecules and different drugs to the nanoparticle, Baker believes scientists eventually will be able to develop effective therapies for many types of cancer, perhaps even personalized therapy for an individual`s specific cancer.
The research was funded by the National Cancer Institute. The University of Michigan has filed a patent application on targeted nanoparticle technology. A licensing agreement is currently being negotiated with Avidimer Therapeutics, a biopharmaceutical company in Ann Arbor , Mich. Baker holds a significant financial interest in the company.
Other U-M collaborators in the research study are Zhengyi Cao, M.D., and Shraddha S. Nigavekar, Ph.D., U-M research associates; Istvan J. Majoros, Ph.D., research investigator; and Thommey P. Thomas, Ph.D., assistant research professor. Additional collaborators who were formerly with the U-M are Lajos P. Balogh, Ph.D., Kimberly A. Candido, and Mohamed K. Khan, M.D.
Citation: Cancer Research 2005: 65 (12), June 15, 2005
Written by Sally Pobojewski
Nanoparticles transport cancer-killing drug into tumor cells to increase efficacy, lower drug toxicity in mice
U-M scientists use folic acid as bait to get methotrexate inside tumor cells
Contact information for:
JOURNALISTS & MEDIA
Information for:
PATIENTS, FAMILIES & HEALTH PROFESSIONALS
Radio news
Current UMHS Releases
Recent UMHS Releases
UMHS in the media
UM main campus news
Subscribe to online UMHS newsletter
ANN ARBOR, MI - University of Michigan scientists have created the nanotechnology equivalent of a Trojan horse to smuggle a powerful chemotherapeutic drug inside tumor cells – increasing the drug`s cancer-killing activity and reducing its toxic side effects.
nanoparticle
This simplified computer model of the U-M nanoparticle shows the dendrimer`s branching structure and how molecules and drugs are attached. Photo credit: Jolanta Kukowska-Latello, Michigan Nanotechnology Institute for Medicine and the Biological Sciences. (click on image for larger view)
Previous studies in cell cultures have suggested that attaching anticancer drugs to nanoparticles for targeted delivery to tumor cells could increase the therapeutic response. Now, U-M scientists have shown that this nanotechnology-based treatment is effective in living animals.
“This is the first study to demonstrate a nanoparticle-targeted drug actually leaving the bloodstream, being concentrated in cancer cells, and having a biological effect on the animal`s tumor,” says James R. Baker Jr., M.D., the Ruth Dow Doan Professor of Biologic Nanotechnology at the University of Michigan, who directed the study.
“We`re very optimistic that nanotechnology can markedly improve cancer therapy,” says Baker, who directs the Michigan Nanotechnology Institute for Medicine and the Biological Sciences. “Targeting drugs directly to cancer cells reduces the amount that gets to normal cells, increases the drug`s anti-cancer effect and reduces its toxicity. By improving the therapeutic index of cancer drugs, we hope to turn cancer into a chronic, manageable disease.”
Results of the study will be published in the June 15, 2005, issue of Cancer Research.
The drug delivery vehicle used by U-M scientists is a manmade polymer molecule called a dendrimer. Less than five nanometers in diameter, these dendrimers are small enough to slip through tiny openings in cell membranes. One nanometer equals one-billionth of a meter, which means it would take 100,000 nanometers lined up side-by-side to equal the diameter of a human hair.
Dendrimers have a tree-like structure with many branches where scientists can attach a variety of molecules, including drugs. In experiments reported in Cancer Research, U-M scientists attached methotrexate, a powerful anticancer drug, to branches of the dendrimer. On other branches, they attached fluorescent imaging agents and their secret ingredient – a vitamin called folic acid.
Folic acid, or folate, is an important vitamin required for the healthy functioning of all cells. But cancer cells, in particular, seem to need more than average amounts. To soak up as much folate as possible, some cancer cells display more docking sites called folate receptors on their cell membranes. By taking advantage of a cancer cell`s appetite for folate, U-M scientists are able to prevent the cells from developing resistance to chemotherapeutic drugs.
James Baker
James R. Baker Jr., M.D.
“It`s like a Trojan horse,” Baker explains. “Folate molecules on the nanoparticle bind to receptors on tumor cell membranes and the cell immediately internalizes it, because it thinks it`s getting the vitamin it needs. But while it`s bringing folate across the cell membrane, the cell also draws in the methotrexate that will poison it.”
In conventional chemotherapy, drugs like methotrexate must diffuse across a cell membrane to get inside cancer cells, according to Baker. It`s a slow process and requires a high concentration of drug in the extra-cellular fluid, which can damage normal cells and tissues.
When tested in laboratory mice that had received injections of human epithelial cancer cells, the nanoparticle-based therapy using folic acid and methotrexate was 10 times more effective at delaying tumor growth than the drug given alone. Nanoparticle treatment also proved to be far less toxic to mice in the study than the anticancer drug alone.
“In our longest trial, which lasted 99 days, 30 percent to 40 percent of the mice given the nanoparticle with methotrexate survived,” says Jolanta Kukowska-Latallo, Ph.D., a U-M research investigator and first author of the study. “All the mice receiving free methotrexate died – either from overgrowth of the tumor or from toxic effects of the drug.
“We saw statistically significant tumor growth reduction in all the mice given targeted nanoparticle therapy, as opposed to mice receiving either free methotrexate or the dendrimer alone,” adds Kukowska-Latallo. “Effectively, we achieved a 30-day tumor growth delay. Taking into account the length of a mouse`s life, that is significant. One month for a mouse is about three years for a person.”
Before they began to study the effects of targeted nanoparticle therapy on cancer, U-M scientists injected dendrimers with fluorescent tags into the bloodstream of laboratory mice to determine where they would be retained in the body. The results showed that the kidneys quickly filtered free nanoparticles from blood and eliminated them in urine. The researchers found no evidence that nanoparticles were able to leave the bloodstream and enter the brain. The nanoparticles did not appear to generate an immune response in mice in the study.
In future research, scientists at the Michigan Nanotechnology Institute will determine the maximum therapeutic dose, in research animals, of targeted nanotherapy with methotrexate, and complete other preliminary studies in preparation for the first human clinical trial, which Baker says is scheduled to begin within two years.
Researchers at the Michigan Nanotechnology Institute also are planning to explore the use of nanotechnology-based therapies using other chemotherapeutic drugs. “There are many cancer drugs that are very effective, but they can`t be used now, because they are too toxic,” Baker says. “If these drugs can be delivered with a targeted nanoparticle system, we may be able to overcome the toxicity problem and provide a broader range of therapeutic agents for people with cancer.”
By attaching different targeting molecules and different drugs to the nanoparticle, Baker believes scientists eventually will be able to develop effective therapies for many types of cancer, perhaps even personalized therapy for an individual`s specific cancer.
The research was funded by the National Cancer Institute. The University of Michigan has filed a patent application on targeted nanoparticle technology. A licensing agreement is currently being negotiated with Avidimer Therapeutics, a biopharmaceutical company in Ann Arbor , Mich. Baker holds a significant financial interest in the company.
Other U-M collaborators in the research study are Zhengyi Cao, M.D., and Shraddha S. Nigavekar, Ph.D., U-M research associates; Istvan J. Majoros, Ph.D., research investigator; and Thommey P. Thomas, Ph.D., assistant research professor. Additional collaborators who were formerly with the U-M are Lajos P. Balogh, Ph.D., Kimberly A. Candido, and Mohamed K. Khan, M.D.
Citation: Cancer Research 2005: 65 (12), June 15, 2005
Written by Sally Pobojewski
28 July 2005
QUARTERLY CASH FLOW REPORT
PERIOD ENDED 30 JUNE 2005
Attached is the Appendix 4C – Quarterly Cash Flow Report – for Starpharma
Holdings Ltd (ASX:SPL, USOTC:SPHRY) for the quarter ended 30 June 2005.
The cash flow results are in line with projections, with net operating cash outflows
of AUD$5.8million for the 12 month period. The Company made equity
investments totalling AUD$1.5million during the year - USD$1million
(AUD$1.3million) was invested in Dendritic NanoTechnologies, Inc (“DNT”, and
AUD$0.2million in Australian biotechnology company Dimerix Bioscience Pty Ltd.
Cash at the end of the year was AUD$8.2million.
Income for the year included AUD$1.8million received under a grant from the
National Institute of Allergy and Infectious Diseases (NIAID), part of the US
National Institutes of Health (NIH). This grant was awarded to Starpharma in
September 2004 for the development of a second generation microbicide for the
prevention of infection by HIV and other sexually transmitted diseases (STDs).
Starpharma continues to focus its activities on epidemic based diseases where
there is a significant unmet medical need and development programs are likely to
be well supported by external agencies thus providing access to additional
development capital - without dilution of Starpharma shareholders’ equity.
John W Raff
Chief Executive Officer
QUARTERLY CASH FLOW REPORT
PERIOD ENDED 30 JUNE 2005
Attached is the Appendix 4C – Quarterly Cash Flow Report – for Starpharma
Holdings Ltd (ASX:SPL, USOTC:SPHRY) for the quarter ended 30 June 2005.
The cash flow results are in line with projections, with net operating cash outflows
of AUD$5.8million for the 12 month period. The Company made equity
investments totalling AUD$1.5million during the year - USD$1million
(AUD$1.3million) was invested in Dendritic NanoTechnologies, Inc (“DNT”
, andAUD$0.2million in Australian biotechnology company Dimerix Bioscience Pty Ltd.
Cash at the end of the year was AUD$8.2million.
Income for the year included AUD$1.8million received under a grant from the
National Institute of Allergy and Infectious Diseases (NIAID), part of the US
National Institutes of Health (NIH). This grant was awarded to Starpharma in
September 2004 for the development of a second generation microbicide for the
prevention of infection by HIV and other sexually transmitted diseases (STDs).
Starpharma continues to focus its activities on epidemic based diseases where
there is a significant unmet medical need and development programs are likely to
be well supported by external agencies thus providing access to additional
development capital - without dilution of Starpharma shareholders’ equity.
John W Raff
Chief Executive Officer
von 04.08.05
Starpharma Honoured with the 2005 Frost & Sullivan Growth Strategy Leadership Award For Its Development of Revolutionary Products MELBOURNE, Australia, Thursday 4 August 2005: Starpharma Holdings Limited (ASX:SPL, USOTC:SPHRY), today announced that it has received the 2005 Frost & Sullivan Growth Strategy Leadership Award in recognition of the company’s development of VivaGel™ and other polyvalent dendrimer-based products relating to the world nanobiotechnology market. This Frost & Sullivan award is given each year to the company that has demonstrated an exceptional growth strategy within its industry. A detailed Award Description is attached. Dr John Raff, Starpharma’s Chief Executive Officer said: “Although we are very proud of the company’s achievements, this award has come as a surprise. We are delighted that Frost & Sullivan, a significant international market analysis group, has recognised Starpharma’s growth strategy leadership and achievements.”
Page 2 of 4
Award Description Frost & Sullivan Growth Strategy Leadership Award in the World Nanobiotechnology Market Award Description Research Methodology Measurement Criteria The Frost & Sullivan Award for Growth Strategy Leadership is given each year to the company that has demonstrated an exceptional growth strategy within its industry A recipient is chosen to receive the Growth Strategy Leadership Award based on specific criteria. Through primary and secondary research methods, all companies` market revenues are tracked and those exhibiting significant growth are noted for their strategy implementation. Revenues are then compared year to year to monitor growth patterns. When a company continues to show high growth rates, it is a candidate for the Frost & Sullivan Growth Strategy Leadership Award. This award is given to the company that has bolstered its position in the market during the base year, and whose strategy will have a lasting impact on the market. The award criteria are based on the following: • Technological innovation and leadership • Discovering new venues for an established product • Strategic mergers, acquisitions or joint ventures to penetrate new markets 2005 Frost & Sullivan Growth Strategy Leadership Award for Starpharma Holdings Limited Frost & Sullivan presents the 2005 Growth Strategy Leadership Award to Starpharma for the development of revolutionary products in a new market sector in the world nanobiotechnology market. The company has established a strong and highly consolidated market position through collaboration and licensing. This position is currently unrivalled by other market participants. Revolutionary Products in a New Market Sector Founded in 1996, Starpharma is headquartered in Melbourne, Australia. The company is leading the nanobiotechnology market in the area of dendrimers; multibranched polymers with high functional specificity due to their highly defined structures. Starpharma’s current product portfolio is focusing on the prevention of sexually transmitted infections (STIs) and systemic viral indications. The Most Developed Lead Product to Date The Starpharma lead product is VivaGel™, a topical polyvalent dendrimer-based vaginal microbicide gel for the prevention of HIV in women. This represents a significant area of unmet medical need. The product is currently in Phase I clinical trials and is currently the most advanced dendrimer-based therapeutic in development. SPL7013, the polylysine
Page 3 of 4
active ingredient of VivaGel™, has shown further effectiveness against a range of STIs, including chlamydia, genital herpes (HSV-2), hepatitis B virus and human papilloma virus. Pipeline Diversification Across a Range of Indications Starpharma is diversifying it’s growth strategy by developing a range of products in-house, which will then be available for licensing to pharmaceutical companies. To date, over 120 different dendrimers have been tested for their effectiveness against STIs. Additionally, Starpharma is diversifying it’s target indication spectrum by investigating the application of dendrimers to the oncology and respiratory sectors. Dendrimers are also being tested for their application in biodefence. They have potential for the remediation of terrorist attack using biological agents such as Ebola virus. The company is aiming to become a knowledge powerhouse in the dendrimer sector, a market which is set to expand rapidly when the first products reach the market and dendrimer manufacture becomes more cost effective. Strong Market Positioning Starpharma has consolidated its position through the establishment of collaborations and licensing agreements with industrial partners. The company is the largest (33%) stakeholder of Dendritic Nanotechnologies, Inc., (DNT) a manufacturer of dendrimers and a developer of dendrimer-based products in other fields of application. DNT is an important source of high quality and novel dendritic materials. Additionally, DNT has a powerful collaboration with the Dow Chemical Company, which has assigned 196 patents to DNT concerning dendrimer manufacture and development in a broad range of applications. Starpharma has exclusive license rights to the entire DNT IP portfolio for the field of ‘polyvalence’, the broadest within the industry and an indication of significant industry consolidation. Starpharma has established further research collaborations with over 35 academic and public institutions across the United States, Europe and Australasia. Starpharma has established supply chain collaborations, is investigating further potential applications of their lead products as well as investigating new sectors, and is developing a wide range of support to future third party partners. Based on these merits, Frost & Sullivan is proud to present Starpharma with the Growth Strategy Leadership Award for 2005. Background Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company`s industry expertise integrates growth consulting, growth partnership services and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community, by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics.
Page 4 of 4
Media Contact: Katja Feick Corporate Communications P: +44 (0) 20 7915 7856 F: +44 (0) 20 7730 3343 E: katja.feick@frost.com About Starpharma: Starpharma Holdings Limited (ASX:SPL, USOTC:SPHRY) is leading the world in nanomedicine. Its lead product in development is VivaGel™, a vaginal microbicide gel that has been developed for women as a preventative against the sexual transmission of HIV. It has also shown activity in animal studies for the prevention of other sexually transmitted infections including genital herpes. The Company has a broad range of opportunities arising from its innovations involving the discovery and development of pharmaceutical nanotechnology products using dendrimers and the multi-binding phenomenon of polyvalence. Development programs include multi-acting respiratory and anti-cancer applications. Starpharma also has equity interests in two companies: • Dendritic NanoTechnologies, Inc. (DNT) – established with the pioneer of dendrimer nanotechnology Dr Donald A. Tomalia and based in Michigan, USA. • Dimerix Biosciences Pty Ltd – a specialist drug development company established to commercialise unique technology developed at the Western Australian Institute for Medical Research in the new field of receptor coupling, specifically G-Protein coupled receptors (“GPCRs”). Microbicides: A microbicide inactivates, kills or destroys microbes. Microbicides may be formulated as gels, creams, sponges, suppositories or films with the purpose of reducing significantly the incidence of STDs. There are currently no vaginal microbicides on the market. They are intended for vaginal or rectal use to afford protection for varying periods, from several hours up to days. Microbicides may also be designed to have a contraceptive function by inhibiting sperm. Dendrimers: Dendrimers are a type of nanoparticle. They are man-made chemicals that form tiny balls made up of a dense network of branches. Dendrimers have applications in the medical, electronics, chemicals and materials industries. American Depositary Receipts (ADRs): Starpharma’s ADRs trade under the code SPHRY (CUSIP number 855563102). Each Starpharma ADR is equivalent to 10 ordinary shares of Starpharma as traded on the Australian Stock Exchange. The Bank of New York is the depositary bank. For further information:Media Rebecca Wilson Buchan 02 9237 2800 / 0417 382 391 rchristie@bcg.com.auDr John Raff Ben Rogers Chief Executive Officer Company Secretary +61 3 8532 2701 +61 3 8532 2702
tomhead
Starpharma Honoured with the 2005 Frost & Sullivan Growth Strategy Leadership Award For Its Development of Revolutionary Products MELBOURNE, Australia, Thursday 4 August 2005: Starpharma Holdings Limited (ASX:SPL, USOTC:SPHRY), today announced that it has received the 2005 Frost & Sullivan Growth Strategy Leadership Award in recognition of the company’s development of VivaGel™ and other polyvalent dendrimer-based products relating to the world nanobiotechnology market. This Frost & Sullivan award is given each year to the company that has demonstrated an exceptional growth strategy within its industry. A detailed Award Description is attached. Dr John Raff, Starpharma’s Chief Executive Officer said: “Although we are very proud of the company’s achievements, this award has come as a surprise. We are delighted that Frost & Sullivan, a significant international market analysis group, has recognised Starpharma’s growth strategy leadership and achievements.”
Page 2 of 4
Award Description Frost & Sullivan Growth Strategy Leadership Award in the World Nanobiotechnology Market Award Description Research Methodology Measurement Criteria The Frost & Sullivan Award for Growth Strategy Leadership is given each year to the company that has demonstrated an exceptional growth strategy within its industry A recipient is chosen to receive the Growth Strategy Leadership Award based on specific criteria. Through primary and secondary research methods, all companies` market revenues are tracked and those exhibiting significant growth are noted for their strategy implementation. Revenues are then compared year to year to monitor growth patterns. When a company continues to show high growth rates, it is a candidate for the Frost & Sullivan Growth Strategy Leadership Award. This award is given to the company that has bolstered its position in the market during the base year, and whose strategy will have a lasting impact on the market. The award criteria are based on the following: • Technological innovation and leadership • Discovering new venues for an established product • Strategic mergers, acquisitions or joint ventures to penetrate new markets 2005 Frost & Sullivan Growth Strategy Leadership Award for Starpharma Holdings Limited Frost & Sullivan presents the 2005 Growth Strategy Leadership Award to Starpharma for the development of revolutionary products in a new market sector in the world nanobiotechnology market. The company has established a strong and highly consolidated market position through collaboration and licensing. This position is currently unrivalled by other market participants. Revolutionary Products in a New Market Sector Founded in 1996, Starpharma is headquartered in Melbourne, Australia. The company is leading the nanobiotechnology market in the area of dendrimers; multibranched polymers with high functional specificity due to their highly defined structures. Starpharma’s current product portfolio is focusing on the prevention of sexually transmitted infections (STIs) and systemic viral indications. The Most Developed Lead Product to Date The Starpharma lead product is VivaGel™, a topical polyvalent dendrimer-based vaginal microbicide gel for the prevention of HIV in women. This represents a significant area of unmet medical need. The product is currently in Phase I clinical trials and is currently the most advanced dendrimer-based therapeutic in development. SPL7013, the polylysine
Page 3 of 4
active ingredient of VivaGel™, has shown further effectiveness against a range of STIs, including chlamydia, genital herpes (HSV-2), hepatitis B virus and human papilloma virus. Pipeline Diversification Across a Range of Indications Starpharma is diversifying it’s growth strategy by developing a range of products in-house, which will then be available for licensing to pharmaceutical companies. To date, over 120 different dendrimers have been tested for their effectiveness against STIs. Additionally, Starpharma is diversifying it’s target indication spectrum by investigating the application of dendrimers to the oncology and respiratory sectors. Dendrimers are also being tested for their application in biodefence. They have potential for the remediation of terrorist attack using biological agents such as Ebola virus. The company is aiming to become a knowledge powerhouse in the dendrimer sector, a market which is set to expand rapidly when the first products reach the market and dendrimer manufacture becomes more cost effective. Strong Market Positioning Starpharma has consolidated its position through the establishment of collaborations and licensing agreements with industrial partners. The company is the largest (33%) stakeholder of Dendritic Nanotechnologies, Inc., (DNT) a manufacturer of dendrimers and a developer of dendrimer-based products in other fields of application. DNT is an important source of high quality and novel dendritic materials. Additionally, DNT has a powerful collaboration with the Dow Chemical Company, which has assigned 196 patents to DNT concerning dendrimer manufacture and development in a broad range of applications. Starpharma has exclusive license rights to the entire DNT IP portfolio for the field of ‘polyvalence’, the broadest within the industry and an indication of significant industry consolidation. Starpharma has established further research collaborations with over 35 academic and public institutions across the United States, Europe and Australasia. Starpharma has established supply chain collaborations, is investigating further potential applications of their lead products as well as investigating new sectors, and is developing a wide range of support to future third party partners. Based on these merits, Frost & Sullivan is proud to present Starpharma with the Growth Strategy Leadership Award for 2005. Background Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company`s industry expertise integrates growth consulting, growth partnership services and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community, by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics.
Page 4 of 4
Media Contact: Katja Feick Corporate Communications P: +44 (0) 20 7915 7856 F: +44 (0) 20 7730 3343 E: katja.feick@frost.com About Starpharma: Starpharma Holdings Limited (ASX:SPL, USOTC:SPHRY) is leading the world in nanomedicine. Its lead product in development is VivaGel™, a vaginal microbicide gel that has been developed for women as a preventative against the sexual transmission of HIV. It has also shown activity in animal studies for the prevention of other sexually transmitted infections including genital herpes. The Company has a broad range of opportunities arising from its innovations involving the discovery and development of pharmaceutical nanotechnology products using dendrimers and the multi-binding phenomenon of polyvalence. Development programs include multi-acting respiratory and anti-cancer applications. Starpharma also has equity interests in two companies: • Dendritic NanoTechnologies, Inc. (DNT) – established with the pioneer of dendrimer nanotechnology Dr Donald A. Tomalia and based in Michigan, USA. • Dimerix Biosciences Pty Ltd – a specialist drug development company established to commercialise unique technology developed at the Western Australian Institute for Medical Research in the new field of receptor coupling, specifically G-Protein coupled receptors (“GPCRs”). Microbicides: A microbicide inactivates, kills or destroys microbes. Microbicides may be formulated as gels, creams, sponges, suppositories or films with the purpose of reducing significantly the incidence of STDs. There are currently no vaginal microbicides on the market. They are intended for vaginal or rectal use to afford protection for varying periods, from several hours up to days. Microbicides may also be designed to have a contraceptive function by inhibiting sperm. Dendrimers: Dendrimers are a type of nanoparticle. They are man-made chemicals that form tiny balls made up of a dense network of branches. Dendrimers have applications in the medical, electronics, chemicals and materials industries. American Depositary Receipts (ADRs): Starpharma’s ADRs trade under the code SPHRY (CUSIP number 855563102). Each Starpharma ADR is equivalent to 10 ordinary shares of Starpharma as traded on the Australian Stock Exchange. The Bank of New York is the depositary bank. For further information:Media Rebecca Wilson Buchan 02 9237 2800 / 0417 382 391 rchristie@bcg.com.auDr John Raff Ben Rogers Chief Executive Officer Company Secretary +61 3 8532 2701 +61 3 8532 2702
tomhead
Klasse, tomhead, danke.
Jetzt muß sich unsere kleine "Perle" nur noch in Investoren-Kreisen rumsprechen..
Wobei SPL für mich (jedenfalls momentan) zu den Investments gehört, die ich bedenkenlos langfristig im Depot schlummern lasse..
Gruß, h.
Jetzt muß sich unsere kleine "Perle" nur noch in Investoren-Kreisen rumsprechen..
Wobei SPL für mich (jedenfalls momentan) zu den Investments gehört, die ich bedenkenlos langfristig im Depot schlummern lasse..
Gruß, h.
: AZoNanotechnology Article
Dendrimers - an Overview of Intellectual Property and Patenting Issues
Topics Covered
Background
How Dendritic NanoTechnologies (DNT) Came to Dominate the Patenting Sector for Dendrimers
Patenting Dendrimers - a Summary of the Current Situation
Background
Dendrimer IP is a “hot potato” because the potential for profit is enormous but commercialization is slow and uncertain - everyone wants to be holding key dendrimer patents at just the right time. Dendritech, a private company spun off from Dow and founded by Donald Tomalia in 1992, sold its dendrimer patents back to Dow in 2000. Then Tomalia left Dendritech and founded a new company, Dendritic NanoTechnologies Inc. (DNT). In January 2005, DNT acquired the mother lode of dendrimer patents when Dow turned over its entire intellectual property portfolio on dendrimers (196 patents worldwide) to DNT in exchange for owning a significant stake in the company.
AZoNano, Nanotechnology - Chart showing US patents and patent applications referring to dendrimers in the patent abstract, from 1999 to 2004.
Figure 1. US patents and patent applications referring to dendrimers in the patent abstract, from 1999 to 2004.
How Dendritic NanoTechnologies (DNT) Came to Dominate the Patenting Sector for Dendrimers
A third company, Starpharma (Melbourne, Australia), which already owned a chunk of DNT, increased its financial stake in the company to 49.9% and also gained exclusive rights to DNT’s and Dow’s intellectual property for dendrimer-based pharmaceutical applications. The flip-flopping dendrimer patent portfolio is now in the hands of DNT which claims to control “the world’s broadest intellectual property position in dendrimer science.” Today, DNT sells and licenses more than 200 variations of dendrimers to pharmaceutical, biotechnology and diagnostic companies.
Table 1. Patents on dendrimers issued by the US PTO (survey conducted on 2 May 2005).
Top Assignees - 272 patents total
Country
Number of patents
Dow Chemical* - these
patents are now owned
by Dendritic
NanoTechnologies Inc.
USA
39
Bayer AG
Germany
9
Phillips Petroleum
Company
USA
9
Xerox Corporation
USA
7
DSM N.V.
Netherlands
6
Dendritech, Inc.
USA
6
Ford Motor Company**
USA
6
University of California
USA
6
ExxonMobil Chemical
Patents Inc.***
USA
6
Bridgestone
Corporation****
Japan
6
* includes Dow Corning Toray Silicone Co., Ltd. and Dow Corning Corporation;
** includes Ford Global Technologies;
*** includes Exxon Research and Engineering Co;
**** includes Bridgestone Tire Company.
Patenting Dendrimers - a Summary of the Current Situation
· Dendritic Nanotechnologies, Inc. clearly holds a dominant position in the dendrimer patent arena.
· The 272 dendrimer patents issued between 1999-2004 were examined by 120 different patent examiners. The lack of uniform handling could result in overlapping and conflicting patents.
· The list of top assignees reveals a particularly broad area of potential industrial applications for dendrimer technology, ranging from oil, pharma, rubber, automotive and even cosmetics.
· While there is uncertainty about the future commercial value of dendrimer IP, there is little room for new, would-be innovators to enter the field without seeking multiple licenses - which may or may not be available from companies seeking to dominate the field.
· The number of issued patents relating to dendrimers has declined every year since 2001. However, the number of dendrimer patent applications at US PTO is rising steadily.
Source: ETC Group report entitled ‘Nanotech’s “Second Nature” Patents: Implications for the Global South’, April/May 2005.
For more information on this source please visit the ETC Group
Dendrimers - an Overview of Intellectual Property and Patenting Issues
Topics Covered
Background
How Dendritic NanoTechnologies (DNT) Came to Dominate the Patenting Sector for Dendrimers
Patenting Dendrimers - a Summary of the Current Situation
Background
Dendrimer IP is a “hot potato” because the potential for profit is enormous but commercialization is slow and uncertain - everyone wants to be holding key dendrimer patents at just the right time. Dendritech, a private company spun off from Dow and founded by Donald Tomalia in 1992, sold its dendrimer patents back to Dow in 2000. Then Tomalia left Dendritech and founded a new company, Dendritic NanoTechnologies Inc. (DNT). In January 2005, DNT acquired the mother lode of dendrimer patents when Dow turned over its entire intellectual property portfolio on dendrimers (196 patents worldwide) to DNT in exchange for owning a significant stake in the company.
AZoNano, Nanotechnology - Chart showing US patents and patent applications referring to dendrimers in the patent abstract, from 1999 to 2004.
Figure 1. US patents and patent applications referring to dendrimers in the patent abstract, from 1999 to 2004.
How Dendritic NanoTechnologies (DNT) Came to Dominate the Patenting Sector for Dendrimers
A third company, Starpharma (Melbourne, Australia), which already owned a chunk of DNT, increased its financial stake in the company to 49.9% and also gained exclusive rights to DNT’s and Dow’s intellectual property for dendrimer-based pharmaceutical applications. The flip-flopping dendrimer patent portfolio is now in the hands of DNT which claims to control “the world’s broadest intellectual property position in dendrimer science.” Today, DNT sells and licenses more than 200 variations of dendrimers to pharmaceutical, biotechnology and diagnostic companies.
Table 1. Patents on dendrimers issued by the US PTO (survey conducted on 2 May 2005).
Top Assignees - 272 patents total
Country
Number of patents
Dow Chemical* - these
patents are now owned
by Dendritic
NanoTechnologies Inc.
USA
39
Bayer AG
Germany
9
Phillips Petroleum
Company
USA
9
Xerox Corporation
USA
7
DSM N.V.
Netherlands
6
Dendritech, Inc.
USA
6
Ford Motor Company**
USA
6
University of California
USA
6
ExxonMobil Chemical
Patents Inc.***
USA
6
Bridgestone
Corporation****
Japan
6
* includes Dow Corning Toray Silicone Co., Ltd. and Dow Corning Corporation;
** includes Ford Global Technologies;
*** includes Exxon Research and Engineering Co;
**** includes Bridgestone Tire Company.
Patenting Dendrimers - a Summary of the Current Situation
· Dendritic Nanotechnologies, Inc. clearly holds a dominant position in the dendrimer patent arena.
· The 272 dendrimer patents issued between 1999-2004 were examined by 120 different patent examiners. The lack of uniform handling could result in overlapping and conflicting patents.
· The list of top assignees reveals a particularly broad area of potential industrial applications for dendrimer technology, ranging from oil, pharma, rubber, automotive and even cosmetics.
· While there is uncertainty about the future commercial value of dendrimer IP, there is little room for new, would-be innovators to enter the field without seeking multiple licenses - which may or may not be available from companies seeking to dominate the field.
· The number of issued patents relating to dendrimers has declined every year since 2001. However, the number of dendrimer patent applications at US PTO is rising steadily.
Source: ETC Group report entitled ‘Nanotech’s “Second Nature” Patents: Implications for the Global South’, April/May 2005.
For more information on this source please visit the ETC Group
Preliminary final report for year ended 30 June 2005 Melbourne (Australia), 6 September 2005: Starpharma Holdings Limited (ASX: SPL, USOTC: SPHRY) today announced financial results for the full year ending 30 June 2005. Revenue for the year included AUD$1.4 million received under a grant from the US National Institutes of Health (NIH) for the development of a second generation microbicide for the prevention of infection by HIV and other sexually transmitted infections. The consolidated operating loss was AUD$7.5 million, and the Company made equity investments totalling AUD$1.5million during the year - USD$1million (AUD$1.3million) was invested in Dendritic NanoTechnologies, Inc (“DNT”), and AUD$0.2million in Australian biotechnology company, Dimerix Bioscience Pty Ltd. The Company had cash reserves of $8.2 million at year end, and in the coming year the company is at an advanced stage of securing significant additional funding to supplement our working capital for the development and commercialisation of VivaGel™ and other products arising from Starpharma’s unique technology. Starpharma is a world leader in the application of dendrimer nanotechnology to pharmaceuticals, and this fact is increasingly receiving recognition from independent sources such as Lux Capital, US Investor magazine The Forbes/Wolfe Nanotech Report (VivaGel™ named in Top 5 Nanotech Breakthroughs of 2004; Starpharma included in Nanosphere List of Leading Nano Stocks), and Frost & Sullivan (2005 Growth Strategy Leadership Award). Starpharma continues to seek to leverage shareholder funds for the development of VivaGel™ and other pharmaceutical products utilising nanotechnology in order to maximise shareholder returns and available working capital. Starpharma has made extensive use of international collaborations and partnerships for product testing at minimal cost, and has also actively pursued funding for trials though public sources. Starpharma’s successful execution of this strategy has enabled the Company to advance VivaGel™ – the first dendrimer nano-pharmaceutical to enter human trials under an IND – to the point of successful completion of a Phase 1 clinical trial. The Company is now in advanced planning stages for further human trials. In the absence of effective vaccines for HIV prevention, microbicides are increasingly seen as an important means of dealing with this major health issue, and the Company remains very confident about our development strategy for VivaGel™ and related products. VivaGel™ is a versatile product with potential applications beyond the initial indication of an HIV preventative. We are also investigating product extensions such as condom coatings, which would require a different and potentially shorter regulatory path to market, to expand the product pipeline. The NIH grant of USD$5.6 million awarded in September 2004 to develop a combination product based on VivaGel™, but with significant contraceptive properties, further enhances our product pipeline. During the year the company has also been able to further leverage its intellectual property, skills and experience in dendrimer nanotechnology to add value through investments in companies with related or complementary technology. Starpharma’s investment in DNT received strong endorsement in January 2005 when the Dow Chemical Company assigned its entire dendrimer nanotechnology IP portfolio to DNT in exchange
for a 30% equity share. The Dow/DNT transaction also further consolidates the positions of Starpharma and DNT as leaders in the dendrimer IP landscape, providing increased licensing and other partnership opportunities in this area of nanotechnology. In May 2005, DNT also announced the development of Priostar™ dendrimers, an ultra-low cost product nanostructure with broad potential applications in a wide range of industries. The Dow/DNT transaction raised Starpharma’s profile in the US, and the company was able to take advantage of this exposure through the establishment of a Level 1 American Depositary Receipts (ADR) Program. Since establishment of the ADR program in January 2005 there has been a steady uptake of these instruments by US shareholders, with around 5.7% of Starpharma currently held through ADRs. We believe that Starpharma offers a great opportunity for shareholders to be part of an exciting initiative with the potential to provide significant capital growth through its strategic investments and in house development programs, at the same time as meeting urgent medical needs in the field of human reproductive health. John W Raff Chief Executive Officer ______________________________________________________________________
tomhead
for a 30% equity share. The Dow/DNT transaction also further consolidates the positions of Starpharma and DNT as leaders in the dendrimer IP landscape, providing increased licensing and other partnership opportunities in this area of nanotechnology. In May 2005, DNT also announced the development of Priostar™ dendrimers, an ultra-low cost product nanostructure with broad potential applications in a wide range of industries. The Dow/DNT transaction raised Starpharma’s profile in the US, and the company was able to take advantage of this exposure through the establishment of a Level 1 American Depositary Receipts (ADR) Program. Since establishment of the ADR program in January 2005 there has been a steady uptake of these instruments by US shareholders, with around 5.7% of Starpharma currently held through ADRs. We believe that Starpharma offers a great opportunity for shareholders to be part of an exciting initiative with the potential to provide significant capital growth through its strategic investments and in house development programs, at the same time as meeting urgent medical needs in the field of human reproductive health. John W Raff Chief Executive Officer ______________________________________________________________________
tomhead
Looking For Buy-o-tech-know-logy?
September 21 2005 - Australasian Investment Review – (AIR)
Life sure ain’t easy for persevering biotech investors. Not only have equity investors and the professionals within the financial scene turned their backs on the sector (also see this week’s feature story), it’s been quite challenging for AIR to obtain some useful information from the remaining professionals who are still following the sector closely.
Analysis by Southern Cross Equities biotech specialist Stuart Roberts suggests Australian biotechnology shares are currently stuck in their longest bear market ever, with the current downturn being identified as having commenced in September 2003. The good news, Roberts points out, is that when the sector does pick up, it does so in a dramatic way, usually leading to a doubling of the Southern Cross biotech index over a nine month period.
Since one of the main criticisms of long running sector specialists like Harry Karelis and Geoff Brooke is that Australian investors have persistently failed to make a distinction in quality between the various ASX-listed biotech stocks, we thought we’d give them a hand and ask the tough question: who is to be considered investment grade among Australia’s listed biotech stocks?
Getting the answer proved to be more difficult than anticipated. Tom Duthy from Taylor Collison declined our offer in a friendly way, saying he did not want to insult anyone for not making it onto his list. Jonathan Buckley from Intersuisse also passed up the opportunity, apologising for not having enough time available to look into the matter while trying to make us happy with the giveaway "ResMed (RMD), CSL (CSL) and Cochlear (COH) are definitely investment grade, though one could argue they are not biotech stocks". (All three are part of the broker’s proprietary biotech index.)
Shaw Stockbroking’s biotech analyst recently moved on to greener pastures (they were still looking for applications last time we checked). Luckily, at ABN Amro Morgans our question received a much warmer welcome, with Tanya Solomon swiftly returning our email with her personal stand out favourites in the sector: Alchemia (ACL), Tissue Therapies (TIS) and Ventracor (VCR).
Stuart Roberts referred us to "The upcoming bull market for Australian biotechnology", a document he published to prepare readers of his bi-weekly biotechbuzz for the inevitable upswing in share prices across the sector.
Under the title "Stocks to play now" the document lists Acrux (ACR), Agenix (AGX), Alchemia (ACL), Avexa (AVX), Biota (BTA), Clinical Cell Culture (CCE), Gropep (GRO), Pharmaxis (PXS), Peplin (PEP), Progen (PGL) and Starpharma (SPL).
Copyright Australasian Investment Review.
AIR publishes a weekly magazine. Subscriptions are free at www.aireview.com
September 21 2005 - Australasian Investment Review – (AIR)
Life sure ain’t easy for persevering biotech investors. Not only have equity investors and the professionals within the financial scene turned their backs on the sector (also see this week’s feature story), it’s been quite challenging for AIR to obtain some useful information from the remaining professionals who are still following the sector closely.
Analysis by Southern Cross Equities biotech specialist Stuart Roberts suggests Australian biotechnology shares are currently stuck in their longest bear market ever, with the current downturn being identified as having commenced in September 2003. The good news, Roberts points out, is that when the sector does pick up, it does so in a dramatic way, usually leading to a doubling of the Southern Cross biotech index over a nine month period.
Since one of the main criticisms of long running sector specialists like Harry Karelis and Geoff Brooke is that Australian investors have persistently failed to make a distinction in quality between the various ASX-listed biotech stocks, we thought we’d give them a hand and ask the tough question: who is to be considered investment grade among Australia’s listed biotech stocks?
Getting the answer proved to be more difficult than anticipated. Tom Duthy from Taylor Collison declined our offer in a friendly way, saying he did not want to insult anyone for not making it onto his list. Jonathan Buckley from Intersuisse also passed up the opportunity, apologising for not having enough time available to look into the matter while trying to make us happy with the giveaway "ResMed (RMD), CSL (CSL) and Cochlear (COH) are definitely investment grade, though one could argue they are not biotech stocks". (All three are part of the broker’s proprietary biotech index.)
Shaw Stockbroking’s biotech analyst recently moved on to greener pastures (they were still looking for applications last time we checked). Luckily, at ABN Amro Morgans our question received a much warmer welcome, with Tanya Solomon swiftly returning our email with her personal stand out favourites in the sector: Alchemia (ACL), Tissue Therapies (TIS) and Ventracor (VCR).
Stuart Roberts referred us to "The upcoming bull market for Australian biotechnology", a document he published to prepare readers of his bi-weekly biotechbuzz for the inevitable upswing in share prices across the sector.
Under the title "Stocks to play now" the document lists Acrux (ACR), Agenix (AGX), Alchemia (ACL), Avexa (AVX), Biota (BTA), Clinical Cell Culture (CCE), Gropep (GRO), Pharmaxis (PXS), Peplin (PEP), Progen (PGL) and Starpharma (SPL).
Copyright Australasian Investment Review.
AIR publishes a weekly magazine. Subscriptions are free at www.aireview.com
Hallo!
http://www.starpharma.com/PDFs/050929%20Response%20to%20Mark…
29 September 2005 Starpharma Holdings Limited wishes to respond to current market rumours and speculation, consistent with the Company’s continuous disclosure obligations under the ASX Listing Rules. One of the Company’s stated key strategies for creating maximum shareholder value is to seek external support from both Australian and international sources to support the Company’s discovery, development and commercialisation activities. The Company is currently in confidential discussions regarding a potential opportunity for funding of the further development of VivaGel™. The potential arrangements are incomplete, and the Company will continue to keep the market fully informed of any relevant developments, although timing of any decision is outside the Company’s control. ______________________________________________________________________ About Starpharma: Starpharma Holdings Limited (ASX:SPL, USOTC:SPHRY) leads the world in the application of nanotechnology to pharmaceuticals. The Company’s lead product in development is VivaGel™, a vaginal microbicide designed to prevent the transmission of STIs, including HIV and genital herpes. VivaGel™ is the first example of a product to come from Starpharma’s Dendrimer-based discovery pipeline, which also includes specific programs in the fields of ADME Engineering™ (using dendrimers to control where and when drugs go when introduced to the body), Polyvalency (using the fact that dendrimers can activate multiple receptors simultaneously) and Targeted Diagnostics (using dendrimers as a scaffold to which both location-signaling and targeting groups are added to allow location of specific cell type, such as cancer cells). Starpharma also has equity interests in two companies: • Dendritic NanoTechnologies, Inc. (DNT) – established with the pioneer of dendrimer nanotechnology Dr Donald A. Tomalia and based in Michigan, USA; and • Dimerix Bioscience Pty Ltd – a specialist drug development company established to commercialise unique technology developed at the Western Australian Institute for Medical Research in the new field of receptor coupling, specifically G-Protein coupled receptors (“GPCRs”). Dendrimers: A type of precisely-defined, branched nanoparticle. Dendrimers have applications in the medical, electronics, chemicals and materials industries. Microbicides: A microbicide inactivates, kills or destroys microbes such as viruses and bacteria. Microbicides may be formulated as gels, creams, sponges, suppositories or films with the purpose of reducing significantly the incidence of STIs. There are currently no vaginal microbicides on the market. They are intended for vaginal or rectal use to afford protection for varying periods, from several hours up to days. Microbicides may also be designed to have a contraceptive function by inhibiting sperm.
American Depositary Receipts (ADRs): Starpharma’s ADRs trade under the code SPHRY (CUSIP number 855563102). Each Starpharma ADR is equivalent to 10 ordinary shares of Starpharma as traded on the Australian Stock Exchange. The Bank of New York is the depositary bank. For further information: Starpharma www.starpharma.com Dr John Raff Chief Executive Officer +61 3 8532 2701 john.raff@starpharma.comBen Rogers Company Secretary +61 3 8532 2702 ben.rogers@starpharma.com
Grüße cristrader
http://www.starpharma.com/PDFs/050929%20Response%20to%20Mark…
29 September 2005 Starpharma Holdings Limited wishes to respond to current market rumours and speculation, consistent with the Company’s continuous disclosure obligations under the ASX Listing Rules. One of the Company’s stated key strategies for creating maximum shareholder value is to seek external support from both Australian and international sources to support the Company’s discovery, development and commercialisation activities. The Company is currently in confidential discussions regarding a potential opportunity for funding of the further development of VivaGel™. The potential arrangements are incomplete, and the Company will continue to keep the market fully informed of any relevant developments, although timing of any decision is outside the Company’s control. ______________________________________________________________________ About Starpharma: Starpharma Holdings Limited (ASX:SPL, USOTC:SPHRY) leads the world in the application of nanotechnology to pharmaceuticals. The Company’s lead product in development is VivaGel™, a vaginal microbicide designed to prevent the transmission of STIs, including HIV and genital herpes. VivaGel™ is the first example of a product to come from Starpharma’s Dendrimer-based discovery pipeline, which also includes specific programs in the fields of ADME Engineering™ (using dendrimers to control where and when drugs go when introduced to the body), Polyvalency (using the fact that dendrimers can activate multiple receptors simultaneously) and Targeted Diagnostics (using dendrimers as a scaffold to which both location-signaling and targeting groups are added to allow location of specific cell type, such as cancer cells). Starpharma also has equity interests in two companies: • Dendritic NanoTechnologies, Inc. (DNT) – established with the pioneer of dendrimer nanotechnology Dr Donald A. Tomalia and based in Michigan, USA; and • Dimerix Bioscience Pty Ltd – a specialist drug development company established to commercialise unique technology developed at the Western Australian Institute for Medical Research in the new field of receptor coupling, specifically G-Protein coupled receptors (“GPCRs”). Dendrimers: A type of precisely-defined, branched nanoparticle. Dendrimers have applications in the medical, electronics, chemicals and materials industries. Microbicides: A microbicide inactivates, kills or destroys microbes such as viruses and bacteria. Microbicides may be formulated as gels, creams, sponges, suppositories or films with the purpose of reducing significantly the incidence of STIs. There are currently no vaginal microbicides on the market. They are intended for vaginal or rectal use to afford protection for varying periods, from several hours up to days. Microbicides may also be designed to have a contraceptive function by inhibiting sperm.
American Depositary Receipts (ADRs): Starpharma’s ADRs trade under the code SPHRY (CUSIP number 855563102). Each Starpharma ADR is equivalent to 10 ordinary shares of Starpharma as traded on the Australian Stock Exchange. The Bank of New York is the depositary bank. For further information: Starpharma www.starpharma.com Dr John Raff Chief Executive Officer +61 3 8532 2701 john.raff@starpharma.comBen Rogers Company Secretary +61 3 8532 2702 ben.rogers@starpharma.com
Grüße cristrader
Annual Report and Annual Review:
http://www.starpharma.com/PDFs/050929%20Annual%20Report%20&%…
http://www.starpharma.com/PDFs/050929%20Annual%20Report%20&%…
Sehr gute news!
Melbourne, Australia – 3 October 2005 – Starpharma’s VivaGel™, a vaginal microbicide against sexually transmitted infections (STIs), received a major boost today with the award of $US20.3m (approximately $A26.4m) development funding by the US-based National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).1
This is one of the largest awards ever made in Australia by the NIAID.
Under this award, the development will be led by Starpharma’s Vice President of Drug Development, Tom McCarthy. "We feel that this significant financial support from the NIH demonstrates that the product rationale and data for VivaGel™ to date is of the highest quality and that VivaGel™ provides a very promising approach to HIV prevention,” said Dr John Raff, CEO of Starpharma.
“In addition to funding the development of VivaGel™, we believe that the relationship with the NIH will also provide access to key investigators and opinion leaders who will play a significant role in ensuring the successful development and commercialisation of VivaGel™."
VivaGel™: externally funded through to the start of large-scale efficacy trials VivaGel™ has already been successfully tested in a number of studies including a Phase 1 human safety trial. This new funding is significant because it accelerates the progress of VivaGel™ to market, and means that VivaGel™ now has fully-external, non-shareholder funding through to the start of large-scale efficacy trials.
Die komplette Meldung ist beispielsweise unter www.stocknessmonster.com (Code "SPL") unter dem Punkt "News" abrufbar..
Gruß, h.
Melbourne, Australia – 3 October 2005 – Starpharma’s VivaGel™, a vaginal microbicide against sexually transmitted infections (STIs), received a major boost today with the award of $US20.3m (approximately $A26.4m) development funding by the US-based National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).1
This is one of the largest awards ever made in Australia by the NIAID.
Under this award, the development will be led by Starpharma’s Vice President of Drug Development, Tom McCarthy. "We feel that this significant financial support from the NIH demonstrates that the product rationale and data for VivaGel™ to date is of the highest quality and that VivaGel™ provides a very promising approach to HIV prevention,” said Dr John Raff, CEO of Starpharma.
“In addition to funding the development of VivaGel™, we believe that the relationship with the NIH will also provide access to key investigators and opinion leaders who will play a significant role in ensuring the successful development and commercialisation of VivaGel™."
VivaGel™: externally funded through to the start of large-scale efficacy trials VivaGel™ has already been successfully tested in a number of studies including a Phase 1 human safety trial. This new funding is significant because it accelerates the progress of VivaGel™ to market, and means that VivaGel™ now has fully-external, non-shareholder funding through to the start of large-scale efficacy trials.
Die komplette Meldung ist beispielsweise unter www.stocknessmonster.com (Code "SPL") unter dem Punkt "News" abrufbar..
Gruß, h.
Heute ein kleiner Rücksetzter, jedoch denke ich das jetzt allen klar sein müsste das diese Aktie enormes Potenzial noch Norden hat.
Kleiner Meinungsaustausch wäre echt schön. Wo ist CyberCoach????? Bitte Stellungnahme.
Bis dahin
tomhead (der nochmals nachkauft unm für die zukunft gesichert zu sein)
Kleiner Meinungsaustausch wäre echt schön. Wo ist CyberCoach????? Bitte Stellungnahme.
Bis dahin
tomhead (der nochmals nachkauft unm für die zukunft gesichert zu sein)
Ich denke cyberCoach ist in Urlaub.
Hier noch eine INfo von Ulrich:
Innovation From Down Under
By Jack Uldrich
October 4, 2005
Australian researchers Robin Warren and Barry Marshall were awarded the Nobel Prize in medicine Monday for their breakthrough discovery that ulcers are caused by a bacterial infection, not -- as was long believed -- by stress. "The idea of stress ... was just so entrenched, nobody could believe that it was bacteria," Marshall said upon learning of the award. His and Warren`s nations to the contrary, he said, "had to come from some weird place like Australia, because I think nobody else would have even considered it."
If Australia really is home to such outside-the-box thinking, it may also be affecting two of its most promising nanotechnology companies, in ways that may transform the companies and the people that their cutting-edge developments aim to serve.
First, pSivida (Nasdaq: PSDV) announced that it is acquiring Boston-based Control Delivery Systems, a U.S. drug-delivery company, for $104 million. The deal, if shareholders of both companies approve, will go a long way toward helping pSivida capitalize on its plans to commercialize its BioSilicon drug delivery platform -- which I wrote about this past May -- and will help put it on the path toward becoming a leading global bio-nanotech company.
Starpharma (OTC BB: SPHRY), meanwhile, announced that it has received $20 million grant from the U.S.-based National Institute of Allergy and Infectious Diseases to help accelerate the progress of VivaGel to market. VivaGel is a microbicide that has been developed for women as a preventive treatment against the sexual transmission of HIV. The topical agent is dendrimer-based (that is, built from a nano-molecule) and has been 100 percent effective in animal trials. It has clearly generated enough excitement from the National Institutes of Health to warrant a sizeable investment.
Starpharma has a lot of other things going for it besides VivaGel, and I intend to write about some of those things soon. But if VivaGel is effective, it is quite likely that Starpharma will also be able to generate additional gels to treat a variety of other diseases, including herpes. It could become a leading global bio-nanotech player. But for the time being, the funding announcement should be enough for you to start watching the company. The funding deal, after all, virtually guarantees an inflow of money for the company through the start of large-scale efficacy trials and doesn`t dilute shareholder value at all in the process.
At the same time, though, remember that both companies are speculative small-cap stocks and, as such, carry big risks, including a predisposition to volatility. If you want to invest, tread carefully. A tolerance for risk is always a good idea in micro-cap land, especially when the companies are on the leading edge of innovation.
Looking to swoop in before nanotech makes it big? Take
tomhead
Hier noch eine INfo von Ulrich:
Innovation From Down Under
By Jack Uldrich
October 4, 2005
Australian researchers Robin Warren and Barry Marshall were awarded the Nobel Prize in medicine Monday for their breakthrough discovery that ulcers are caused by a bacterial infection, not -- as was long believed -- by stress. "The idea of stress ... was just so entrenched, nobody could believe that it was bacteria," Marshall said upon learning of the award. His and Warren`s nations to the contrary, he said, "had to come from some weird place like Australia, because I think nobody else would have even considered it."
If Australia really is home to such outside-the-box thinking, it may also be affecting two of its most promising nanotechnology companies, in ways that may transform the companies and the people that their cutting-edge developments aim to serve.
First, pSivida (Nasdaq: PSDV) announced that it is acquiring Boston-based Control Delivery Systems, a U.S. drug-delivery company, for $104 million. The deal, if shareholders of both companies approve, will go a long way toward helping pSivida capitalize on its plans to commercialize its BioSilicon drug delivery platform -- which I wrote about this past May -- and will help put it on the path toward becoming a leading global bio-nanotech company.
Starpharma (OTC BB: SPHRY), meanwhile, announced that it has received $20 million grant from the U.S.-based National Institute of Allergy and Infectious Diseases to help accelerate the progress of VivaGel to market. VivaGel is a microbicide that has been developed for women as a preventive treatment against the sexual transmission of HIV. The topical agent is dendrimer-based (that is, built from a nano-molecule) and has been 100 percent effective in animal trials. It has clearly generated enough excitement from the National Institutes of Health to warrant a sizeable investment.
Starpharma has a lot of other things going for it besides VivaGel, and I intend to write about some of those things soon. But if VivaGel is effective, it is quite likely that Starpharma will also be able to generate additional gels to treat a variety of other diseases, including herpes. It could become a leading global bio-nanotech player. But for the time being, the funding announcement should be enough for you to start watching the company. The funding deal, after all, virtually guarantees an inflow of money for the company through the start of large-scale efficacy trials and doesn`t dilute shareholder value at all in the process.
At the same time, though, remember that both companies are speculative small-cap stocks and, as such, carry big risks, including a predisposition to volatility. If you want to invest, tread carefully. A tolerance for risk is always a good idea in micro-cap land, especially when the companies are on the leading edge of innovation.
Looking to swoop in before nanotech makes it big? Take
tomhead
Hallo Leute,
melde mich nur ganz kurz. In den nächsten 3 Wochen kann ich wegen Umzug nur beschränkt ins Internet. Nutze aber jede Pause, um mal wenigstens einen Blick auf Starpharma zu werfen. Nach Umzug melde ich mich wieder regelmässig.
melde mich nur ganz kurz. In den nächsten 3 Wochen kann ich wegen Umzug nur beschränkt ins Internet. Nutze aber jede Pause, um mal wenigstens einen Blick auf Starpharma zu werfen. Nach Umzug melde ich mich wieder regelmässig.
tja Cyber, dann bring deinen Umzug mal gut über die Bühne
Kursverlauf bei SPL versteh ich offen gesagt aber nicht so richtig - da kommt ne Supernews und die Aktie wird unter hohen Umsätzen tagtäglich nur nach Süden geprügelt???
jetzt stehen wir mittlerweile schon wieder tiefer als VOR der news!!!
kapier das wer will, ich tu`s nicht
Kursverlauf bei SPL versteh ich offen gesagt aber nicht so richtig - da kommt ne Supernews und die Aktie wird unter hohen Umsätzen tagtäglich nur nach Süden geprügelt???
jetzt stehen wir mittlerweile schon wieder tiefer als VOR der news!!!
kapier das wer will, ich tu`s nicht
[posting]18.161.851 von hooray1 am 06.10.05 12:30:49[/posting]wer kennt schon die Börse. Aber diesen Kursverlauf versteh weiss wer will, ich nicht. Vielleicht prügeln "SIE" den Kurs nach unten weil noch eine gute NEWS folgen wird. Vermutungen, aber gut deshalb habe ich aus Frust heute nochmals nachgelegt.
tomhead
tomhead
Guten Morgen zusammen, hier die heutige "Preis sensitive" Nachricht Nr.1 ( zumindest nach ASX Einschätzung ):
http://www.asx.com.au/asxpdf/20051011/pdf/3spt5062kzf0w.pdf
Gruß C.
http://www.asx.com.au/asxpdf/20051011/pdf/3spt5062kzf0w.pdf
Gruß C.
...und hier "Preis sensitive" Nachricht Nr.2:
http://www.asx.com.au/asxpdf/20051011/pdf/3sq0fyyyhlgs0.pdf
Schönen Tag noch
Colophonius
http://www.asx.com.au/asxpdf/20051011/pdf/3sq0fyyyhlgs0.pdf
Schönen Tag noch
Colophonius
und hier der SK: 0.63 Aussies = 0.39645 Euro bei einem Volumen von: 474.000 nicht schlecht.
bis dahin
tomhead
p.s.: Die News sind auch nicht shlecht!!!
bis dahin
tomhead
p.s.: Die News sind auch nicht shlecht!!!
und um 5.07 noch zwei news die noch nicht aktiviert sind.
siehe: http://stocknessmonster.com/stock-quote?S=SPL&E=ASX
tomhead
siehe: http://stocknessmonster.com/stock-quote?S=SPL&E=ASX
tomhead
Hab jetzt auch ein paar.
Von August, nochmal, weil besser strukturiert.
Geht runter wie Oel:
"Starpharma Honoured with the 2005 Frost & Sullivan Growth Strategy Leadership Award For Its Development of Revolutionary Products
BUSINESS WIRE - August 08, 2005
Starpharma Holdings Limited today announced that it has received the 2005 Frost & Sullivan Growth Strategy Leadership Award in recognition of the company`s development of VivaGel(TM) and other polyvalent dendrimer-based products relating to the world nanobiotechnology market.
MELBOURNE, Australia--(BUSINESS WIRE)--Aug. 8, 2005--Starpharma Holdings Limited (Pink Sheets:SPHRY) (ASX:SPL) today announced that it has received the 2005 Frost & Sullivan Growth Strategy Leadership Award in recognition of the company`s development of VivaGel(TM) and other polyvalent dendrimer-based products relating to the world nanobiotechnology market.
This Frost & Sullivan award is given each year to the company that has demonstrated an exceptional growth strategy within its industry. A detailed Award Description is attached.
Dr John Raff, Starpharma`s Chief Executive Officer, said: "Although we are very proud of the company`s achievements, this award has come as a surprise. We are delighted that Frost & Sullivan, a significant international market analysis group, has recognised Starpharma`s growth strategy leadership and achievements."
Frost & Sullivan Growth Strategy Leadership Award in the World Nanobiotechnology Market
Award Description
The Frost & Sullivan Award for Growth Strategy Leadership is given each year to the company that has demonstrated an exceptional growth strategy within its industry.
Research Methodology
A recipient is chosen to receive the Growth Strategy Leadership Award based on specific criteria. Through primary and secondary research methods, all companies` market revenues are tracked and those exhibiting significant growth are noted for their strategy implementation. Revenues are then compared year to year to monitor growth patterns. When a company continues to show high growth rates, it is a candidate for the Frost & Sullivan Growth Strategy Leadership Award.
Measurement Criteria
This award is given to the company that has bolstered its position in the market during the base year, and whose strategy will have a lasting impact on the market. The award criteria are based on the following:
-- Technological innovation and leadership
-- Discovering new venues for an established product
-- Strategic mergers, acquisitions or joint ventures to penetrate new markets
2005 Frost & Sullivan Growth Strategy Leadership Award for Starpharma Holdings Limited
Frost & Sullivan presents the 2005 Growth Strategy Leadership Award to Starpharma for the development of revolutionary products in a new market sector in the world nanobiotechnology market. The company has established a strong and highly consolidated market position through collaboration and licensing. This position is currently unrivalled by other market participants.
Revolutionary Products in a New Market Sector
Founded in 1996, Starpharma is headquartered in Melbourne, Australia. The company is leading the nanobiotechnology market in the area of dendrimers; multibranched polymers with high functional specificity due to their highly defined structures. Starpharma`s current product portfolio is focusing on the prevention of sexually transmitted infections (STIs) and systemic viral indications.
The Most Developed Lead Product to Date
The Starpharma lead product is VivaGel(TM), a topical polyvalent dendrimer-based vaginal microbicide gel for the prevention of HIV in women. This represents a significant area of unmet medical need. The product is currently in Phase I clinical trials and is currently the most advanced dendrimer-based therapeutic in development. SPL7013, the polylysine active ingredient of VivaGel(TM), has shown further effectiveness against a range of STIs, including chlamydia, genital herpes (HSV-2), hepatitis B virus and human papilloma virus.
Pipeline Diversification Across a Range of Indications
Starpharma is diversifying its growth strategy by developing a range of products in-house, which will then be available for licensing to pharmaceutical companies. To date, over 120 different dendrimers have been tested for their effectiveness against STIs.
Additionally, Starpharma is diversifying its target indication spectrum by investigating the application of dendrimers to the oncology and respiratory sectors. Dendrimers are also being tested for their application in biodefence. They have potential for the remediation of terrorist attack using biological agents such as Ebola virus.
The company is aiming to become a knowledge powerhouse in the dendrimer sector, a market which is set to expand rapidly when the first products reach the market and dendrimer manufacture becomes more cost effective.
Strong Market Positioning
Starpharma has consolidated its position through the establishment of collaborations and licensing agreements with industrial partners. The company is the largest (33%) stakeholder of Dendritic Nanotechnologies, Inc., (DNT) a manufacturer of dendrimers and a developer of dendrimer-based products in other fields of application. DNT is an important source of high quality and novel dendritic materials. Additionally, DNT has a powerful collaboration with the Dow Chemical Company, which has assigned 196 patents to DNT concerning dendrimer manufacture and development in a broad range of applications. Starpharma has exclusive license rights to the entire DNT IP portfolio for the field of "polyvalence," the broadest within the industry and an indication of significant industry consolidation. Starpharma has established further research collaborations with over 35 academic and public institutions across the United States, Europe and Australasia.
Starpharma has established supply chain collaborations, is investigating further potential applications of their lead products as well as investigating new sectors, and is developing a wide range of support to future third party partners. Based on these merits, Frost & Sullivan is proud to present Starpharma with the Growth Strategy Leadership Award for 2005.
About Frost & Sullivan
Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company`s industry expertise integrates growth consulting, growth partnership services and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community, by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics.
About Starpharma
Starpharma Holdings Limited (Pink Sheets:SPHRY) (ASX:SPL) is leading the world in nanomedicine. Its lead product in development is VivaGel(TM), a vaginal microbicide gel that has been developed for women as a preventative against the sexual transmission of HIV. It has also shown activity in animal studies for the prevention of other sexually transmitted infections including genital herpes. The Company has a broad range of opportunities arising from its innovations involving the discovery and development of pharmaceutical nanotechnology products using dendrimers and the multi-binding phenomenon of polyvalence. Development programs include multi-acting respiratory and anti-cancer applications.
Starpharma also has equity interests in two companies:
-- Dendritic NanoTechnologies, Inc. (DNT) - established with the pioneer of dendrimer nanotechnology Dr Donald A. Tomalia and based in Michigan, USA.
-- Dimerix Biosciences Pty Ltd - a specialist drug development company established to commercialise unique technology developed at the Western Australian Institute for Medical Research in the new field of receptor coupling, specifically G-Protein coupled receptors ("GPCRs").
Microbicides: A microbicide inactivates, kills or destroys microbes. Microbicides may be formulated as gels, creams, sponges, suppositories or films with the purpose of reducing significantly the incidence of STDs. There are currently no vaginal microbicides on the market. They are intended for vaginal or rectal use to afford protection for varying periods, from several hours up to days. Microbicides may also be designed to have a contraceptive function by inhibiting sperm.
Dendrimers: Dendrimers are a type of nanoparticle. They are man-made chemicals that form tiny balls made up of a dense network of branches. Dendrimers have applications in the medical, electronics, chemicals and materials industries.
American Depositary Receipts (ADRs): Starpharma`s ADRs trade under the code SPHRY (CUSIP number 855563102). Each Starpharma ADR is equivalent to 10 ordinary shares of Starpharma as traded on the Australian Stock Exchange. The Bank of New York is the depositary bank.!
Von August, nochmal, weil besser strukturiert.
Geht runter wie Oel:
"Starpharma Honoured with the 2005 Frost & Sullivan Growth Strategy Leadership Award For Its Development of Revolutionary Products
BUSINESS WIRE - August 08, 2005
Starpharma Holdings Limited today announced that it has received the 2005 Frost & Sullivan Growth Strategy Leadership Award in recognition of the company`s development of VivaGel(TM) and other polyvalent dendrimer-based products relating to the world nanobiotechnology market.
MELBOURNE, Australia--(BUSINESS WIRE)--Aug. 8, 2005--Starpharma Holdings Limited (Pink Sheets:SPHRY) (ASX:SPL) today announced that it has received the 2005 Frost & Sullivan Growth Strategy Leadership Award in recognition of the company`s development of VivaGel(TM) and other polyvalent dendrimer-based products relating to the world nanobiotechnology market.
This Frost & Sullivan award is given each year to the company that has demonstrated an exceptional growth strategy within its industry. A detailed Award Description is attached.
Dr John Raff, Starpharma`s Chief Executive Officer, said: "Although we are very proud of the company`s achievements, this award has come as a surprise. We are delighted that Frost & Sullivan, a significant international market analysis group, has recognised Starpharma`s growth strategy leadership and achievements."
Frost & Sullivan Growth Strategy Leadership Award in the World Nanobiotechnology Market
Award Description
The Frost & Sullivan Award for Growth Strategy Leadership is given each year to the company that has demonstrated an exceptional growth strategy within its industry.
Research Methodology
A recipient is chosen to receive the Growth Strategy Leadership Award based on specific criteria. Through primary and secondary research methods, all companies` market revenues are tracked and those exhibiting significant growth are noted for their strategy implementation. Revenues are then compared year to year to monitor growth patterns. When a company continues to show high growth rates, it is a candidate for the Frost & Sullivan Growth Strategy Leadership Award.
Measurement Criteria
This award is given to the company that has bolstered its position in the market during the base year, and whose strategy will have a lasting impact on the market. The award criteria are based on the following:
-- Technological innovation and leadership
-- Discovering new venues for an established product
-- Strategic mergers, acquisitions or joint ventures to penetrate new markets
2005 Frost & Sullivan Growth Strategy Leadership Award for Starpharma Holdings Limited
Frost & Sullivan presents the 2005 Growth Strategy Leadership Award to Starpharma for the development of revolutionary products in a new market sector in the world nanobiotechnology market. The company has established a strong and highly consolidated market position through collaboration and licensing. This position is currently unrivalled by other market participants.
Revolutionary Products in a New Market Sector
Founded in 1996, Starpharma is headquartered in Melbourne, Australia. The company is leading the nanobiotechnology market in the area of dendrimers; multibranched polymers with high functional specificity due to their highly defined structures. Starpharma`s current product portfolio is focusing on the prevention of sexually transmitted infections (STIs) and systemic viral indications.
The Most Developed Lead Product to Date
The Starpharma lead product is VivaGel(TM), a topical polyvalent dendrimer-based vaginal microbicide gel for the prevention of HIV in women. This represents a significant area of unmet medical need. The product is currently in Phase I clinical trials and is currently the most advanced dendrimer-based therapeutic in development. SPL7013, the polylysine active ingredient of VivaGel(TM), has shown further effectiveness against a range of STIs, including chlamydia, genital herpes (HSV-2), hepatitis B virus and human papilloma virus.
Pipeline Diversification Across a Range of Indications
Starpharma is diversifying its growth strategy by developing a range of products in-house, which will then be available for licensing to pharmaceutical companies. To date, over 120 different dendrimers have been tested for their effectiveness against STIs.
Additionally, Starpharma is diversifying its target indication spectrum by investigating the application of dendrimers to the oncology and respiratory sectors. Dendrimers are also being tested for their application in biodefence. They have potential for the remediation of terrorist attack using biological agents such as Ebola virus.
The company is aiming to become a knowledge powerhouse in the dendrimer sector, a market which is set to expand rapidly when the first products reach the market and dendrimer manufacture becomes more cost effective.
Strong Market Positioning
Starpharma has consolidated its position through the establishment of collaborations and licensing agreements with industrial partners. The company is the largest (33%) stakeholder of Dendritic Nanotechnologies, Inc., (DNT) a manufacturer of dendrimers and a developer of dendrimer-based products in other fields of application. DNT is an important source of high quality and novel dendritic materials. Additionally, DNT has a powerful collaboration with the Dow Chemical Company, which has assigned 196 patents to DNT concerning dendrimer manufacture and development in a broad range of applications. Starpharma has exclusive license rights to the entire DNT IP portfolio for the field of "polyvalence," the broadest within the industry and an indication of significant industry consolidation. Starpharma has established further research collaborations with over 35 academic and public institutions across the United States, Europe and Australasia.
Starpharma has established supply chain collaborations, is investigating further potential applications of their lead products as well as investigating new sectors, and is developing a wide range of support to future third party partners. Based on these merits, Frost & Sullivan is proud to present Starpharma with the Growth Strategy Leadership Award for 2005.
About Frost & Sullivan
Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company`s industry expertise integrates growth consulting, growth partnership services and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community, by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics.
About Starpharma
Starpharma Holdings Limited (Pink Sheets:SPHRY) (ASX:SPL) is leading the world in nanomedicine. Its lead product in development is VivaGel(TM), a vaginal microbicide gel that has been developed for women as a preventative against the sexual transmission of HIV. It has also shown activity in animal studies for the prevention of other sexually transmitted infections including genital herpes. The Company has a broad range of opportunities arising from its innovations involving the discovery and development of pharmaceutical nanotechnology products using dendrimers and the multi-binding phenomenon of polyvalence. Development programs include multi-acting respiratory and anti-cancer applications.
Starpharma also has equity interests in two companies:
-- Dendritic NanoTechnologies, Inc. (DNT) - established with the pioneer of dendrimer nanotechnology Dr Donald A. Tomalia and based in Michigan, USA.
-- Dimerix Biosciences Pty Ltd - a specialist drug development company established to commercialise unique technology developed at the Western Australian Institute for Medical Research in the new field of receptor coupling, specifically G-Protein coupled receptors ("GPCRs").
Microbicides: A microbicide inactivates, kills or destroys microbes. Microbicides may be formulated as gels, creams, sponges, suppositories or films with the purpose of reducing significantly the incidence of STDs. There are currently no vaginal microbicides on the market. They are intended for vaginal or rectal use to afford protection for varying periods, from several hours up to days. Microbicides may also be designed to have a contraceptive function by inhibiting sperm.
Dendrimers: Dendrimers are a type of nanoparticle. They are man-made chemicals that form tiny balls made up of a dense network of branches. Dendrimers have applications in the medical, electronics, chemicals and materials industries.
American Depositary Receipts (ADRs): Starpharma`s ADRs trade under the code SPHRY (CUSIP number 855563102). Each Starpharma ADR is equivalent to 10 ordinary shares of Starpharma as traded on the Australian Stock Exchange. The Bank of New York is the depositary bank.!
Was heißt ein paar?
Der Austr. Staat bezahlt im wesentlichen die Kosten.
Die DNT-Beteiligung hat 1a Auszeichnung von Frost u. Gullivan erhalten - ebenso wie Starpharma zu Anfang diesen Jahren.
Mal ganz im Ernst: Ich rechne in 8 Jahren mit 3,5 Mrd. € Umsatz; netto 150 Mio Lizenzen = 100 Mio Gewinn = 2 Mrd. Marktkap. bei dann 200 Mio Aktien (statt jetzt knapp 120 Mio) ===> Kursziel in 8 Jahren: ca. 10 €
===> Daraus ergibt sich für mich ein heutiger, risikodiskontierter und abgezinster Wert von ca. 1 € je Aktie mit einem Kursziel von 2,50 € in max. 2,5 Jahren bei erfolgreichem Phase II-Abschluss.
Bei momentan zeitweise nur 0,33 € darf man ruhig ein paar mehr ordern - was ich schon getan habe.
Der Austr. Staat bezahlt im wesentlichen die Kosten.
Die DNT-Beteiligung hat 1a Auszeichnung von Frost u. Gullivan erhalten - ebenso wie Starpharma zu Anfang diesen Jahren.
Mal ganz im Ernst: Ich rechne in 8 Jahren mit 3,5 Mrd. € Umsatz; netto 150 Mio Lizenzen = 100 Mio Gewinn = 2 Mrd. Marktkap. bei dann 200 Mio Aktien (statt jetzt knapp 120 Mio) ===> Kursziel in 8 Jahren: ca. 10 €
===> Daraus ergibt sich für mich ein heutiger, risikodiskontierter und abgezinster Wert von ca. 1 € je Aktie mit einem Kursziel von 2,50 € in max. 2,5 Jahren bei erfolgreichem Phase II-Abschluss.
Bei momentan zeitweise nur 0,33 € darf man ruhig ein paar mehr ordern - was ich schon getan habe.
http://www.starpharma.com/framemaster.htm
also wieder einen award
Forschung und Innovation ausgezeichnet - PR mangelhaft!
winorloose
also wieder einen awardForschung und Innovation ausgezeichnet - PR mangelhaft!
winorloose
STARPHARMA RAISES A$15M THROUGH INSTITUTIONAL PLACEMENT AND SHARE PURCHASE PLAN
Melbourne, Australia – 14 November 2005.
Starpharma Holdings Limited (ASX: SPL, USOTC:SPHRY) today announced a successful A$15 million capital raising, positioning the company for further significant growth. The structure of the capital raising included a $12 million institutional placement at $0.51 and an underwritten Share Purchase Plan (SPP) to raise an additional $3 million.
The institutional placement, which closed on Friday 11 November, was over subscribed. The SPP, also priced at $0.51, is expected to be well supported by Starpharma’s more than 2000 shareholders. The SPP is expected to run from 22 November to December 15 2005.
Patersons Securities, the lead manager of the Placement and underwriter of the SPP, has confirmed more than 70% of the Placement was raised through new and existing institutional investors.
Last month Starpharma also received US$20.3m (A$26m) of non-dilutive funding from one of the most significant health organisations in the world, the National Institutes of Health (NIH), to develop VivaGel™, a topical vaginal microbicide to protect women from HIV.
The new capital will be used to fund the development of line extensions of VivaGel™ including the prevention of Genital Herpes, to further build the company’s product pipeline, and to increase collaborative activities with its investee company, US based Dendritic NanoTechnologies, Inc (DNT).
Dr John Raff, CEO of Starpharma said “We are very pleased to have received support from our existing institutional investors as well as attracting a number of new institutional investors to our share register through this capital raising.”
“The support of some of Australia’s leading financial institutions is validation of the commercial opportunities for VivaGel™, and recognition of the future value of our dendrimer nanotechnology pipeline and of our 33% equity stake in DNT,” said Dr Raff.
Melbourne, Australia – 14 November 2005.
Starpharma Holdings Limited (ASX: SPL, USOTC:SPHRY) today announced a successful A$15 million capital raising, positioning the company for further significant growth. The structure of the capital raising included a $12 million institutional placement at $0.51 and an underwritten Share Purchase Plan (SPP) to raise an additional $3 million.
The institutional placement, which closed on Friday 11 November, was over subscribed. The SPP, also priced at $0.51, is expected to be well supported by Starpharma’s more than 2000 shareholders. The SPP is expected to run from 22 November to December 15 2005.
Patersons Securities, the lead manager of the Placement and underwriter of the SPP, has confirmed more than 70% of the Placement was raised through new and existing institutional investors.
Last month Starpharma also received US$20.3m (A$26m) of non-dilutive funding from one of the most significant health organisations in the world, the National Institutes of Health (NIH), to develop VivaGel™, a topical vaginal microbicide to protect women from HIV.
The new capital will be used to fund the development of line extensions of VivaGel™ including the prevention of Genital Herpes, to further build the company’s product pipeline, and to increase collaborative activities with its investee company, US based Dendritic NanoTechnologies, Inc (DNT).
Dr John Raff, CEO of Starpharma said “We are very pleased to have received support from our existing institutional investors as well as attracting a number of new institutional investors to our share register through this capital raising.”
“The support of some of Australia’s leading financial institutions is validation of the commercial opportunities for VivaGel™, and recognition of the future value of our dendrimer nanotechnology pipeline and of our 33% equity stake in DNT,” said Dr Raff.
@all
hier noch ein pasar Infos vom AGM:
Financially secure
Non-dilutive, external funding for VivaGel™in place
VivaGel™Phase I trial successful; further human trials scheduled and funded
Dendrimer platform yielding multiple commercial opportunities
Exceptional uptake of US ADRs
Valuable equity and strategic holding in DNT
Experienced management team
2004 / 2005: The Year in Review
September $US5.4M NIH funding for ComboGel™
December Phase I VivaGel™ trial → Forbes/Wolfe “Top 5 Nanotech breakthroughs of 2004”
January Dow : Entire dendrimer portfolio to DNT for 30% share of DNT equity
February Signed development deal with Anadis Ltd
April $5.5M P3 product development grant
May Investee company DNT announces breakthrough Priostar™ technology
June US ADRs: > 5% of Starpharma equity
September NCI comprehensive funding of DNT ovarian cancer detection
October A$26.4m non-dilutive NIH funding to develop VivaGel™
October Exchanged 25% royalty stream on VivaGel™ etc for 7.11M shares
November Oversubscribed institutional placement raises $12M
weiter Infos siehe hier:
http://stocknessmonster.com/news-item?S=SPL&E=ASX&N=246086
tomhead (der bis 2008 Zeit investiert bleibt)
hier noch ein pasar Infos vom AGM:
Financially secure
Non-dilutive, external funding for VivaGel™in place
VivaGel™Phase I trial successful; further human trials scheduled and funded
Dendrimer platform yielding multiple commercial opportunities
Exceptional uptake of US ADRs
Valuable equity and strategic holding in DNT
Experienced management team
2004 / 2005: The Year in Review
September $US5.4M NIH funding for ComboGel™
December Phase I VivaGel™ trial → Forbes/Wolfe “Top 5 Nanotech breakthroughs of 2004”
January Dow : Entire dendrimer portfolio to DNT for 30% share of DNT equity
February Signed development deal with Anadis Ltd
April $5.5M P3 product development grant
May Investee company DNT announces breakthrough Priostar™ technology
June US ADRs: > 5% of Starpharma equity
September NCI comprehensive funding of DNT ovarian cancer detection
October A$26.4m non-dilutive NIH funding to develop VivaGel™
October Exchanged 25% royalty stream on VivaGel™ etc for 7.11M shares
November Oversubscribed institutional placement raises $12M
weiter Infos siehe hier:
http://stocknessmonster.com/news-item?S=SPL&E=ASX&N=246086
tomhead (der bis 2008 Zeit investiert bleibt)
wo ist cyberCoach: Gebe doch mal deine Meinung zum jetzigen Stand ab.
hier noch eine News von heute 251105.
25 November 2005
Australian Stock Exchange Limited
Company Announcements Office
Exchange Centre
Level 4, 20 Bridge Street
Sydney NSW 2000
Starpharma Holdings Limited (ASX:SPL, USOTC:SPHRY)
Share Purchase Plan
Please find attached documentation for Starpharma Holdings Limited`s Share
Purchase Plan. The offer was announced to the ASX on 14 November 2005, and
closes at 5pm on Friday 15 December 2005.
Yours sincerely
Ben Rogers
Company Secretary
STARPHARMA HOLDINGS LTD ABN 20 078 532 180
Baker Building, 75 Commercial Road,
Melbourne, Victoria 3004 Australia
PO Box 6535, St Kilda Road Central, Vic 8008
Telephone: +613 8532 2700 Facsimile: +613 9510 5955 www.starpharma.com
STARPHARMA HOLDINGS LTD ABN 20 078 532 180
Baker Building, 75 Commercial Road,
Melbourne, Victoria 3004 Australia
PO Box 6535, St Kilda Road Central, Vic 8008
Telephone: +613 8532 2700 Facsimile: +613 9510 5955 www.starpharma.com
25 November 2005
STARPHARMA HOLDINGS LIMITED
SHARE PURCHASE PLAN
?? Eligible shareholders entitled to purchase up to $5000 of ordinary shares
?? Price will be $0.51 per ordinary share
?? No brokerage or additional transaction costs
?? Offer closes 5.00pm on Friday, 15 December 2005
Dear Shareholder
As announced to the Australian Stock Exchange on 14 November 2005, the Board of Starpharma Holdings
Limited (Starpharma) is pleased to provide eligible shareholders the opportunity to participate in the capital
raising initiatives of Starpharma through a Share Purchase Plan (SPP). Starpharma recently announced the
completion of an institutional placement to raise A$12m. Starpharma has established the SPP to provide an
opportunity for all eligible shareholders to purchase additional shares in Starpharma at the same discounted
price that was offered to the institutions that participated in the recent capital raising. We encourage all
eligible shareholders to consider taking advantage of this opportunity to acquire Starpharma shares at a
discount. The SPP is underwritten by Patersons Securities Limited up to A$3m.
SPP – At a Glance
The accompanying Terms and Application Form set out the terms of the offer under the SPP. By accepting
the offer to purchase shares under the SPP, you agree to be bound by the accompanying terms.
Starpharma currently has 128 million shares on issue (142 million on completion of the second tranche of the
A$12m institutional placement), held by approximately 2,200 shareholders. Patersons Securities Limited is
underwriting the issue of 5,882,353 shares to raise A$3m. The Board reserves the right to accept
oversubscriptions, if it receives applications in excess of A$3m.
Key points of the SPP are:
?? You may acquire up to 9,804 shares as set out in the Application Form. There are no brokerage or other
transaction costs payable on the allotment of shares under the SPP.
?? Shares allotted under the SPP will rank equally with existing fully paid ordinary shares.
011156_00H7NB
?? Should you elect to participate in the SPP, all shares will be issued at A$0.51. This has been set at a
15.6% discount to the volume weighted average price in the market on the 30 trading days starting on
3 October and concluding on the record date, which was Friday 18 November 2005.
?? The SPP is underwritten by Patersons Securities Limited up to A$3m. This means that if less than
5,882,353 shares are taken up by shareholders, those shortfall shares will be subscribed for by
Patersons Securities Limited (or persons nominated by Patersons Securities Limited in consultation with
Starpharma).
?? If you wish to participate in the SPP, please fill out the enclosed Application Form and attach a cheque or
bank draft to the acceptance slip and mail it in the reply paid envelope so that it is received by the share
registrar before 5.00pm Melbourne time on 15 December 2005.
Shareholder Update
We believe that Starpharma’s prospects for building shareholder value continue to improve. Sexually
transmitted infections represent significant market opportunities (in excess of US$1b) in both developed and
developing nations. Efforts to develop vaccines have so far failed, and condoms cannot be fully effective
when used improperly and infrequently. Starpharma is well positioned to develop its lead product, the
microbicide VivaGel™, for the prevention of sexually transmitted infections in women.
In October of this year one of the world’s leading research organisations, the National Institutes of Health
(NIH), selected VivaGel™ as a microbicide candidate with the potential to prevent the global spread of HIV.
The NIH awarded Starpharma US$20.3m (A$26.4m) to develop VivaGel™ for prevention of HIV. This NIH
funding significantly reduces VivaGel™’s development risk as the funding supports development through to
the final population study. Furthermore, the NIH relationship will facilitate access to world class clinicians,
opinion leaders and facilities for its development work.
Starpharma is also developing VivaGel™ for Genital Herpes and expects to enter human trials for this
serious disease during calendar year 2006. In addition, the company is exploring the use of VivaGel™ as a
coating for premium condoms. We expect other opportunities to arise in our discovery pipeline as we
continue to apply our nanotechnology expertise to the development of therapeutics and diagnostics in:
?? Cancer;
?? Respiratory diseases; and
?? Anti-angiogenesis applications.
Purpose of the Capital Fund Raising
The purpose of the SPP is to support ongoing operating costs, including funding the development of line
extensions of VivaGel™ e.g. for prevention of Genital Herpes, to further build the company`s product
pipeline, and to increase collaborative activities with its investee company, US based Dendritic
NanoTechnologies, Inc (DNT). The capital raised from the institutional placement and SPP combined with
the funding received from the NIH ensures that the company has more than two years’ cash reserves.
Thank you for your continuing support as a shareholder of Starpharma.
Yours sincerely
Peter T Bartels, AO
CHAIRMAN
STARPHARMA HOLDINGS LIMITED
011156_00H7NB
TERMS
The following are the Terms applicable to the SPP approved by the Directors of Starpharma Holdings
Limited (ABN 20 078 532 180).
Participation in the SPP
You are eligible to participate in the SPP if you were a registered holder of fully paid ordinary shares of
Starpharma on 18 November 2005 with a registered address in either Australia or New Zealand. The offer
under the SPP is non-renounceable. This means that you cannot transfer your right to purchase shares
under the offer to anyone else.
If you are eligible to participate in the SPP, you may apply for new shares in Starpharma up to $5,000.
There is no minimum subscription. You have the option to apply in increments as set out below:
Option A A$5000
Option B A$4000
Option C A$3000
Option D A$2000
Option E A$1000
Option F A$500
The offer under the SPP has been structured to comply with the Australian Securities and Investments
Commission Class Order 02/831. For this purpose, the maximum number of 9,804 new shares applies to all
eligible shareholders (irrespective of the size of your current holding).
If, however, you are registered as a trustee or nominee in respect of more than 1 beneficiary, you may apply
for up to $5,000 of new shares for each occasion that you are separately recorded as a trustee or nominee
for a different beneficiary.
Maximum raising
The board is seeking to raise approximately A$3 million through the SPP, and reserves the right to scale
back the issue on a pro-rata basis in the event of over-subscription. This means, for example, that if you
apply for a $5,000 parcel and applications are scaled back by 5%, then your application will be scaled back
to $4,750. In that event, you will receive a refund cheque at the same time as your transaction confirmation
statement for the amount to be refunded.
Alternatively the Board reserves the right to accept additional funds if applications are received for more than
A$3 million.
Participation Costs
No brokerage or other transaction costs apply to the application for and allotment of new shares under the
SPP.
Pricing
The issue price for each new share is $0.51. The issue price is an amount equal to 15.6% of the volume
weighted average price of Starpharma`s ordinary shares traded on ASX during the 30 business days starting
on 3 October 2005 and concluding on the record date, which was Friday 18 November 2005. You should
note, however, that the market price of Starpharma`s shares could rise or fall between the date of this offer
011156_00H7SC
and the date when Starpharma allots the new shares to you. This means that the price you pay for every
new share under this offer might exceed the market price of Starpharma`s shares at the time the new shares
are allotted to you under the SPP.
You should consult your stockbroker or professional adviser in relation to this offer and your participation
under the SPP.
Issue of new shares
New shares will be issued on or about 20 December 2005. New shares will rank equally with existing fully
paid ordinary shares in Starpharma.
It is expected that the new shares allotted to you under the SPP will be quoted on ASX on or about
23 December 2005 and you should receive your holding statement or confirmation advice shortly after that
date.
Application
The offer will close at 5pm on 15 December 2005.
Applications to participate in the SPP must be made on the enclosed Application Form and sent with your
payment by cheque made payable to "Starpharma Holdings Limited Share Purchase Plan" to our Share
Registry so that it is received by 5pm on 15 December 2005.
Variations, waivers and resolutions of disputes
Starpharma reserves the right to vary the closing date and share issue date for the SPP, waive compliance
with any of the terms of the offer, refuse to allot shares where it believes there has been a breach of these
terms and settle in any manner it thinks fit any disputes or anomalies which may arise in connection with the
SPP.
Questions
If you have any questions about the SPP, please contact:
Computershare Investor Services Pty Limited
GPO Box 505
MELBOURNE VIC 8060
Phone: 1300 850 505 (within Australia)
61 3 9415 4000 (outside Australia)
THIS DOCUMENT CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE RISKS AND UNCERTAINTIES.
ALTHOUGH WE BELIEVE THAT THE EXPECTATIONS REFLECTED IN THE FORWARD-LOOKING STATEMENTS
ARE REASONABLE AT THIS TIME, STARPHARMA CAN GIVE NO ASSURANCE THAT THESE EXPECTATIONS
WILL PROVE TO BE CORRECT. ACTUAL RESULTS COULD DIFFER MATERIALLY FROM THOSE ANTICIPATED,
BECAUSE OF VARIOUS IMPORTANT FACTORS, RISKS AND UNCERTAINTIES. THESE INCLUDE RISKS
ASSOCIATED WITH DRUG DEVELOPMENT AND MANUFACTURE, RISKS INHERENT IN THE EXTENSIVE
REGULATORY APPROVAL PROCESSES MANDATED BY REGULATORY AUTHORITIES, DELAYS IN CLINICAL
TRIALS, FUTURE CAPITAL NEEDS AND GENERAL ECONOMIC UNCERTAINTY. ALSO, THERE CAN BE NO
ASSURANCE THAT OTHERS WILL NOT INDEPENDENTLY DEVELOP SIMILAR PRODUCTS OR PROCESSES OR
DESIGN AROUND PATENTS OWNED OR LICENSED BY THE COMPANY, OR THAT PATENTS OWNED OR
LICENSED BY THE COMPANY WILL PROVIDE MEANINGFUL PROTECTION OR COMPETITIVE ADVANTAGES.
011156_00H7SC
SHARE PURCHASE PLAN APPLICATION FORM
Pursuant to the terms and conditions of the Starpharma Holdings Limited Share Purchase Plan (“SPP” contained in the letter to Starpharma Holdings Limited
shareholders dated 25 November 2005, Starpharma Holdings Limited is offering eligible shareholders the opportunity to purchase Ordinary Fully Paid Shares up to a
maximum value of A$5,000.00 per eligible shareholder, subject to a minimum application of A$500.00. If you do not wish to purchase additional shares under this
offer there is no need to take action.
By submitting this form you agree to be bound by the Constitution of Starpharma Holdings Limited and agree that the submission of this form constitutes an irrevocable
offer by you to Starpharma Holdings Limited to subscribe for Starpharma Holdings Limited Shares on the terms of the SPP. In addition, you also certify as at the
date this application form is received by Starpharma Holdings Limited that the aggregate amount of shares applied for by you under the SPP (under this application
and any other application submitted by you) does not exceed A$5,000.00.
METHOD OF ACCEPTANCE
Your cheque or Bank Draft should be in Australian dollars and drawn on an Australian bank made payable to ‘Starpharma Holdings Limited SPP’ for the relevant
amount and crossed ‘Not Negotiable’. Please ensure you submit the correct amount. Incorrect payments may result in your application being rejected.
Your acceptance slip and cheque or Bank Draft must be received by the share registry before the close of the offer 5.00pm AEDST on 15 December 2005. You
should allow sufficient time for this to occur. A reply paid envelope is enclosed for shareholders in Australia. New Zealand holders will need to affix the appropriate
postage. Your Application Form should be returned in the envelope provided or delivered to our registry at the address shown on the reverse of this form. Refer
overleaf for instructions.
Starpharma Holdings Limited may make determinations in any manner it thinks fit, in relation to any difficulties, anomalies or disputes which may arise in connection
with or by reason of the operation of the SPP whether generally or in relation to any participant or application. Any determinations by Starpharma Holdings Limited
will be conclusive and binding on all eligible shareholders and other persons to whom the determination relates. Starpharma Holdings Limited reserves the right to
waive strict compliance with any provision of the terms and conditions of the SPP, to amend or vary those terms and conditions and to suspend or terminate the
SPP at any time. Any such amendment, variation, suspension or termination will be binding on all eligible shareholders even where Starpharma Holdings Limited
does not notify you of that event.
THIS IS AN IMPORTANT DOCUMENT
Should you have any doubt about how to deal with it please consult a financial advisor
This offer is non-renounceable - No Signature is required
Return Acceptance Slip and Cheque or Bank Draft in the envelope provided
9,804
shares or
A$5,000.00
I/We wish to purchase shares:
or
* These share amounts may be subject to scale-back in accordance with the terms of the SPP.
7,844
shares or
A$4,000.00
or
5,883
shares or
A$3,000.00
or
3,922
shares or
A$2,000.00
or
1,961
shares or
A$1,000.00
or
981
shares or
A$500.00
Entitlement Number:
Record Date: 18 November 2005
Offer Closes: 5.00pm AEDST on 15 December 2005
Price per Security: A$0.51
Please return completed form to:
Computershare Investor Services Pty Limited
GPO Box 505 Melbourne
Victoria 8060 Australia
Enquiries (within Australia) 1300 850 505
(outside Australia) 61 3 9415 4000
Facsimile 61 3 9473 2500
web.queries@computershare.com.au
www.computershare.com
S P R M 011156_00H7MC S P L
Contact Name Telephone Number - Business Hours / After Hours
Enter your contact details
( )
Make your cheque or bank draft payable to “Starpharma Holdings Limited SPP”
Payment Details
BSB Number Account Number Drawer Amount of cheque
A$
Cheque Number
Pin cheque(s) here. Do not staple.
1234567890123456+1234567890-1234+12
Entitlement Number: <xxxxxxxxxx>
I 1234567890 I N D
Securityholder Reference Number (SRN) 000001
1301011221012102012221332120133322113
Instructions
Payment Details
Make your cheque or bank draft payable to “Starpharma Holdings Limited SPP” in Australian currency and cross it Not Negotiable. Your cheque or bank
draft must be drawn on an Australian Bank. Please ensure you submit the correct amount. Incorrect payments may result in your application being
rejected.
Complete cheque details in the boxes provided.
Cheques will be processed on the day of receipt and as such, sufficient cleared funds must be held in your account as cheques returned unpaid may
not be re-presented and may result in your Application being rejected. Pin (do not staple) your cheque(s) to the Share Purchase Plan Application Form
where indicated. Cash will not be accepted. A receipt for payment will not be forwarded.
Contact Details
Enter your contact details. These are not compulsory but will assist us if we need to contact you.
Lodgement of Application
Application Forms must be received at the Melbourne office of Computershare Investor Services Pty Limited by no later than 5.00pm (AEDST) on
15 December 2005. You should allow sufficient time for this to occur. The postal acceptance rule does not apply to the Share Purchase Plan. A reply
paid envelope is enclosed for shareholders in Australia. New Zealand holders will need to affix the appropriate postage.
Return the Application Form with cheque(s) attached to:
MAILING ADDRESS DELIVERY ADDRESS
Starpharma Holdings Limited Computershare Investor Services Pty Limited
Computershare Investor Services Pty Limited Yarra Falls
GPO BOX 505 452 Johnston Street
Melbourne, Victoria 8060 Abbotsford, Victoria 3067
AUSTRALIA
Privacy Statement
Personal information is collected on this form by Computershare Investor Services Pty Limited ("CIS"), as registrar for securities issuers ("the issuer"),
for the purpose of maintaining registers of securityholders, facilitating distribution payments and other corporate actions and communications. Your
personal information may be disclosed to our related bodies corporate, to external service companies such as print or mail service providers, or as
otherwise required or permitted by law. If you would like details of your personal information held by CIS, or you would like to correct information that
is inaccurate, incorrect or out of date, please contact CIS. In accordance with the Corporations Act 2001, you may be sent material (including
marketing material) approved by the issuer in addition to general corporate communications. You may elect not to receive marketing material by
contacting CIS. You can contact CIS using the details provided on the front of this form or E-mail privacy@computershare.com.au
If you have any enquiries concerning this form, please contact Computershare Investor Services Pty Limited on 1300 850 505.
S P L S P R M 011156_00H7MC
tomhead
Quelle: http://stocknessmonster.com/ und dann SPL eingeben, dann auf news
hier noch eine News von heute 251105.
25 November 2005
Australian Stock Exchange Limited
Company Announcements Office
Exchange Centre
Level 4, 20 Bridge Street
Sydney NSW 2000
Starpharma Holdings Limited (ASX:SPL, USOTC:SPHRY)
Share Purchase Plan
Please find attached documentation for Starpharma Holdings Limited`s Share
Purchase Plan. The offer was announced to the ASX on 14 November 2005, and
closes at 5pm on Friday 15 December 2005.
Yours sincerely
Ben Rogers
Company Secretary
STARPHARMA HOLDINGS LTD ABN 20 078 532 180
Baker Building, 75 Commercial Road,
Melbourne, Victoria 3004 Australia
PO Box 6535, St Kilda Road Central, Vic 8008
Telephone: +613 8532 2700 Facsimile: +613 9510 5955 www.starpharma.com
STARPHARMA HOLDINGS LTD ABN 20 078 532 180
Baker Building, 75 Commercial Road,
Melbourne, Victoria 3004 Australia
PO Box 6535, St Kilda Road Central, Vic 8008
Telephone: +613 8532 2700 Facsimile: +613 9510 5955 www.starpharma.com
25 November 2005
STARPHARMA HOLDINGS LIMITED
SHARE PURCHASE PLAN
?? Eligible shareholders entitled to purchase up to $5000 of ordinary shares
?? Price will be $0.51 per ordinary share
?? No brokerage or additional transaction costs
?? Offer closes 5.00pm on Friday, 15 December 2005
Dear Shareholder
As announced to the Australian Stock Exchange on 14 November 2005, the Board of Starpharma Holdings
Limited (Starpharma) is pleased to provide eligible shareholders the opportunity to participate in the capital
raising initiatives of Starpharma through a Share Purchase Plan (SPP). Starpharma recently announced the
completion of an institutional placement to raise A$12m. Starpharma has established the SPP to provide an
opportunity for all eligible shareholders to purchase additional shares in Starpharma at the same discounted
price that was offered to the institutions that participated in the recent capital raising. We encourage all
eligible shareholders to consider taking advantage of this opportunity to acquire Starpharma shares at a
discount. The SPP is underwritten by Patersons Securities Limited up to A$3m.
SPP – At a Glance
The accompanying Terms and Application Form set out the terms of the offer under the SPP. By accepting
the offer to purchase shares under the SPP, you agree to be bound by the accompanying terms.
Starpharma currently has 128 million shares on issue (142 million on completion of the second tranche of the
A$12m institutional placement), held by approximately 2,200 shareholders. Patersons Securities Limited is
underwriting the issue of 5,882,353 shares to raise A$3m. The Board reserves the right to accept
oversubscriptions, if it receives applications in excess of A$3m.
Key points of the SPP are:
?? You may acquire up to 9,804 shares as set out in the Application Form. There are no brokerage or other
transaction costs payable on the allotment of shares under the SPP.
?? Shares allotted under the SPP will rank equally with existing fully paid ordinary shares.
011156_00H7NB
?? Should you elect to participate in the SPP, all shares will be issued at A$0.51. This has been set at a
15.6% discount to the volume weighted average price in the market on the 30 trading days starting on
3 October and concluding on the record date, which was Friday 18 November 2005.
?? The SPP is underwritten by Patersons Securities Limited up to A$3m. This means that if less than
5,882,353 shares are taken up by shareholders, those shortfall shares will be subscribed for by
Patersons Securities Limited (or persons nominated by Patersons Securities Limited in consultation with
Starpharma).
?? If you wish to participate in the SPP, please fill out the enclosed Application Form and attach a cheque or
bank draft to the acceptance slip and mail it in the reply paid envelope so that it is received by the share
registrar before 5.00pm Melbourne time on 15 December 2005.
Shareholder Update
We believe that Starpharma’s prospects for building shareholder value continue to improve. Sexually
transmitted infections represent significant market opportunities (in excess of US$1b) in both developed and
developing nations. Efforts to develop vaccines have so far failed, and condoms cannot be fully effective
when used improperly and infrequently. Starpharma is well positioned to develop its lead product, the
microbicide VivaGel™, for the prevention of sexually transmitted infections in women.
In October of this year one of the world’s leading research organisations, the National Institutes of Health
(NIH), selected VivaGel™ as a microbicide candidate with the potential to prevent the global spread of HIV.
The NIH awarded Starpharma US$20.3m (A$26.4m) to develop VivaGel™ for prevention of HIV. This NIH
funding significantly reduces VivaGel™’s development risk as the funding supports development through to
the final population study. Furthermore, the NIH relationship will facilitate access to world class clinicians,
opinion leaders and facilities for its development work.
Starpharma is also developing VivaGel™ for Genital Herpes and expects to enter human trials for this
serious disease during calendar year 2006. In addition, the company is exploring the use of VivaGel™ as a
coating for premium condoms. We expect other opportunities to arise in our discovery pipeline as we
continue to apply our nanotechnology expertise to the development of therapeutics and diagnostics in:
?? Cancer;
?? Respiratory diseases; and
?? Anti-angiogenesis applications.
Purpose of the Capital Fund Raising
The purpose of the SPP is to support ongoing operating costs, including funding the development of line
extensions of VivaGel™ e.g. for prevention of Genital Herpes, to further build the company`s product
pipeline, and to increase collaborative activities with its investee company, US based Dendritic
NanoTechnologies, Inc (DNT). The capital raised from the institutional placement and SPP combined with
the funding received from the NIH ensures that the company has more than two years’ cash reserves.
Thank you for your continuing support as a shareholder of Starpharma.
Yours sincerely
Peter T Bartels, AO
CHAIRMAN
STARPHARMA HOLDINGS LIMITED
011156_00H7NB
TERMS
The following are the Terms applicable to the SPP approved by the Directors of Starpharma Holdings
Limited (ABN 20 078 532 180).
Participation in the SPP
You are eligible to participate in the SPP if you were a registered holder of fully paid ordinary shares of
Starpharma on 18 November 2005 with a registered address in either Australia or New Zealand. The offer
under the SPP is non-renounceable. This means that you cannot transfer your right to purchase shares
under the offer to anyone else.
If you are eligible to participate in the SPP, you may apply for new shares in Starpharma up to $5,000.
There is no minimum subscription. You have the option to apply in increments as set out below:
Option A A$5000
Option B A$4000
Option C A$3000
Option D A$2000
Option E A$1000
Option F A$500
The offer under the SPP has been structured to comply with the Australian Securities and Investments
Commission Class Order 02/831. For this purpose, the maximum number of 9,804 new shares applies to all
eligible shareholders (irrespective of the size of your current holding).
If, however, you are registered as a trustee or nominee in respect of more than 1 beneficiary, you may apply
for up to $5,000 of new shares for each occasion that you are separately recorded as a trustee or nominee
for a different beneficiary.
Maximum raising
The board is seeking to raise approximately A$3 million through the SPP, and reserves the right to scale
back the issue on a pro-rata basis in the event of over-subscription. This means, for example, that if you
apply for a $5,000 parcel and applications are scaled back by 5%, then your application will be scaled back
to $4,750. In that event, you will receive a refund cheque at the same time as your transaction confirmation
statement for the amount to be refunded.
Alternatively the Board reserves the right to accept additional funds if applications are received for more than
A$3 million.
Participation Costs
No brokerage or other transaction costs apply to the application for and allotment of new shares under the
SPP.
Pricing
The issue price for each new share is $0.51. The issue price is an amount equal to 15.6% of the volume
weighted average price of Starpharma`s ordinary shares traded on ASX during the 30 business days starting
on 3 October 2005 and concluding on the record date, which was Friday 18 November 2005. You should
note, however, that the market price of Starpharma`s shares could rise or fall between the date of this offer
011156_00H7SC
and the date when Starpharma allots the new shares to you. This means that the price you pay for every
new share under this offer might exceed the market price of Starpharma`s shares at the time the new shares
are allotted to you under the SPP.
You should consult your stockbroker or professional adviser in relation to this offer and your participation
under the SPP.
Issue of new shares
New shares will be issued on or about 20 December 2005. New shares will rank equally with existing fully
paid ordinary shares in Starpharma.
It is expected that the new shares allotted to you under the SPP will be quoted on ASX on or about
23 December 2005 and you should receive your holding statement or confirmation advice shortly after that
date.
Application
The offer will close at 5pm on 15 December 2005.
Applications to participate in the SPP must be made on the enclosed Application Form and sent with your
payment by cheque made payable to "Starpharma Holdings Limited Share Purchase Plan" to our Share
Registry so that it is received by 5pm on 15 December 2005.
Variations, waivers and resolutions of disputes
Starpharma reserves the right to vary the closing date and share issue date for the SPP, waive compliance
with any of the terms of the offer, refuse to allot shares where it believes there has been a breach of these
terms and settle in any manner it thinks fit any disputes or anomalies which may arise in connection with the
SPP.
Questions
If you have any questions about the SPP, please contact:
Computershare Investor Services Pty Limited
GPO Box 505
MELBOURNE VIC 8060
Phone: 1300 850 505 (within Australia)
61 3 9415 4000 (outside Australia)
THIS DOCUMENT CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE RISKS AND UNCERTAINTIES.
ALTHOUGH WE BELIEVE THAT THE EXPECTATIONS REFLECTED IN THE FORWARD-LOOKING STATEMENTS
ARE REASONABLE AT THIS TIME, STARPHARMA CAN GIVE NO ASSURANCE THAT THESE EXPECTATIONS
WILL PROVE TO BE CORRECT. ACTUAL RESULTS COULD DIFFER MATERIALLY FROM THOSE ANTICIPATED,
BECAUSE OF VARIOUS IMPORTANT FACTORS, RISKS AND UNCERTAINTIES. THESE INCLUDE RISKS
ASSOCIATED WITH DRUG DEVELOPMENT AND MANUFACTURE, RISKS INHERENT IN THE EXTENSIVE
REGULATORY APPROVAL PROCESSES MANDATED BY REGULATORY AUTHORITIES, DELAYS IN CLINICAL
TRIALS, FUTURE CAPITAL NEEDS AND GENERAL ECONOMIC UNCERTAINTY. ALSO, THERE CAN BE NO
ASSURANCE THAT OTHERS WILL NOT INDEPENDENTLY DEVELOP SIMILAR PRODUCTS OR PROCESSES OR
DESIGN AROUND PATENTS OWNED OR LICENSED BY THE COMPANY, OR THAT PATENTS OWNED OR
LICENSED BY THE COMPANY WILL PROVIDE MEANINGFUL PROTECTION OR COMPETITIVE ADVANTAGES.
011156_00H7SC
SHARE PURCHASE PLAN APPLICATION FORM
Pursuant to the terms and conditions of the Starpharma Holdings Limited Share Purchase Plan (“SPP”
contained in the letter to Starpharma Holdings Limitedshareholders dated 25 November 2005, Starpharma Holdings Limited is offering eligible shareholders the opportunity to purchase Ordinary Fully Paid Shares up to a
maximum value of A$5,000.00 per eligible shareholder, subject to a minimum application of A$500.00. If you do not wish to purchase additional shares under this
offer there is no need to take action.
By submitting this form you agree to be bound by the Constitution of Starpharma Holdings Limited and agree that the submission of this form constitutes an irrevocable
offer by you to Starpharma Holdings Limited to subscribe for Starpharma Holdings Limited Shares on the terms of the SPP. In addition, you also certify as at the
date this application form is received by Starpharma Holdings Limited that the aggregate amount of shares applied for by you under the SPP (under this application
and any other application submitted by you) does not exceed A$5,000.00.
METHOD OF ACCEPTANCE
Your cheque or Bank Draft should be in Australian dollars and drawn on an Australian bank made payable to ‘Starpharma Holdings Limited SPP’ for the relevant
amount and crossed ‘Not Negotiable’. Please ensure you submit the correct amount. Incorrect payments may result in your application being rejected.
Your acceptance slip and cheque or Bank Draft must be received by the share registry before the close of the offer 5.00pm AEDST on 15 December 2005. You
should allow sufficient time for this to occur. A reply paid envelope is enclosed for shareholders in Australia. New Zealand holders will need to affix the appropriate
postage. Your Application Form should be returned in the envelope provided or delivered to our registry at the address shown on the reverse of this form. Refer
overleaf for instructions.
Starpharma Holdings Limited may make determinations in any manner it thinks fit, in relation to any difficulties, anomalies or disputes which may arise in connection
with or by reason of the operation of the SPP whether generally or in relation to any participant or application. Any determinations by Starpharma Holdings Limited
will be conclusive and binding on all eligible shareholders and other persons to whom the determination relates. Starpharma Holdings Limited reserves the right to
waive strict compliance with any provision of the terms and conditions of the SPP, to amend or vary those terms and conditions and to suspend or terminate the
SPP at any time. Any such amendment, variation, suspension or termination will be binding on all eligible shareholders even where Starpharma Holdings Limited
does not notify you of that event.
THIS IS AN IMPORTANT DOCUMENT
Should you have any doubt about how to deal with it please consult a financial advisor
This offer is non-renounceable - No Signature is required
Return Acceptance Slip and Cheque or Bank Draft in the envelope provided
9,804
shares or
A$5,000.00
I/We wish to purchase shares:
or
* These share amounts may be subject to scale-back in accordance with the terms of the SPP.
7,844
shares or
A$4,000.00
or
5,883
shares or
A$3,000.00
or
3,922
shares or
A$2,000.00
or
1,961
shares or
A$1,000.00
or
981
shares or
A$500.00
Entitlement Number:
Record Date: 18 November 2005
Offer Closes: 5.00pm AEDST on 15 December 2005
Price per Security: A$0.51
Please return completed form to:
Computershare Investor Services Pty Limited
GPO Box 505 Melbourne
Victoria 8060 Australia
Enquiries (within Australia) 1300 850 505
(outside Australia) 61 3 9415 4000
Facsimile 61 3 9473 2500
web.queries@computershare.com.au
www.computershare.com
S P R M 011156_00H7MC S P L
Contact Name Telephone Number - Business Hours / After Hours
Enter your contact details
( )
Make your cheque or bank draft payable to “Starpharma Holdings Limited SPP”
Payment Details
BSB Number Account Number Drawer Amount of cheque
A$
Cheque Number
Pin cheque(s) here. Do not staple.
1234567890123456+1234567890-1234+12
Entitlement Number: <xxxxxxxxxx>
I 1234567890 I N D
Securityholder Reference Number (SRN) 000001
1301011221012102012221332120133322113
Instructions
Payment Details
Make your cheque or bank draft payable to “Starpharma Holdings Limited SPP” in Australian currency and cross it Not Negotiable. Your cheque or bank
draft must be drawn on an Australian Bank. Please ensure you submit the correct amount. Incorrect payments may result in your application being
rejected.
Complete cheque details in the boxes provided.
Cheques will be processed on the day of receipt and as such, sufficient cleared funds must be held in your account as cheques returned unpaid may
not be re-presented and may result in your Application being rejected. Pin (do not staple) your cheque(s) to the Share Purchase Plan Application Form
where indicated. Cash will not be accepted. A receipt for payment will not be forwarded.
Contact Details
Enter your contact details. These are not compulsory but will assist us if we need to contact you.
Lodgement of Application
Application Forms must be received at the Melbourne office of Computershare Investor Services Pty Limited by no later than 5.00pm (AEDST) on
15 December 2005. You should allow sufficient time for this to occur. The postal acceptance rule does not apply to the Share Purchase Plan. A reply
paid envelope is enclosed for shareholders in Australia. New Zealand holders will need to affix the appropriate postage.
Return the Application Form with cheque(s) attached to:
MAILING ADDRESS DELIVERY ADDRESS
Starpharma Holdings Limited Computershare Investor Services Pty Limited
Computershare Investor Services Pty Limited Yarra Falls
GPO BOX 505 452 Johnston Street
Melbourne, Victoria 8060 Abbotsford, Victoria 3067
AUSTRALIA
Privacy Statement
Personal information is collected on this form by Computershare Investor Services Pty Limited ("CIS"), as registrar for securities issuers ("the issuer"),
for the purpose of maintaining registers of securityholders, facilitating distribution payments and other corporate actions and communications. Your
personal information may be disclosed to our related bodies corporate, to external service companies such as print or mail service providers, or as
otherwise required or permitted by law. If you would like details of your personal information held by CIS, or you would like to correct information that
is inaccurate, incorrect or out of date, please contact CIS. In accordance with the Corporations Act 2001, you may be sent material (including
marketing material) approved by the issuer in addition to general corporate communications. You may elect not to receive marketing material by
contacting CIS. You can contact CIS using the details provided on the front of this form or E-mail privacy@computershare.com.au
If you have any enquiries concerning this form, please contact Computershare Investor Services Pty Limited on 1300 850 505.
S P L S P R M 011156_00H7MC
tomhead
Quelle: http://stocknessmonster.com/ und dann SPL eingeben, dann auf news
Hat jemand schon mal bei seinem Broker oder seiner Bank angefragt ob auch ausländische (deutsche) Anleger von diesem Angebot Gebrauch machen können?
cyber Coach scheint ohen Verbindung zum Netz auf Weltreise zu sein (Einhand segeln?). Hoffe aber er ist noch investiert und meldet sich mal wieder.
Fritz
cyber Coach scheint ohen Verbindung zum Netz auf Weltreise zu sein (Einhand segeln?). Hoffe aber er ist noch investiert und meldet sich mal wieder.
Fritz
hallo keiner mehr investiert??????
HIer noch vor Jahresende eine kleine nicht unbedeutende News:
STARPHARMA COMPLETES A$15 MILLION RAISING Melbourne, Australia – 20 December 2005. Starpharma Holdings Limited (ASX: SPL, USOTC:SPHRY) today announced the successful completion of the second tranche of its institutional placement and the finalisation of its Share Purchase Plan (SPP), which together raised a total of A$15M. The institutional placement was oversubscribed and raised a total of A$12 million through the issue of shares in two tranches. The first tranche of the share placement to raise A$4.88 million was the maximum number of shares permitted under ASX Listing Rule 7.1 to be issued without shareholder approval. The second tranche of shares to raise A$7.12 million was approved at an extraordinary general meeting of shareholders on 16 December 2005. This meeting also ratified the issue of the first tranche of shares and approved the underwriting of the SPP. The underwritten SPP closed on 15 December 2005 and raised A$3 million. CEO Dr John Raff said: “Starpharma is now in the fortunate position where our lead project is largely externally funded and cash reserves are sufficient to support the company’s operations for more than two years.”
tomhead
HIer noch vor Jahresende eine kleine nicht unbedeutende News:
STARPHARMA COMPLETES A$15 MILLION RAISING Melbourne, Australia – 20 December 2005. Starpharma Holdings Limited (ASX: SPL, USOTC:SPHRY) today announced the successful completion of the second tranche of its institutional placement and the finalisation of its Share Purchase Plan (SPP), which together raised a total of A$15M. The institutional placement was oversubscribed and raised a total of A$12 million through the issue of shares in two tranches. The first tranche of the share placement to raise A$4.88 million was the maximum number of shares permitted under ASX Listing Rule 7.1 to be issued without shareholder approval. The second tranche of shares to raise A$7.12 million was approved at an extraordinary general meeting of shareholders on 16 December 2005. This meeting also ratified the issue of the first tranche of shares and approved the underwriting of the SPP. The underwritten SPP closed on 15 December 2005 and raised A$3 million. CEO Dr John Raff said: “Starpharma is now in the fortunate position where our lead project is largely externally funded and cash reserves are sufficient to support the company’s operations for more than two years.”
tomhead
investiert schon noch, aber bereits im "Winterschlaf"
bleibt nur zu hoffen, daß die performance von unserem baby nächstes Jahr etwas erfreulicher ausfallen wird als dieses..
Gruß & schöne Weihnachten,
h.
bleibt nur zu hoffen, daß die performance von unserem baby nächstes Jahr etwas erfreulicher ausfallen wird als dieses..
Gruß & schöne Weihnachten,
h.
Welche Spezies nennt eine Aktie "unser Baby"?
Raten Sie mit! Es locken hohe Gewinne!
Bitte ankreuzen:
a) Mutanten
b) hirnamputierte pubertierende Jüngelchen
c) von Gebärneid zerfressene Hagestolze
Unter allen richtigen Einsendungen werden bis zu 50 Starpharma-Aktien verlost!
Raten Sie mit! Es locken hohe Gewinne!
Bitte ankreuzen:
a) Mutanten
b) hirnamputierte pubertierende Jüngelchen
c) von Gebärneid zerfressene Hagestolze
Unter allen richtigen Einsendungen werden bis zu 50 Starpharma-Aktien verlost!
Achtung: dies ist bitte ausschliesslich ein Faktenthread !!
Danke
Danke
Vivagel(TM) Receives Fast Tracks Status from FDA
Monday January 9, 9:30 am ET
MELBOURNE, Australia, Jan. 9 /PRNewswire-FirstCall/ -- Starpharma (ASX: SPL, USOTC: SPHRY) today announced that the US Food & Drug Administration (FDA) has granted Fast Track status to VivaGel(TM), an Investigational New Drug (IND) for the prevention of HIV.
"There are currently no approved products for the prevention of HIV infection. The FDA recognises the potential of VivaGel(TM) to address this unmet medical need," commented John Raff, CEO of Starpharma. "VivaGel`s(TM) New Drug Application (NDA) will receive Priority Review which has a shorter review time. Fast Track status also provides more opportunity for Starpharma to communicate with the FDA to ensure the success of the VivaGel(TM) development program. This is excellent news for VivaGel(TM) and for Starpharma."
Under the FDA Modernization Act of 1997, the Fast Track drug development program facilitates and expedites the development of products that serve unmet medical needs of serious or life-threatening conditions. This program provides formal mechanisms for sponsors to communicate with the FDA on product development issues, including clinical trial design. Under the Fast Track program, portions of the NDA can be submitted to the FDA before the application is completed. This early review is expected to shorten FDA approval times significantly.
VivaGel(TM) is currently being developed as a vaginal microbicide gel to prevent the transmission of genital herpes and HIV. VivaGel(TM) was also recently awarded US$20 million by the US-based NIAID, a division of the National Institutes of Health (NIH) to accelerate its development.
The commercial opportunity for VivaGel(TM) is very significant, both in industrialized nations and the developing world. In the USA, AIDS (a result of HIV infection) is now the number one cause of death among African-American women between the ages of 25 and 34 and genital herpes affects approximately 50 million Americans. With no cure currently available for HIV or genital herpes, and the limited success of existing prevention strategies, infection rates in the US and elsewhere are expected to continue to rise sharply. Microbicides such as VivaGel(TM) are now recognised as a key element in this fight against genital herpes and HIV.
About Starpharma:
Starpharma Holdings Limited (ASX: SPL, USOTC: SPHRY) leads the world in the application of nanotechnology to pharmaceuticals. The Company`s lead development product is VivaGel(TM) (SPL7013 Gel), a vaginal microbicide designed to prevent the transmission of STIs, including HIV and genital herpes.
VivaGel(TM) is the first example of a product to come from Starpharma`s dendrimer-based discovery pipeline, which also includes specific programs in the fields of ADME Engineering(TM) (using dendrimers to control where and when drugs go when introduced to the body), Polyvalency (using the fact that dendrimers can activate multiple receptors simultaneously) and Targeted Diagnostics (using dendrimers as a scaffold to which both location -- signalling and targeting groups are added to allow location of specific cell type, such as cancer cells).
Starpharma also has equity interests in two companies:
-- Dendritic NanoTechnologies, Inc. (DNT) -- established with the pioneer
of dendrimer nanotechnology Dr Donald A. Tomalia and based in Michigan,
USA; and
-- Dimerix Bioscience Pty Ltd -- a specialist drug development company
established to commercialise unique technology developed at the Western
Australian Institute for Medical Research in the new field of receptor
coupling, specifically G-Protein coupled receptors ("GPCRs").
Dendrimers: A type of precisely-defined, branched nanoparticle. Dendrimers have applications in the medical, electronics, chemicals and materials industries.
Microbicides: A microbicide inactivates, kills or destroys microbes such as viruses and bacteria. Microbicides may be formulated as gels, creams, sponges, suppositories or films with the purpose of reducing significantly the incidence of STIs. They are intended for vaginal or rectal use to afford protection for varying periods, from several hours up to days. Microbicides may also be designed to have a contraceptive function.
American Depositary Receipts (ADRs): Starpharma`s ADRs trade under the code SPHRY (CUSIP number 855563102). Each Starpharma ADR is equivalent to 10 ordinary shares of Starpharma as traded on the Australian Stock Exchange. The Bank of New York is the depositary bank.
Grüße cristrader
Monday January 9, 9:30 am ET
MELBOURNE, Australia, Jan. 9 /PRNewswire-FirstCall/ -- Starpharma (ASX: SPL, USOTC: SPHRY) today announced that the US Food & Drug Administration (FDA) has granted Fast Track status to VivaGel(TM), an Investigational New Drug (IND) for the prevention of HIV.
"There are currently no approved products for the prevention of HIV infection. The FDA recognises the potential of VivaGel(TM) to address this unmet medical need," commented John Raff, CEO of Starpharma. "VivaGel`s(TM) New Drug Application (NDA) will receive Priority Review which has a shorter review time. Fast Track status also provides more opportunity for Starpharma to communicate with the FDA to ensure the success of the VivaGel(TM) development program. This is excellent news for VivaGel(TM) and for Starpharma."
Under the FDA Modernization Act of 1997, the Fast Track drug development program facilitates and expedites the development of products that serve unmet medical needs of serious or life-threatening conditions. This program provides formal mechanisms for sponsors to communicate with the FDA on product development issues, including clinical trial design. Under the Fast Track program, portions of the NDA can be submitted to the FDA before the application is completed. This early review is expected to shorten FDA approval times significantly.
VivaGel(TM) is currently being developed as a vaginal microbicide gel to prevent the transmission of genital herpes and HIV. VivaGel(TM) was also recently awarded US$20 million by the US-based NIAID, a division of the National Institutes of Health (NIH) to accelerate its development.
The commercial opportunity for VivaGel(TM) is very significant, both in industrialized nations and the developing world. In the USA, AIDS (a result of HIV infection) is now the number one cause of death among African-American women between the ages of 25 and 34 and genital herpes affects approximately 50 million Americans. With no cure currently available for HIV or genital herpes, and the limited success of existing prevention strategies, infection rates in the US and elsewhere are expected to continue to rise sharply. Microbicides such as VivaGel(TM) are now recognised as a key element in this fight against genital herpes and HIV.
About Starpharma:
Starpharma Holdings Limited (ASX: SPL, USOTC: SPHRY) leads the world in the application of nanotechnology to pharmaceuticals. The Company`s lead development product is VivaGel(TM) (SPL7013 Gel), a vaginal microbicide designed to prevent the transmission of STIs, including HIV and genital herpes.
VivaGel(TM) is the first example of a product to come from Starpharma`s dendrimer-based discovery pipeline, which also includes specific programs in the fields of ADME Engineering(TM) (using dendrimers to control where and when drugs go when introduced to the body), Polyvalency (using the fact that dendrimers can activate multiple receptors simultaneously) and Targeted Diagnostics (using dendrimers as a scaffold to which both location -- signalling and targeting groups are added to allow location of specific cell type, such as cancer cells).
Starpharma also has equity interests in two companies:
-- Dendritic NanoTechnologies, Inc. (DNT) -- established with the pioneer
of dendrimer nanotechnology Dr Donald A. Tomalia and based in Michigan,
USA; and
-- Dimerix Bioscience Pty Ltd -- a specialist drug development company
established to commercialise unique technology developed at the Western
Australian Institute for Medical Research in the new field of receptor
coupling, specifically G-Protein coupled receptors ("GPCRs").
Dendrimers: A type of precisely-defined, branched nanoparticle. Dendrimers have applications in the medical, electronics, chemicals and materials industries.
Microbicides: A microbicide inactivates, kills or destroys microbes such as viruses and bacteria. Microbicides may be formulated as gels, creams, sponges, suppositories or films with the purpose of reducing significantly the incidence of STIs. They are intended for vaginal or rectal use to afford protection for varying periods, from several hours up to days. Microbicides may also be designed to have a contraceptive function.
American Depositary Receipts (ADRs): Starpharma`s ADRs trade under the code SPHRY (CUSIP number 855563102). Each Starpharma ADR is equivalent to 10 ordinary shares of Starpharma as traded on the Australian Stock Exchange. The Bank of New York is the depositary bank.
Grüße cristrader
@all
hier noch etwas von Jack Uldrich
Sunday, January 08, 2006
Nano Gets Fast Tracked
I have long been very bullish on Starpharma`s long-term prospects and today the company announced yet another round of good news that provided me yet another reason to remain bullish. Company officials announced it`s investigational new drug, VivaGel, has been granted "Fast Track" status by the Food and Drug Administration.
In the press release the company explains the significance of this event. Essentially, it is a vote of confidence regarding the potential effectiveness of VivaGel, which is a dendrimer-based vaginal mirocibe gel drug designed to prevent the transmission of HIV. The net effect is that it could ultimately speed up the time it takes for the FDA to render final approval for the drug.
Be advised that the "Fast Track" stamp of approval doesn`t guarantee that the treatment will necessarily receive final approval, but apparently the FDA sees enough promise in the treatment to give it this priority status.
This news, combined with the $20 million grant the company received from the National Institute of Health this past fall, is just another feather in the company`s cap and why I think risk-tolerant investors should consider investing in Starpharma. (Full disclosure: I own stock in Starpharma.)
tomhead
hier noch etwas von Jack Uldrich
Sunday, January 08, 2006
Nano Gets Fast Tracked
I have long been very bullish on Starpharma`s long-term prospects and today the company announced yet another round of good news that provided me yet another reason to remain bullish. Company officials announced it`s investigational new drug, VivaGel, has been granted "Fast Track" status by the Food and Drug Administration.
In the press release the company explains the significance of this event. Essentially, it is a vote of confidence regarding the potential effectiveness of VivaGel, which is a dendrimer-based vaginal mirocibe gel drug designed to prevent the transmission of HIV. The net effect is that it could ultimately speed up the time it takes for the FDA to render final approval for the drug.
Be advised that the "Fast Track" stamp of approval doesn`t guarantee that the treatment will necessarily receive final approval, but apparently the FDA sees enough promise in the treatment to give it this priority status.
This news, combined with the $20 million grant the company received from the National Institute of Health this past fall, is just another feather in the company`s cap and why I think risk-tolerant investors should consider investing in Starpharma. (Full disclosure: I own stock in Starpharma.)
tomhead
[posting]19.674.768 von tomhead am 12.01.06 13:03:41[/posting]@tomhead
kannst du mal bitte den Link posten ?
Danke
kannst du mal bitte den Link posten ?
Danke
[posting]19.675.426 von 500cx am 12.01.06 13:43:46[/posting]ups glatt vergessen:
anbei der Link:
http://www.nanoveritas.com/nanonovus/index.html
tomhead
anbei der Link:
http://www.nanoveritas.com/nanonovus/index.html
tomhead
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| -12,46 | |
| 0,00 | |
| 0,00 | |
| -0,96 | |
| +19,13 | |
| +53,85 | |
| 0,00 | |
| 0,00 | |
| +2,21 | |
| 0,00 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 57 | ||
| 56 | ||
| 48 | ||
| 46 | ||
| 24 | ||
| 17 | ||
| 15 | ||
| 12 | ||
| 12 | ||
| 11 |
Starpharma - Der Faktenthread
